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This is my fourth foreword to the NDSC annual report. As in
previous years, it reflects the commitment, vision and
professionalism of our Director, Dr Darina O’Flanagan and all
the staff at NDSC.
NDSC continued to make an important contribution to public
health in Ireland in 2002 through a range of activities
including the provision of expert advice, epidemiological
investigation, scientific research, data collection and through
participation in health promotion and training.
The wide range of valuable work carried out at NDSC was
enhanced during the year by the recruitment of additional,
highly qualified and committed staff across a number of
disciplines.
Furthermore, the move to our new Gardiner Street
headquarters in April 2002, allowed for greater cohesion and
communication amongst the various professional strands of
the centre. The fact that the transfer to the new premises
went so smoothly and without disruption to any of the
services provided by NDSC is a credit to all involved.
The next couple of years will provide an exciting challenge for
the health services in Ireland. NDSC is in a position to
confidently take part and contribute to the change process
and to continue our invaluable work in improving the health
of the Irish population.
It remains for me to thank the present Board members, our
Director, and all the staff whose efforts have contributed to
the ongoing success of NDSC.
Professor Dermot Hourihane
Chairman
Board of the National Disease Surveillance Centre
Foreword
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Introduction
This is the fourth annual report from the National Disease
Surveillance Centre.
This report highlights achievements in recent years in the field
of communicable disease control.
It is particularly gratifying to see the 90% reduction in cases
of group C meningococcal disease since the introduction of
men C vaccine in October 2000. While the benefits of an
immunisation programme are often more apparent
immediately after its introduction, the success of the
programme has meant that one hundred and twenty five
fewer families suffered the trauma of childhood
meningococcal disease in 2002.
The continuing rise in the notification of sexually transmitted
diseases and increases in reports of HIV infections are a
matter for concern. The rising incidence of sexually
transmitted diseases is consistent with an increase in unsafe
sex and mirrors the situation in many other European
countries. Tragically, we are once again seeing infants born
with congenital syphilis.
New and emerging diseases continue to demand our
attention but it is important that we remember the dangers
associated with those infectious diseases that we have not
yet managed to confine to history.
Work continues on major projects like the Strategy for the
control of Antimicrobial Resistance in Ireland (SARI) and the
Computerised Infectious Disease Reporting (CIDR) system.
These projects will make a major contribution to the control
of infectious diseases in Ireland.
Once again the scientific advisory committee has worked hard
and many of the subcommittees have completed guidelines
which are available on the NDSC website. The work of all who
have contributed to these sub-committees is gratefully
acknowledged, as is the work of all staff at NDSC.
Dr Darina O'Flanagan
Director
National Disease Surveillance Centre
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Bacterial Meningitis, 2002
KEY POINTS
In 2002,
• 297 cases of bacterial meningitis were notified in
Ireland.
• 253 of the cases (including 3 imported) were due to
meningococcal disease.
• Excluding imported cases meningococcal disease
notifications declined by 51% compared with 2000 and
by 23% compared with 2001.
• Serogroup C meningococcal disease notifications
declined by 90% when compared with 2000 highlighting
the impact meningococcal serogroup C conjugate
vaccine has had in Ireland.
• There were 12 deaths due to bacterial meningitis
including eight due to meningococcal disease.
Introduction
Bacterial meningitis is still a significant cause of childhood
morbidity and mortality in Ireland. The majority of cases of
bacterial meningitis are due to invasive meningococcal disease
(IMD), a serious life-threatening illness caused by Neisseria
meningitidis.
However, the introduction of the meningococcal serogroup C
conjugate (MenC) vaccine in Ireland (October 2000) as part
of the primary childhood immunisation schedule and in the
catch-up programme for everyone up to and including 22
years of age, has reduced the burden of serogroup C
meningococcal disease significantly.
Material and Methods
Enhanced surveillance of bacterial meningitis (including
meningococcal septicaemia) commenced in Ireland in 1997.
The Community Care Areas (CCAs) simultaneously notify the
Departments of Public Health and NDSC of each suspected
case of bacterial meningitis. Follow-up information on each
case notified is collected by the Department of Public
Health/CCA and forwarded to NDSC. At NDSC data are
entered into a MS Access database. The Irish Meningococcal
and Meningitis Reference Laboratory (IMMRL) at the
Children’s Hospital, Temple Street, Dublin, perform active
surveillance on laboratory confirmed cases of IMD. The NDSC
database is reconciled monthly with the IMMRL database and
quarterly with the Departments of Public Health databases. A
final data validation is performed with the Departments of
Public Health and IMMRL following year-end.
Data analysis was performed using MS Access and MS Excel.
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Of note when analysing the years 2000-2002, the population
data were taken from the 2002 census, while denominator
data for the years 1997-1999 were taken from the 1996
census.
For surveillance purposes the diagnosis of IMD is classified as
Definite, Presumed and Possible as outlined in the
Department of Health and Children’s Working Group report.1
A summary of the case definitions are as follows:
Definite: A case where Neisseria meningitidis is detected by
culture or PCR in a normally sterile site (CSF, blood, synovial
fluid etc).
Presumed: A case where the convalescent serology test is
positive or Gram-negative diplococci are detected in CSF or
skin-scrapings or N. meningitidis is isolated from an eye,
throat or nasal swab together with either the characteristic
purpuric rash or clinical or laboratory features of bacterial
meningitis (CSF pleocytosis).
Possible: A case with evidence of acute sepsis with or without
meningitis, together with the characteristic purpuric rash or a
case with clinical evidence of sepsis without a purpuric rash
and in whom N. meningitidis is isolated from an eye, throat or
nasal swab.
Results
Bacterial Meningitis
Two hundred and ninety seven cases of bacterial meningitis
(including 3 imported cases) were notified in Ireland in 2002.
Invasive meningococcal disease (IMD) accounted for 85% of
the bacterial meningitis notifications (253 cases including 3
imported cases). Streptococcus pneumoniae accounted for 5%
(n=15) of the bacterial meningitis cases notified, while
Haemophilus influenzae type b accounted for 1% of the cases
(n=3).
Invasive Meningococcal Disease
Imported cases of IMD
An imported case is defined as a case where the onset of
illness occurs within two days of arrival in the country or
where the infection is known to have been acquired abroad. In
2002, three imported cases of IMD were notified in Ireland.
These were serogroup B cases with one notified by each of
the following health boards, NEHB, SEHB and WHB. These
imported IMD cases will be excluded from subsequent
analysis in this report.
Total IMD
Excluding the three imported cases, 250 cases of IMD were
notified in Ireland in 2002, which is equivalent to a rate of
6.4/100,000. IMD notifications declined by 51% in 2002
compared with 2000 (13.1/100,000; 513 cases; excluding 2
imported cases) and by 23% compared with 2001
(8.3/100,000; 326 cases, excluding 4 imported cases) (Figure
1). The incidence rate in 2002 is the lowest recorded since the
enhanced surveillance system for bacterial meningitis
(including meningococcal septicaemia) commenced in 1997
(Figure 1). Two hundred and eight IMD (83.2%) were classified
as definite, 17 (6.8%) as presumed and 25 (10%) as possible
cases. Eighty seven percent (n=218) of cases were laboratory
confirmed by the IMMRL. Of the 218 cases confirmed by
Meningococcal disease
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Figure 1. Crude incidence rates for meningococcal disease in Ireland, 1997-2002
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IMMRL, 59.6% (130 cases) were by PCR, 35.8% (78 cases) by
culture and 4.6% (10 cases) by convalescent serology.
IMD by serogroup
Of the 250 cases of IMD notified, the breakdown by
serogroup was as follows: 196 serogroup B, 14 serogroup C, 6
serogroup W135 (none were Hajj related), 2 serogroup Y, 1
non-groupable (NG) and 31 had no organism detected.
Serogroup B IMD accounted for 90% of cases with a
serogroup result. The incidence of serogroup B IMD dropped
by 19% in 2002 (5.0/100,0000, 196 cases) when compared
with 2001 (6.2/100,000; 242 cases) and by 23.4% when
compared with 2000 (6.5/100,000; 256 cases) (Figure 1).
Furthermore, the incidence rate for serogroup B IMD in 2002
was lower than those reported for 1997 and 1998, 5.0 and 6.2
per 100,000, respectively (Figure 1).
Serogroup C IMD accounted for just 6.4% of the serogrouped
cases in 2002 compared to 34% of these cases in 2000. The
incidence of serogroup C IMD declined by 59% in 2002
(0.4/100,000; 14 cases) compared with the previous year
(0.9/100,000; 34 cases) and by a dramatic 90% compared
with 2000 (3.6/100,000; 139 cases) (Figure 2).
IMD by age and sex
The male:female ratio was 1:0.9, with males accounting for
51.6% (n=129) of the cases. Fifty eight percent (n=146) of
IMD cases were in those under 5 years of age, while 90%
(n=225) of the cases were under 25 years of age. The highest
age specific incidence rates were in the under 1 year olds
(119.3/100,000) and 1-4 year olds (36.3/100,0000). The age
specific incidence rates for serogroup B IMD in 2002 were
similar to those seen in 2001, with the highest rates in the
under1 year olds (93.6/100,000) and 1-4 year olds
(28.2/100,000) (Figure 3a). In 2002, the age specific incidence
rate for serogroup C IMD was highest in the less than 1 year
olds (3.7/100,000) followed by the 1-4 year olds
(2.2/100,0000). Compared with 2000, the age specific
incidence rates for serogroup C IMD in 2002 declined in all
the age groups under 25 years of age (Figure 3b).
IMD by health board
In 2002, as in previous years the crude incidence rates (CIR)
and age standardised incidence rates (ASIR) for IMD varied by
health board (Table 1a). When compared to the national rates
none of these differences were statistically significant.
However, the rates in the WHB for IMD were less that the
national rate and this was close to significance. The ASIR of
serogroup B and C IMD by health board in 2000, 2001 and
2002 are presented in Figures 4 and 5, respectively. For both
serogroup B and C, no statistical differences were noted
between the national incidence rates and the health board
rates.
In 2000, the highest incidence rates for serogroup C were in
the south of the country with the SEHB and SHB reporting
ASIR of greater than 5.0/100,000. In 2001, the incidence rates
declined in all health boards, with no health board reporting
ASIR of greater than 1.2/100,000 (Figure 4). This decline
continued in 2002 with no health board reporting ASIR of
greater than 0.9/100,000 while in the NWHB, SHB and WHB
no serogroup C cases occurred.
Impact of MenC vaccine on serogroup C IMD
Serogroup C IMD declined by 92% in the age group targeted
by the campaign (now aged under 25 years), dropping from
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Figure 3a. Age specific incidence rates for serogroup B disease 2000-2002
0
120
60
100
40
80
20
1-4<1 5-9 10-14 15-19 20-24 25-34 35-44 45-54 55-64 >65
2000 2001 2002
Age group (years)
Ra
te
 p
er
 1
00
,0
00
 p
op
ul
at
io
n
Figure 3b.  Age specific incidence rates for serogroup C disease, 2000-2002
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131 cases in 2000 to 10 cases in 2002 (Table 2). Seventy one
percent (10/14) of the serogroup C cases occurred in the
target age group (now aged under 25 years) and four of these
cases had received the MenC vaccine. However, only one of
these can be classified as a true vaccine failure. This case
received one dose four days after turning one year of age and
became ill at 23 months of age. The other three cases were
partial vaccine failures. Two of these received one dose of the
vaccine at 11 months of age (with one receiving it just nine
days prior to their first birthday). They became ill at 26 and
19 months of age, respectively. The third case received two
doses of vaccine at four and six months of age and had onset
of illness at 20 months of age.
Bacterial meningitis other than IMD
Forty four cases (1.1/100,000) of bacterial meningitis other
than IMD were notified in 2002 (Table 3). The breakdown by
aetiological agent of these meningitis cases was as follows; 15
Streptococcus pneumoniae, two serogroup B streptococci
(GBS), three Haemophilus influenzae type b (Hib), three
Mycobacterium tuberculosis, one Staphlococcus aureus and 20
organism unknown. The incidence rate of bacterial meningitis
other than IMD was highest in the under 1 year olds, 31.2 per
100,1000 (Table 4). Streptococcus pneumoniae and bacterial
meningitis (organism unknown) accounted for the majority of
these cases. In relation to the Hib cases, one case developed
the illness at 15 months of age and had not received the
vaccine. The two other cases had each received three doses of
the vaccine and were therefore regarded as true vaccine
failures. One received the Hib vaccine at the correct schedule
and developed illness at 31 months of age. The other received
the vaccine in the UK as per the schedule there i.e. at two,
three and four months of age, and developed illness at 4
years.
Deaths due to bacterial meningitis
There were 12 deaths due to bacterial meningitis in 2002,
compared to 30 in 2000 and 15 in 2001. In 2001, these
included 12 deaths due to meningococcal disease (8 group B,
3 group C, 1 group W135), two pneumococcal meningitis
deaths and one due to bacterial meningitis (organism
unknown). Eight of the deaths in 2002 were due to IMD (all
group serogroup B), one each due to pneumococcal
meningitis, Staphlococcus aureus meningitis, Group B
streptococcus meningitis and bacterial meningitis (organism
unknown). The case fatality rate (CFR) for IMD in 2002 was
3.2% (Table 4). The CFR for serogroup B IMD was 4.1% and
was highest in the under 1 year olds at 7.8% (Table 4). All of
the eight serogroup B deaths occurred in those under 5 years
of age. There were no serogroup C deaths in 2002 whereas in
1999 and 2000 there were five and 11 deaths, respectively,
thereby highlighting the positive impact that the MenC
vaccine has had in reducing not only morbidity but also
mortality due to group C disease in Ireland.
Discussion
The lowest incidence of IMD since the enhanced surveillance
system commenced in Ireland in 1997 was in 2002, with rates
falling from between 12 and 15 per 100,000 in the years
previous to 2001 to 6.4 per 100,000 in 2002. One of the
main reasons for the decline in IMD was due to the
introduction of the MenC vaccine in October 2000, with the
incidence rate in 2002 declining by an impressive 90% since
2000. This reduction in Group C meningococcal disease has
Table 1a
Health Board Number CIR [95% CI] ASIR [95% CI]
ERHA 89 6.4 [5.0-7.7] 6.5 [5.2-7.9]
MHB 18 8.0 [4.3-11.7] 7.6 [4.1-11.1]
MWHB 27 8.0 [5.0-10.9] 8.0 [5.0-11.0]
NEHB 24 7.0 [4.2-9.7] 6.4 [3.8-8.9]
NWHB 14 6.3 [3.0-9.6] 6.5 [3.1-9.9]
SEHB 23 5.4 [3.5-7.8] 5.3 [3.1-7.4]
SHB 41 7.1 [4.9-9.2] 7.2 [5.0-9.5]
WHB 14 3.7 [1.8-5.6] 3.7 [1.7-5.6]
IRELAND 250 6.4 [5.6-7.2] – 
Table 1.  Numbers, crude incidence rates (CIR) and age standardised incidence rates (ASIR) 
with 95% confidence intervals (CI) of total IMD (Table 1a), serogroup B (Table 1b) and 
serogroup C (Table 1c) by health board, in 2002.
Table 1b
Health Board Number CIR [95% CI] ASIR [95% CI]
ERHA 71 5.1 [3.9-6.2] 5.2 [4.0-6.4]
MHB 15 6.7 [3.3-10.0] 6.3 [3.1-9.4]
MWHB 19 5.6 [3.1-8.1] 5.6 [3.1-8.1]
NEHB 22 6.4 [6.7-9.0] 5.8 [3.4-8.2]
NWHB 10 4.5 [1.7-7.3] 4.6 [1.7-7.4]
SEHB 13 3.1 [1.4-4.7] 3.0 [1.7-4.6]
SHB 32 5.5 [3.6-7.4] 5.7 [3.7-7.6]
WHB 14 3.7 [1.6-5.3] 3.7 [1.7-5.6]
Ireland 196 5.0 [4.3-5.7] – 
Table 1c
Health Board Number CIR [95% CI] ASIR [95% CI]
ERHA 9 0.6 [0.2-1.1] 0.6 [0.2-1.1]
MHB 2 0.9 [0.3-2.1] 0.9 [-0.4-2.2]
MWHB 1 0.3 [-0.3-0.9] 0.3 [-0.3-0.9]
NEHB 1 0.3 [-0.3-0.9] 0.3 [-0.3-0.8]
NWHB 0 0.00 0.00
SEHB 1 0.2 [-0.2-0.7] 0.2 [-0.2-0.7]
SHB 0 0.00 0.00
WHB 0 0.00 0.00
Ireland 14 0.36 [0.2-0.6] – 
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been observed in all age groups in 2002 when compared with
the same period in 2000. The most dramatic reductions were
seen in the age groups targeted by the MenC vaccine, ranging
from a 100% reduction in 5-9 year olds to 86% reduction in
the 1-4 years. The incidence of serogroup C IMD reduced in all
health boards/health authorities in 2002. Mortality due to
serogroup C disease also declined in 2002 with no deaths
occurring.
The incidence rate of serogroup B disease also declined in
2002 (by 23% compared with 2000), but not to the same
magnitude as serogroup C disease. In 2002, all health boards
except NEHB showed a decline in the incidence of serogroup
B disease. Five of the eight health boards have similar
incidence rates (4.5-6.0/100,000).
The six serogroup W135 cases notified in Ireland in 2002 were
not Hajj related and no serogroup W135 2a; P1.2, 5 have been
reported in Ireland to date. This serogroup W135 2a; P1.2, 5
was the serogroup associated in 2000 with returning pilgrims
and their contacts following the Hajj pilgrimage to Mecca in
Saudia Arabia.
In comparison to IMD, the incidence of pneumococcal
meningitis remains low in Ireland (0.4/100,000) and there
were one associated death in 2002, which occurred in an
infant.
Although group C disease has declined since the introduction
of the MenC vaccine, group B disease is still very common in
Ireland. Since there is no suitable vaccine yet to combat group 
B disease, parents and healthcare professionals should be ever
vigilant and alert to the signs and symptoms of the disease.
Table 2. Number of cases of Group C disease notified in 2000 and 2002
Age group (years) 2000 2002 % Reduction
<1 20 2 90
1-4 37 5 86
5-9 15 0 100
10-14 20 1 95
15-19 31 1 97
19-24 8 1 88
25+ 8 4 50
Total 139 14 90
Table 3. Bacterial meningitis other than IMD in Ireland in 2002
Organism  Age group (years)                         CIR
<1 1-4 5-14 15-24 >25 Total
Group B streptococcus 2 0 0 0 0 2 0.05
H. influenzae b 0 3 0 0 0 3 0.08
M. tuberculosis 0 0 0 2 1 3 0.08
S. pneumoniae 8 3 0 1 3 15 0.38
S. aureus 0 0 0 0 1 1 0.03
Organism unknown 7 1 5 4 3 20 0.51
Total 17 7 5 7 8 64 1.12
ASIR 31.2 3.14 0.90 1.09 0.33 1.12 
CIR = Crude incidence rate per 100,000    ASIR = age -specific incidence rate per 100,000
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Table 4.  Deaths due to total and serogroup B  IMD by age group in Ireland, in 2002
Age group (years) Total IMD Serogroup B
 Deaths Cases CFR (%) Deaths Cases CFR (%)
<1 4 65 6.2 4 51 7.8
1-4 4 81 4.9 4 63 6.4
5-9 0 24 0.0 0 21 0.0
10-14 0 22 0.0 0 18 0.0
15-19 0 23 0.0 0 20 0.0
20-24 0 10 0.0 0 6 0.0
≥25 0 25 0.0 0 17 0.0
Total 8 250 3.2 8 196 4.1
CFR = case fatality rate
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Key Points
• There were 381 new cases of TB in 2001, giving a crude
incidence rate of 9.7/100,000 population.
• Sixty three cases (16.5%) were born outside Ireland.
• Although the highest rate was observed in the 65+ age
group, there was a 30% decrease in this age group in
2001, compared to 2000.
• There were 204 isolates of M. tuberculosis, seven were
M. bovis and one was M. africanum.
• There were two multi-drug resistant M. tuberculosis
cases.
• Five deaths were attributed to TB.
• Outcome data were reported in 60% of TB cases only.
Introduction
Since 1998, all information concerning TB notifications in
Ireland has been reported by each of the health boards to the
National Disease Surveillance Centre (NDSC) for analysis.
Beginning on January 1st 2000, this information has included
enhanced surveillance data based on the minimum dataset
reported to EuroTB, the European agency that collates
national TB data within Europe and contributes that data to
the WHO global TB control programme. The resulting
National Tuberculosis Surveillance System (NTBSS) was set up
following consultation between NDSC, the eight health
boards and the National Tuberculosis (TB) Advisory Group.
Materials and Methods
For each individual case of tuberculosis notified in 2001, an
enhanced notification form was completed by public health
doctors, using the available clinical, microbiological,
histological and epidemiological data. These forms were then
collated in the regional Departments of Public Health. In all
but one health board, data were also entered onto an Epi Info
6 database locally and an anonymised version of each
database was submitted to NDSC on a quarterly basis. A
single health board submitted anonymised facsimiles of
enhanced TB forms directly to NDSC. All cases were then
collated at a national level on a single Epi Info database for
detailed analysis. Reports summarising results were produced
on a quarterly basis by NDSC. Information on all cases was
updated in late 2002 / early 2003 by each health board to
include outcome data.
Tuberculosis in Ireland, 2001
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Population figures, used as the denominator, were taken from
the 2002 census of population. The 95% confidence intervals
were used to compare rates between groups of interest. Direct
methods of standardisation were used to allow comparison of
rates between geographical areas using the Irish population as
the standard population.
As in previous years, the case definitions used were as
recommended by the National Tuberculosis (TB) Working
Group.1
• A notified case of TB refers to clinically active disease due
to infection with organisms of the Mycobacterium
tuberculosis complex (M. tuberculosis, M. bovis, M.
africanum). Active disease is presumed if the patient is
commenced on a full curative course of anti-tuberculosis
chemotherapy. Persons placed on chemoprophylaxis for
preventive treatment or infected by mycobacterium other
than M. tuberculosis complex are not included as cases.
• Pulmonary TB is defined as a laboratory-confirmed case –
either a positive smear, histology or culture of a respiratory
sample – with or without radiological abnormalities
consistent with active pulmonary TB or a case where the
physician takes the decision that the patient’s clinical
symptoms and/or radiological signs are compatible with
pulmonary TB.
• Extrapulmonary TB is defined as a patient with a smear,
culture or histological specimen, from an extrapulmonary
site, that is positive for M. tuberculosis complex or a case
with clinical signs of active extrapulmonary disease in
conjunction with a decision taken by the attending physician
to treat the patient with a full curative course of anti-
tuberculosis chemotherapy.
Results
Three hundred and eighty one cases of TB were notified in
2001, giving a notification rate of 9.7/100,000 population.
This represents a 3.5% decrease on the corresponding figure
in 2000 (395 cases: 10.1/100,000) (table 1) and is the lowest
annual number of cases reported in Ireland to date.
The highest age standardised TB incidence rates were reported
in the Eastern Regional Health Authority and the Southern
Health Board, both at 12.4 per 100,000 population (table 2).
The Midland Health Board had the lowest rate at 3.1/100,000.
In addition, the rates in the MHB, SEHB and NWHB were
significantly lower than the national age standardised
incidence rate (9.7 per 100,000).
Age and sex distribution of cases
Two hundred and forty one cases were male (63.3%) and 139
were female (36.5%). The gender of one case was not
recorded. The average age of those diagnosed with TB was
45.6 years with a range from one to 93 years and the highest
rate was observed in those over 65 years (at 20.6/100,000
population). Almost a quarter of cases occurred in those aged
65 and over (n=91). This is a 30% decrease when compared
with TB data from 2000 (n=130). The age- and sex-specific
incidence rates per 100,000 population in Ireland, in 2001 are
illustrated in figure 1.
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Figure 1: Age- and sex-specific TB incidence rates in Ireland, 2001
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Geographic origin
Sixty three (16.5%) of the patients diagnosed with TB were
born outside Ireland. This represents a 43.2% increase on TB
figures from 2000 (n = 44). Twenty seven were born in Africa,
23 in Asia, nine in Europe, one in South America. The country
of origin was unknown in three cases.
Diagnostic details
Of the 381 TB notifications, 224 (58.8%) were definite cases
which were culture confirmed. Two hundred and fifty three
cases were pulmonary (66.4%), 92 cases were extrapulmonary
(24.1%) and 35 cases were pulmonary and extrapulmonary TB
(9.2%). In one case the TB site was unspecified (0.03%). The
diagnostic breakdown in each health board is shown in
table 3.
Of the 288 TB cases with a pulmonary disease component,
128 (44.4%) were sputum positive.
Of the 224 culture-confirmed cases, 204 (96.2%) of isolates
were M. tuberculosis, seven (3.3%) were M. bovis and one
(0.5%) was M. africanum. The isolate was not specified in 12
culture positive cases.
Resistance
Resistance was documented in fourteen cases out of a total
of 204 M. tuberculosis isolates (6.9%). In 2001, two multi-
drug resistant TB cases, defined as resistance to at least
isoniazid and rifampicin, were notified. Three cases were
resistant to isoniazid and streptomycin and one case was
resistant to isoniazid, streptomycin and ethambutol. Mono-
resistance to isoniazid was recorded in four cases, mono-
resistance to streptomycin in three cases and mono-
resistance to pyrazinamide in one case. Six of the drug-
resistant cases were born outside Ireland.
HIV status
Seven patients were reported as having HIV in association
with TB. Six of these cases had pulmonary TB and one had
extrapulmonary TB. Five were culture positive for M.
tuberculosis. None of these cases were resistant to any
standard TB drugs. There were two deaths in this group, one of
which was attributed to TB.
Outcome
The outcome was recorded in 228 cases (59.8%) in 2001. One
hundred and ninety of these cases (83.3%) completed
treatment. Eleven patients (4.8%) were recorded as being lost
to follow up. There were 20 deaths (8.8%) recorded, of which
five were attributed to TB. A summary profile of the
epidemiology of TB in Ireland from 1999 to 2001 is shown in
table 4.
Discussion
In Ireland, the year 2001 saw a 3.5% decrease in the TB
notification rate when compared to 2000. There was an
increase in the percentage of cases who were born outside
Ireland (16.5% vs 11.1% in 2000). However, this percentage
remains low when compared to that in other European
countries. Differences in age standardised TB incidence rates
persist between health board areas (figure 2). Although the
highest rate was observed in the 65+ age group
(20.6/100,000 population), there was a 30% decrease in this
age group in 2001 (n=91) when compared with 2000
Table 1. Notified TB cases in Ireland, 1991 – 2001, with 3-year moving average, 
1992 - 2000
Year Number Crude rate per 100,000 3 year moving average
1991 640 18.2 
1992 604 17.1 612
1993 598 16.9 581
1994 524 14.5 526
1995 458 12.6 469
1996 434 12.0 436
1997 416 11.5 423
1998 424 11.7 433
1999 469 12.9 439
2000 395 10.1 410
2001 381 9.7 
Table 2: Total and age standardised incidence rates [95% confidence interval (CI)] 
for TB in Ireland by health board, 2001
Health Board TB cases Age standardised incidence rate 95% CI
ERHA 173 12.4 10.4–14.2
MHB 7 3.1 0.8-5.3
MWHB 24 6.9 4.2-9.7
NEHB 38 11.3 7.7-14.9
NWHB 13 5.4 2.5-8.4
SEHB 20 4.7 2.7-7.0
SHB 72 12.4 9.6-15.3
WHB 34 8.5 5.6-11.4
Ireland 381 9.7 8.7-10.6
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(n=130). In 2001, the ERHA and the SHB had the highest
rates of TB. In 2000, TB rates were highest in the MWHB and
the SHB. Rates were below the national average in the MHB,
MWHB, NWHB, SEHB and WHB in 2001. There were two
cases of multi-drug resistant TB which is the same as the
2000 figure. As in 2000, only sixty percent of all cases had
outcome information recorded.
In the future, the introduction of the Computerised Infectious
Disease Reporting (CIDR) system will provide a framework
whereby all existing TB data from a variety of media (paper
form, Epi Info 6 and Epi 2000 databases) will be consolidated
into a single database, allowing comparisons between data
over a number of years. In addition, CIDR will facilitate more
comprehensive integration of clinical and laboratory TB
notifications resulting in more timely reporting in the future.
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Table 4. Summary of epidemiology of TB in Ireland, 1999 – 2001
 1999 2000 2001
Total number of cases 469 395 381
Notification rate (per 100,000) 12.9 10.9 9.7
Foreign born TB patients 65 44 63
% culture positive patients 55.4 58.0 58.8
M. tuberculosis 242 222 204
M. bovis  11 2 7
M. africanum – 3 1
% smear positive pulmonary cases 38.0 47.2 44.4
Monoresistance to isoniazid 4 2 4
Monoresistance to streptomycin 0 1 3
Monoresistance to pyrizinamide 0 1 1
Multi drug resistant cases  2 2 2
Deaths attributed to TB 9 6 5
Table 3: Diagnostic categories of TB by health board, 2001
Health Board Pulmonary P+E Extrapulmonary Unspecified Total
ERHA 115 16 41 1 173
MHB 5 1 1 0 7
MWHB 17 1 6 0 24
NEHB 24 5 9 0 38
NWHB  9 2 2 0 13
SEHB 12 3 5 0 20
SHB 44 7 21 0 72
WHB 27 0 7 0 34
Total 253 35 92 1 381
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Key Points
• During 2002, there were 364 newly diagnosed cases of
HIV infection, a 22% increase in the number of cases
diagnosed in 2001.
• The cumulative total of HIV infections reported in
Ireland to the end of December 2002 is 3,009.
• The majority of cases diagnosed in 2002 (63.5%) were
among heterosexuals. The number of cases among
heterosexuals increased by 34% between 2001 and
2002.
• During 2002, over 80% of the cases were between 20
and 40 years of age. The mean age was 30.8 years.
• Of the 364 cases diagnosed in 2002, 198 (54.4%) were
female and 165 (45.3%) were male. The mean age at
HIV diagnosis in males was 34.0 years and 28.1 years in
females.
• One hundred and eighty six (51.1%) of the newly
diagnosed cases in 2002 were born in sub-Saharan
Africa.
• In 2002, 57.6% of cases were resident in the Eastern
Regional Health Authority (ERHA) at HIV diagnosis.
• There were five cases of AIDS reported to the National
Disease Surveillance Centre in Ireland in Quarter 3&4
2002. This brings the number of AIDS cases reported in
2002 to 12 and the total number of AIDS cases reported
in Ireland to date to 731.
• There were two reports of AIDS related deaths in
Quarter 3&4 2002. This brings the total of AIDS related
deaths reported in 2002 to 4 and the total number of
AIDS related deaths which have been reported in Ireland
to date to 369.
HIV and AIDS Surveillance 
in Ireland, 2002
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Background
At the end of 2002, it was estimated that 42 million around
the world were living with HIV/AIDS, including the five million
people who acquired HIV in 20021. HIV/AIDS is the leading
cause of death in Africa and is the fourth biggest global killer.
During 2002, the epidemic is estimated to have claimed 3.1
million lives1. Sub-Saharan Africa remains the most affected
region of the world with 70% of people living with HIV/AIDS.
Current projections suggest that globally an additional 45
million will become infected between 2002 and 2010, unless
the world succeeds in mounting a drastically expanded global
prevention effort1.
Increasing numbers of people newly diagnosed with HIV have
been seen in Ireland since the late 1990s. The national HIV
case based reporting system which was introduced in Ireland
in July 2001, on a recommendation of the National AIDS
Strategy Committee2, aims to ensure the collection of
accurate and complete epidemiological data on the
distribution and mode of transmission of HIV infection. It also
enables linkage between reports of HIV infection and AIDS
which will allow the progression of the disease to be
monitored.
Methods
The national HIV case based reporting system has been
operational since July 2001. For every newly confirmed HIV
diagnosis, the National Virus Reference Laboratory (NVRL)
send a partially completed HIV/AIDS surveillance report form
to the clinician who requested the confirmatory test. A copy
of the surveillance report form is also sent to the Director of
Public Health (or nominee on his/her behalf) where the
patient resides. The clinician completes the form and returns
it to the relevant Director of Public Health. The forms are then
forwarded to the NDSC where national figures are collated.
Analysis of HIV and AIDS data is carried out by the NDSC
every six months and reports are provided to clinicians,
microbiologists, public health personnel, DoHC, non-
governmental organizations (NGOs) and other interested
parties. The report is also posted on the NDSC website. In
addition, every six months, a summary of the data is
forwarded to EuroHIV, the European Centre for the
Epidemiological Monitoring of AIDS.
Results
A: HIV Infection
There were 364 newly diagnosed HIV infections in Ireland in
2002. This compares to 299 cases diagnosed in 2001, and
represents a 22% increase. This brings the cumulative total of
HIV cases reported in Ireland to December 2002 to 3,009.
Figure 1 shows the number of cases diagnosed annually in
Ireland from 1990 to 2002.
Exposure Category 
A breakdown by exposure category in 2002 can be seen in
Table 1. This is compared to the breakdown by exposure
category in 2001. Figure 2 shows the trends in newly
diagnosed cases among the three major risk groups since
1995.
The majority of cases diagnosed in 2002 (63.5%) were in
heterosexuals. The number of cases in heterosexuals increased
by 34% between 2001 and 2002. There were 46 new
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Figure 1: Annual number of HIV infections (1990 to 2002)
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Figure 2: Newly diagnosed HIV infections in Ireland among Heterosexuals, 
MSM and IDUs (1995 to 2002) 
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diagnoses in men who have sex with men (MSM) during
2002. This compares with 73 diagnosed in 2001 and
represents a 37% decrease. There were 50 new diagnoses
among injecting drug users (IDU) during 2002. This compares
with 38 diagnosed in 2001 and represents a 32% increase.
There were 8 children diagnosed with HIV infection during
2002. In addition to these 8 children, there were 119 babies
born to a HIV infected mother during 2002. Their infection
status is indeterminate (i.e. they do not meet the criteria for
HIV infection and are less than 18 months of age at time of
test or they were born to a HIV infected mother but their
antibody status is unknown).
Age Distribution and Sex 
A breakdown of cases by exposure category and sex is shown
in Table 2. Of the 364 cases diagnosed in 2002, 198 (54.4%)
were female and 165 (45.3%) were male. Seventy two
percent of all newly diagnosed heterosexual cases were
female. Sixty six percent of all newly diagnosed IDUs cases
were male.
A breakdown of cases by exposure category and age group is
shown in Table 3. Over 80% of the cases were between 20
and 40 years of age and the mean age of cases was 30.8
years. The mean age in females was 28.1 years and in males
was 34.0 years, a difference of 5.9 years. The mean age of
cases in heterosexuals was 30.0 years, in IDU was 30.6 years
and in MSM was 38.5 years.
Geographic Origin
Data on the geographic origin of HIV cases are available since
the introduction of HIV case based reporting in July 2001.
Geographic origin is based on the country of birth for adults
and on the country of birth of the mother for children.
Analysis of 2002 cases by geographic origin is shown in Figure
3 and 4. Of the 364 cases diagnosed in 2002, 186 (51.1%)
were born in sub-Saharan Africa and 92 (25.3%) were born in
the Republic of Ireland (figure 3). The majority of
heterosexuals (76.6%) diagnosed in 2002 were born in sub-
Saharan Africa. The majority of MSM (65.2%) and IDUs
(70.0%) diagnosed in 2002 were born in the Republic of
Ireland.
The majority of women (70.7%) diagnosed in 2002 were born
in sub-Saharan Africa. Forty two percent of males were born in
the Republic of Ireland.
Area of Residence
A breakdown of HIV cases by area of residence is shown in
Table 4. Of the newly diagnosed cases in 2002, 57.7% of
cases were resident in the Eastern Regional Health Authority
(ERHA) at HIV diagnosis. The area of residence was unknown
for 20% of the newly diagnosed cases. By exposure category,
60.6% of heterosexuals, 67.4% of MSM and 72.0% of IDUs
were resident in the ERHA.
B: AIDS 
AIDS cases 
There were five cases of AIDS reported to the National
Disease Surveillance Centre during Quarter 3&4 2002. This
brings the number of AIDS cases reported in 2002 to 12 and
the total number of AIDS cases reported in Ireland to the end
of December 2002 to 731. Figure 5 illustrates the number of
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Figure 3. Geographic origin of HIV cases by exposure category (2002)
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Figure 4. Geographic origin of HIV cases by sex (2002)
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reported AIDS cases in Ireland since the start of the epidemic.
A breakdown of AIDS cases reported in 2002 and all AIDS
cases reported to date is shown in Table 5. Seven of the
twelve cases (58%) reported in 2002 were in heterosexuals.
There were two cases reported in IDUs and two cases
reported in MSM. Of the 12 cases reported during 2002, 9
(75%) were male and 3 (25%) were female. Of the 12 cases
reported during 2002, the mean age at AIDS diagnosis was
41.4 years.
AIDS related deaths
There were two AIDS related deaths reported to the National
Disease Surveillance Centre during Quarter 3&4 2002. This
brings the total of AIDS related deaths reported in 2002 to 4
and the total number of AIDS related deaths which have been
reported in Ireland to date to 369. It is important to note that
there is a significant delay in reporting AIDS related deaths
and the number reported may not accurately reflect the true
number.
Discussion
Increasing numbers of people newly diagnosed with HIV
infection have been seen in Ireland since the late 1990s.
Between 1998 and 2002, there was over a three-fold increase
in the number of newly diagnosed HIV infections. It is
important to note that these figures do not represent the
numbers of people infected with the HIV virus in Ireland but
rather provide information on the number of new diagnoses
in a given time period. The number of new diagnoses is
dependent on patterns of HIV testing and reporting.
Heterosexual transmission accounts for an increasing share of
new HIV infections in Ireland and over the last five years, the
number of newly diagnosed HIV infections among
heterosexuals has increased six-fold. During 2002, the
majority of heterosexual cases were born in sub-Saharan
Africa with 10% born in Ireland. Sub-Saharan Africa is the
region of the world worst affected by the HIV/AIDS epidemic
with 29.4 million people currently living with HIV/AIDS,
including approximately 3.5 million people newly infected in
20021. Therefore, the number of cases of HIV infection
diagnosed among people of sub-Saharan African origin is not
unexpected. It is important to remember that people from
sub-Saharan Africa do not form a homogenous group and
include students, immigrant workers, refugees, economic
migrants, asylum seekers and others. The epidemiology of the
HIV epidemic in Ireland mirrors the situation in many other
Western European countries where persons originating from
sub-Saharan Africa bear an increasing share of the burden of
the epidemic.3 Heterosexual transmission is now the most
frequent transmission mode in Western Europe.3
There was a decrease in the number of cases reported in the
MSM category, from 73 in 2001 to 46 in 2002. However, this
decrease must be interpreted with caution as the numbers
involved are small and it remains to be seen whether this
downward trend will be sustained in the future. Concern has
been raised in the United States over a resurgence of risky
sexual behaviours and infections among men who have sex
with men4 and there have been a number of reported
outbreaks of syphilis in MSM in countries in Europe, including
Ireland.5, 6
Table 3: Newly diagnosed HIV infections in Ireland by exposure category and age group (2002)
Age group (years)           Exposure Category
Heterosexual MSM IDU Children Haemophiliac Other Undetermined Total
0-9 - - - 8 - - - 8
10-19 14 - 1 - - - - 15
20-29 112 8 24 - - - 16 160
30-39 86 22 22 - - 1 5 136
40-49 14 8 2 - 1 1 3 29
50-59 5 8 1 - - 2 - 16
60-69 - - - - - - - -
Total 231 46 50 8 1 4 24 364
Table 1: Newly diagnosed HIV infections in Ireland by exposure category (2001 and 2002)
Exposure category   2001            2002
Number % Number %
Heterosexual 173 57.9 231 63.5
MSM 73 24.4 46 12.6
IDU 38 12.7 50 13.7
Children 6 2.0 8 2.2
Transfusion Recipient 2 0.7 - -
Haemophiliac - - 1 0.3
Other - - 4 0.6
Undetermined 7 2.3 24 6.6
Total 299 100 364 100
Table 2: Newly diagnosed HIV infections in Ireland by exposure category and sex (2002)
Exposure category       Sex
Male Female Unknown Total 
Heterosexual 64 167 - 231
MSM 46 - - 46
IDU 3 17 - 50
Children 5 3 - 8
Haemophiliac - 1 - 1
Other 4 - - 4
Undetermined 3 10 1 24
Total 165 198 1 364
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Among IDUs, there was a 32% increase in the numbers of
cases diagnosed, from 38 in 2001 to 50 in 2002. However, as
the numbers involved are small and the figures tend to
fluctuate from year to year (for example, between 2000 and
2001, there was a 54% increase in the number of cases),
these figures need to be interpreted with caution.
The majority of people diagnosed with HIV infection in 2002
were aged between 20 and 40 years. There was a notable
difference in age distribution between the sexes and females
were younger at HIV diagnosis then males. This trend has
been seen worldwide and it has been suggested that women
may be at risk for infection at an earlier age due to infection
by older sexual partners.7 Women made up nearly half of the
HIV-infected people globally in 2002.1 In addition, the
availability of routine antenatal HIV screening in Ireland and
differences in health seeking behaviour may result in women
being diagnosed more promptly than their male counterparts.
It has been clearly shown that transmission of the HIV virus
from mother to child can be dramatically reduced or
prevented by antenatal screening and treatment of HIV
positive women with antiretroviral drugs and by careful
management of the delivery.8 In April 1999, the Department
of Health and Children officially launched the national linked
antenatal HIV screening programme in Ireland. This
programme recommends that HIV testing be offered to all
women who attend for antenatal care. During 2002, 119
babies were born to a HIV infected mother. The infection
status of these babies is indeterminate. This reflects the
effectiveness of the antenatal HIV screening programme and
treatment and follow up services for HIV infected pregnant
women in Ireland in preventing transmission of the infection
from mother to baby.
A disproportionately high number of newly diagnosed HIV
infections were resident in the ERHA area. In 2002, the rate in
the ERHA was 149.8 per million population  compared to 32.2
per million population in the rest of the country. In particular,
the rate of IDUs in the ERHA area was 25.7 per million
population compared to 2.4 per million population in the rest
of the country.
The introduction of highly active antiretroviral therapy
(HAART) during 1996 and 1997 led to a well-documented
reduction in mortality and risk of AIDS-defining illnesses in
countries where HAART is available9. The number of AIDS
cases and AIDS related deaths in Ireland has declined in all
exposure categories since the mid 1990’s10. However, it is
important to note that there is a significant delay in reporting
AIDS cases and AIDS related deaths and the number reported
in 2002 is likely to be an underestimation of the number
diagnosed.
Table 4: Newly diagnosed HIV infections in Ireland by exposure category and area 
of residence at diagnosis (2002)
Exposure Category         Area
ERHA Non-ERHA Unknown Total 
Heterosexual 140 64 27 231
MSM 31 10 5 46
IDU 36 5 9 50
Children 3 3 2 8
Haemophiliac - 1 - 1
Other 3 1 - 4
Undetermined 3 2 19 24
Total 210 81 73 364
Table 5: AIDS cases reported in Ireland by exposure category (2002)
Exposure category   2001            Total
Number % Number %
Heterosexual 7 58.3 108 14.8
MSM 2 16.7 252 34.5
IDU 2 16.7 285 39.0
Haemophiliacs - - 33 4.5
Transfusion Recipient - - 3 0.4
IDU+ MSM - - 10 1.4
Children - - 25 3.3
Other/Undetermined 1 8.3 15 2.1
Total 12 100 731 100.0
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Figure 5: AIDS cases reported in Ireland (1983 to 2002)
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Sexually Transmitted Infections 
in Ireland, 2001
Key Points
• Total number of notified STIs increased by 9.4% in 2001,
compared to 2000.
• The highest increases recorded during 2001, compared
to 2000 were for syphilis (506.5%), infectious hepatitis
B (160.0%), genital herpes simplex (23.1%), Chlamydia
trachomatis (22.8%) and gonorrhoea (20.3%).
• The three most commonly notified STIs in 2001 were
ano-genital warts, Chlamydia trachomatis and non-
specific urethritis.
Introduction
During 2001, 14 sexually transmitted infections (STIs) were
legally notifiable in Ireland: ano-genital warts, candidiasis,
chancroid, Chlamydia trachomatis, genital herpes simplex,
gonorrhoea, granuloma inguinale, infectious hepatitis B,
lymphogranuloma venereum, molluscum contagiosum, non-
specific urethritis, Pediculosis pubis, syphilis and
trichomoniasis. This report details the 14 STIs notifiable during
2001.
Aggregate data on the number of notified STIs from
Departments of Public Health is collated quarterly.
Departments of Public Health are notified of STIs mostly from
STI clinics. The number of STIs notified by quarter, health
board, age group and gender for 2001 are presented in this
report. It should be noted that cases of infectious hepatitis B
that are sexually transmitted may also be reported through
the weekly infectious disease report published by NDSC.
During 2001, the total number of notified STIs increased by
9.4%, when compared to 2000.
Materials and Methods
Aggregate STI data is collected quarterly from STI clinics
including age group, gender and diagnosis. Rates per 100,000
population for 1989 to 1993 are based on the 1991
population census; rates for 1994 to 1999 are based on the
1996 population census and rates for 2000 and 2001 are
based on the 2002 population census.
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Results
Notified STIs between 1989 and 2001
During 2001, 9703 cases of STIs were notified compared to
8869 in 2000, a 9.4% increase (table 1). Notified STIs have
been increasing steadily each year since 1994, increasing by
103.0% between 1995 and 2001 and by 335.5% between
1989 and 2001. A total of 69003 STIs have been notified
since 1989, 14.1% of these were notified in 2001. The number
of STIs notified in 2001 is the highest number reported in any
year on record. Notified cases of ano-genital warts,
candidiasis, C. trachomatis, genital herpes simplex, gonorrhoea,
infectious hepatitis B and syphilis all increased during 2001,
compared to 2000. Significantly, notified cases of syphilis
increased by 506.5% and infectious hepatitis B by 160.0%.
Chancroid, molluscum contagiosum, non-specific urethritis,
P. pubis and trichomoniasis decreased in 2001, compared to
2000. No cases of granuloma inguinale or lymphogranuloma
venereum were notified in 2001 or 2000. The cumulative rate
per 100,000 population for all notified STIs increased in 2001
to 247.7 per 100,000 population; compared to a rate of 226.4
per 100,000 in 2000 (table 9).
Notified STIs by quarter during 2001
The total number of notified STIs in 2001 peaked during Q3
(tables 2 & 3). Ano-genital warts, chancroid and genital herpes
simplex peaked during Q1 and gonorrhoea, molluscum
contagiosum and non-specific urethritis during Q2. P. pubis
peaked during quarters 1 and 2 in 2001 and candidiasis and
syphilis during Q3 2001. C. trachomatis, infectious hepatitis B
and trichomoniasis reached their highest numbers for 2001
in Q4.
Notified STIs by health board during 2001
During 2001, 50.7% (4920) of all STI notifications were from
the ERHA, 14.2% (1380) from the MWHB, 11.4% (1110) from
the SHB, 8.8% (856) from the WHB, 8.7% (846) from the
SEHB, 6.1% (587) from the NWHB, 0.03% (3) from the MHB
and 0.01% (1) from the NEHB (table 4). It is important to
note that STI surveillance is mainly clinic based and there are
currently no STI clinics in the MHB and NEHB.
Notified STIs by age group & gender during 2001
For 2001, where the age group was known (n=5195), 13.6%
(706) of notified STIs were 0 to 19 years old, 61.5% (3195)
were 20 to 29, 17.8% (924) were 30 to 39 and 7.1% (370)
were aged over 40 years of age. For all STIs, the 20-29 year
age group represented the largest age group, with the
exception of syphilis where the majority of cases were aged
between 30 and 39 years of age (tables 5, 6 & 7).
Fifty-two percent (4944) of all notified STIs were amongst
males during 2001, whilst 48.8% (4732) were amongst
females. Data was not available for 27 cases. The majority of
cases of syphilis (82.4%), non-specific urethritis (77.4%),
infectious hepatitis B (76.9%), gonorrhoea (75.9%), P. pubis
(68.0%) and molluscum contagiosum (61.3%) were amongst
males. The majority of cases of chancroid (100.0%),
candidiasis (85.0%), trichomoniasis (76.6%), genital herpes
simplex (62.8%), C. trachomatis (52.9%) and ano-genital
warts (51.2%) were amongst females (tables 5, 6 & 7).
Disease-specific trends (figure 1 & tables 8 & 9)
Please note that quarterly STI data is only available from Q1
1995 & annual STI data is only available from 1989.
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Figure 1a
Figure 1: Number of notifications of ano-genital warts, non-specific urethritis, C. trachomatis,
genital herpes simplex, gonorrhoea, syphilis & infectious hepatitis B, by year between 1989 
and 2001.
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Ano-genital warts
Ano-genital warts accounted for the majority (41.2%) of all
STI notifications in 2001. Notifications of ano-genital warts
have increased each year since 1992. In 1989, 505
(14.3/100,000) cases were notified, increasing to 1972
(54.4/100,000) in 1995 and 3993 (101.9/100,000) in 2001.
From Q1 2000 to Q4 2001, notified cases of ano-genital
warts have remained stable, with a mean of 966 cases per
quarter. In 2001, males accounted for 48.8% of cases and
females for 51.2% with gender unknown for 0.05%. Where
the age group was known (in 55.5% of cases), 0-19 year olds
accounted for 14.0% of cases, 65.4% of cases were 20-29,
16.1% were 30-39 and 4.6% were aged 40 years or older.
Candidiasis
Between 1990 and 1997, the mean number of notified
candidiasis cases was 1293 per year, peaking in 1997 at 1521
cases (42.0/100,000). Notified cases have decreased each year
since 1997, reaching 1095 in 2000 (28.0/100,000). During
2001, this decreasing trend was reversed, with 29.4
candidiasis cases per 100,000 population notified. In Q3 2001,
8.9 candidiasis cases per 100,000 population were notified,
the highest rate for any quarter since Q4 1998 (9.5/100,000).
Candidiasis accounted for 11.9% of all STI notifications in
2001. In 2001, males accounted for 14.8% of cases and
females for 85.0%. Where the age group was known (in 55.3%
of cases), 0-19 year olds accounted for 15.7% of cases, 20-29
year olds for 48.9%, 30-39 year olds for 20.6% and 14.8%
were aged 40 years or older.
Chancroid
One case of chancroid was notified in 2001, in Q1. With the
exception of the year 2000 (when 16 cases were notified),
between 0 and 3 cases of chancroid were notified each year
between 1989 and 1999.
Chlamydia trachomatis
During Q4 2001, 454 cases of C. trachomatis were notified,
the highest number notified in any one quarter on record.
From 1989 to 1995 the number of notified cases of
C. trachomatis generally remained stable fluctuating around a
mean of 205 per year. In 1995 there was a marked increase of
84.2% on the previous year (from 133 cases, 3.7/100,000 to
245 cases, 6.8/100,000). Since 1995 there has been an
increasing number of cases reported each year reaching 1649
in 2001 (42.1/100,000). Notified cases have increased by
573.1% between 1995 and 2001. During 2001, the number of
male cases increased by 15.6% and the number of female
cases by 28.4%, when compared to 2000. In 2001, where the
age group was known (in 51.1% of cases), 0-19 year olds
accounted for 18.2% of cases, 20-29 year olds for 66.2%, 30-
39 year olds for 12.1% and 3.6% were 40 years or older.
Genital herpes simplex
There was a 23.1% increase in the number of notified cases of
genital herpes simplex during 2001 compared to 2000.
Genital herpes simplex cases increased from 78 (2.2/100,000)
in 1989 to 198 (5.5/100,000) in 1995 and 331 (8.5/100,000)
in 2001. During 2001, the number of male cases increased by
34.8% and the number of female cases by 15.6%, when
compared to 2000. In 2001, where the age group was known
(in 41.1% of cases), 0-19 year olds accounted for 15.4% of
cases, 20-29 year olds for 55.9%, 30-39 year olds for 20.6%
and 8.1% were 40 years or older.
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Figure 1c
Genital Herpes Simplex
0
50
100
150
200
250
300
19
89
19
90
19
91
19
92
19
93
19
94
19
95
19
96
19
97
19
98
19
99
20
00
20
01
Year of notification
N
um
be
r 
of
 c
as
es
Figure 1d
SyphilisGonorrhoea
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Gonorrhoea
Reported notifications of gonorrhoea have increased
consistently since 1996; increasing from 83 (2.3/100,000) in
1996 to 349 (8.9/100,000) in 2001. Notifications of
gonorrhoea have remained high since Q3 2000, when there
was a 92.0% increase in the number of cases (from 50 in Q2
2000 to 96 in Q3 2000). During 2001, gonorrhoea cases
increased by 20.3% compared to 2000. However in Q4 2001,
74 cases were notified, the lowest number since Q2 2000. In
2001, males accounted for 75.9% of cases and females for
23.5%. Where the age group was known (37.8%), 0-19 year
olds accounted for 10.6% of cases, 20-29 year olds for 57.6%,
30-39 year olds for 21.2% and those 40 years or older for
10.6% of cases in 2001.
Granuloma inguinale
No cases of granuloma inguinale were notified during 2001.
The number of cases of granuloma inguinale has ranged from
0 to 6 cases per year, between 1989 and 2000.
Infectious hepatitis B
Between 1989 and 1999, infectious hepatitis B cases reported
through the STI quarterly notification system ranged from 0
to 4 cases per year. Between 1999 and 2000, there was a
650.0% increase in notifications, when 15 cases were notified
in the last 2 quarters of 2000. During 2001, this increase has
continued with 39 cases reported, a 160.0% increase on 2000.
Thirteen cases were notified in Q4 2001, the highest number
notified in any one quarter on record. During 2001, the
number of male cases increased by 130.8% and the number
of female cases increased by 350.0%, compared to 2000. In
2001, where age group data was known (in 30.8% of cases),
66.7% of cases were aged between 20 and 29 years and
33.3% of cases were aged between 30-39 years.
Lymphogranuloma venereum
No cases of lymphogranuloma venereum were notified during
2001. The number of notified cases of lymphogranuloma
venereum ranged from 0 to 5 cases per year, between 1989
and 2000.
Molluscum contagiosum
Notified cases of molluscum contagiosum have increased
from 31 (0.9/100,000) in 1989, to 59 (1.6/100,000) in 1995
and 111 (2.8/100,000) in 2001. During 2001, the number of
molluscum contagiosum notifications decreased by 5.9%
compared to 2000. Nineteen notified cases of molluscum
contagiosum were reported in Q3 2001 and again in Q4
2001, the lowest quarterly levels since Q3 1999. During 2001,
the number of male cases increased by 4.6% and female
cases decreased by 17.3%, compared to the same period in
2000. In 2001, where the age group was known (51.4% of
cases), 0-19 year olds accounted for 10.5% of cases, 66.7%
were 20-29, 17.5% were 30-39 and 5.3% were aged 40 years
or older.
Non-specific urethritis 
Non-specific urethritis notifications increased marginally
between 1990 and 1995, from 738 (20.9/100,000) in 1990 to
781 (21.5/100,000) in 1995, a 5.8% increase. Between 1995
and 2001, notified cases increased by 109.2%, to 1634
(41.7/100,000) in 2001. However compared to 2000, notified
cases decreased in 2001, by 5.3%. During 2001, the number
of male and female cases decreased by 4.5% and 8.5%,
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Table 1: Notified sexually transmitted infections for 2001 and 2000
Sexually Transmitted Infection 2001 2000 Increase % Increase
Ano-Genital Warts 3993 3735 258 6.91
Candidiasis 1150 1095 55 5.02
Chancroid 1 16 -15 -93.75
Chlamydia Trachomatis 1649 1343 306 22.78
Genital Herpes Simplex 331 269 62 23.05
Gonorrhoea 349 290 59 20.34
Granuloma Inguinale 0 0 0 0.00
Infectious Hepatitis B 39 15 24 160.00
Lymphogranuloma Venereum 0 0 0 0.00
Molluscum Contagiosum 111 118 -7 -5.93
Non-Specific Urethritis 1634 1726 -92 -5.33
Pediculosis Pubis 103 138 -35 -25.36
Syphilis 279 46 233 506.52
Trichomoniasis 64 78 -14 -17.95
Total 9703 8869 834 9.40
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Table 2: Notified sexually transmitted infections by quarter from Q1 1999 to Q4 2001
Sexually Transmitted Infection 1999 2000 2001
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 
 Ano-Genital Warts 762 905 671 711 953 952 832 998 1060 1025 974 934
 Candidiasis 269 263 273 300 317 262 272 244 222 282 347 299
 Chancroid 0 0 0 1 0 3 5 8 1 0 0 0
 Chlamydia Trachomatis 169 295 152 253 309 346 310 378 375 379 441 454
 Genital Herpes Simplex 94 53 38 90 75 50 74 70 97 73 72 89
 Gonorrhoea 21 55 59 40 54 50 96 90 86 100 89 74
 Granuloma Inguinale 0 0 1 0 0 0 0 0 0 0 0 0 
 Infectious Hepatitis B 2 0 0 0 0 0 5 10 7 10 9 13
 Lymphogranuloma Venereum 0 0 2 0 0 0 0 0 0 0 0 0
 Molluscum Contagiosum 23 29 10 21 33 37 21 27 35 38 19 19
 Non-Specific Urethritis 243 389 304 329 425 385 404 512 400 421 407 406
 Pediculosis Pubis 35 25 21 32 37 38 25 38 30 30 19 24
 Syphilis 2 1 1 2 2 7 21 16 49 72 87 71
 Trichomoniasis 10 15 9 13 18 15 27 18 15 11 16 22
 Total 1630 2030 1541 1792 2223 2145 2092 2409 2377 2441 2480 2405
Table 3: Notified sexually transmitted infections per 100,000* population by quarter from Q1 1999 to Q4 2001
Sexually Transmitted Infection 1999 2000 2001
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 
 Ano-Genital Warts 21.01 24.96 18.50 19.61 24.33 24.30 21.24 25.48 27.06 26.17 24.86 23.84
 Candidiasis 7.42 7.25 7.53 8.27 8.09 6.69 6.94 6.23 5.67 7.20 8.86 7.63
 Chancroid 0.00 0.00 0.00 0.03 0.00 0.08 0.13 0.20 0.03 0.00 0.00 0.00
 Chlamydia Trachomatis 4.66 8.14 4.19 6.98 7.89 8.83 7.91 9.65 9.57 9.68 11.26 11.59
 Genital Herpes Simplex 2.59 1.46 1.05 2.48 1.91 1.28 1.89 1.79 2.48 1.86 1.84 2.27
 Gonorrhoea 0.58 1.52 1.63 1.10 1.38 1.28 2.45 2.30 2.20 2.55 2.27 1.89
 Granuloma Inguinale 0.00 0.00 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
 Infectious Hepatitis B 0.06 0.00 0.00 0.00 0.00 0.00 0.13 0.26 0.18 0.26 0.23 0.33
 Lymphogranuloma Venereum 0.00 0.00 0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
 Molluscum Contagiosum 0.63 0.80 0.28 0.58 0.84 0.94 0.54 0.69 0.89 0.97 0.49 0.49
 Non-Specific Urethritis 6.70 10.73 8.38 9.07 10.85 9.83 10.31 13.07 10.21 10.75 10.39 10.36
 Pediculosis Pubis 0.97 0.69 0.58 0.88 0.94 0.97 0.64 0.97 0.77 0.77 0.49 0.61
 Syphilis 0.06 0.03 0.03 0.06 0.05 0.18 0.54 0.41 1.25 1.84 2.22 1.81
 Trichomoniasis 0.28 0.41 0.25 0.36 0.46 0.38 0.69 0.46 0.38 0.28 0.41 0.56
 Total 44.95 55.98 42.50 49.42 56.75 54.76 53.41 61.50 60.68 62.31 63.31 61.40
Table 4: Notified sexually transmitted infections by health board for 2001
Sexually Transmitted Infection ERHA MHB MWHB NEHB NWHB SEHB SHB WHB Total
Ano-Genital Warts 1893 0 499 0 277 354 586 384 3993
Candidiasis 532 0 145 0 57 59 100 257 1150
Chancroid 1 0 0 0 0 0 0 0 1
Chlamydia Trachomatis 905 1 219 0 42 177 197 108 1649
Genital Herpes Simplex 225 0 25 0 6 29 22 24 331
Gonorrhoea 240 0 24 0 11 33 27 14 349
Granuloma Inguinale 0 0 0 0 0 0 0 0 0
Infectious Hepatitis B 27 0 6 0 0 4 2 0 39
Lymphogranuloma Venereum 0 0 0 0 0 0 0 0 0
Molluscum Contagiosum 57 0 2 0 5 17 19 11 111
Non-Specific Urethritis 723 0 430 0 172 151 130 28 1634
Pediculosis Pubis 44 0 10 0 8 10 13 18 103
Syphilis 230 2 15 1 7 8 9 7 279
Trichomoniasis 43 0 5 0 2 4 5 5 64
Total 4920 3 1380 1 587 846 1110 856 9703
NDSC Annual Report 2002 33
Table 5: Notified sexually transmitted infections by age group (years) & gender for 2001
Sexually Transmitted Infection 0-19 20-29 30-39 40+ Age unknown Male Female Gender unknown Total
Ano-Genital Warts 310 1449 357 101 1776 1947 2044 2 3993
Candidiasis 100 311 131 94 514 170 978 2 1150
Chancroid 0 0 0 0 1 0 1 0 1
Chlamydia Trachomatis 153 557 102 30 807 765 872 12 1649
Genital Herpes Simplex 21 76 28 11 195 120 208 3 331
Gonorrhoea 14 76 28 14 217 265 82 2 349
Granuloma Inguinale 0 0 0 0 0 0 0 0 0
Infectious Hepatitis B 0 8 4 0 27 30 9 0 39
Lymphogranuloma Venereum 0 0 0 0 0 0 0 0 0
Molluscum Contagiosum 6 38 10 3 54 68 43 0 111
Non-Specific Urethritis 89 576 189 64 716 1265 368 1 1634
Pediculosis Pubis 10 38 9 3 43 70 31 2 103
Syphilis 3 52 62 45 117 230 47 2 279
Trichomoniasis 0 14 4 5 41 14 49 1 64
Total 706 3195 924 370 4508 4944 4732 27 9703
Table 6: Notified sexually transmitted infections per 100,000* population by age group (years) for 2001
Sexually Transmitted Infection 0-19 20-29 30-39 40+ Unknown Total
Ano-Genital Warts 27.18 226.04 59.94 6.56 45.34 101.93
Candidiasis 8.77 48.52 22.00 6.10 13.12 29.36
Chancroid 0.00 0.00 0.00 0.00 0.03 0.03
Chlamydia Trachomatis 13.41 86.89 17.13 1.95 20.60 42.10
Genital Herpes Simplex 1.84 11.86 4.70 0.71 4.98 8.45
Gonorrhoea 1.23 11.86 4.70 0.91 5.54 8.91
Granuloma Inguinale 0.00 0.00 0.00 0.00 0.00 0.00
Infectious Hepatitis B 0.00 1.25 0.67 0.00 0.69 1.00
Lymphogranuloma Venereum 0.00 0.00 0.00 0.00 0.00 0.00
Molluscum Contagiosum 0.53 5.93 1.68 0.19 1.38 2.83
Non-Specific Urethritis 7.80  89.86  31.73  4.16 18.28 41.71
Pediculosis Pubis 0.88 5.93 1.51 0.19 1.10 2.63
Syphilis 0.26 8.11 10.41 2.92 2.99 7.12
Trichomoniasis 0.00 2.18 0.67 0.32 1.05 1.63
Total 61.90 498.42 155.14 24.03 115.08 247.70
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respectively, compared to 2000. Where the age group was
known (56.2% of cases), 0-19 year olds accounted for 9.7%
of cases, 62.7% were 20-29, 20.6% were 30-39 and 7.0%
were aged 40 years or older.
Pediculosis pubis
P. pubis notifications increased gradually between 1996 and
2000, with 79 (2.2/100,000) cases notified in 1996 and 138
(3.5/100,000) cases in 2000. This increasing trend was
reversed in 2001, when 103 (2.6/100,000) cases were notified,
the lowest number notified since 1997. During 2001, 70 male
and 31 female P. pubis cases were notified, a decrease of
24.7% and 31.1%, respectively, compared to 2000. In 2001,
where the age group was known (58.3% of cases), 0-19 year
olds accounted for 16.7% of cases, 63.3% were 20-29, 15.0%
were 30-39 and 5.0% were aged 40 years or older.
Syphilis
There has been a dramatic increase in syphilis amongst men
who have sex with men (MSM) in Dublin since early 2000.
This was against a low incidence of syphilis nationally
throughout the 1990s, which in 1999 reached its lowest level
in 10 years (6 cases, 0.2/100,000). Between Q2 and Q3 2000,
syphilis notifications increased significantly by 200.0% (from
7, 0.2/100,000 to 21, 0.5/100,000). A total of 46 syphilis cases
were notified through the STI quarterly notification system in
2000, the highest number on record. This was followed by a
206.0% increase between Q4 2000 (16, 0.4/100,00) and Q1
2001 (49, 1.3/100,000). In 2001, 279 (7.1/100,000) syphilis
cases were notified, an increase of 506.5% compared to 2000,
peaking in Q3 2001. More syphilis cases were notified in the
first 3 quarters of 2001, than the yearly totals for each year
between 1989 and 2000. During 2001, 82.4% (230) of cases
were male and 16.8% (47) were female. The gender was
unknown for 2 cases. Where the age group was known (in
58.1% of cases), 0-19 year olds accounted for 1.9% of cases,
32.1% were 20-29, 38.3% were 30-39 and 27.8% were aged
40 years or older. The age group of syphilis cases is markedly
different to all other STIs notified, with the majority of cases
aged between 30 and 39 years. It is important to note that
these syphilis numbers differ slightly from those reported
through the enhanced surveillance system.
Trichomoniasis
The mean number of trichomoniasis notifications reported
between 1989 and 2001 was 68, peaking in 1991 at 163
(4.6/100,000). During 2001, 64 (1.6/100,000) cases were
notified, a decrease of 18.0% compared to 2000 when 78
(2.0/100,000) cases were notified. In 2001, 21.9% (14) of
cases were male and 76.6% (49) were female. Where the age
group was known (in 35.9% of cases), 0-19 year olds
accounted for 0.0% of cases, 60.9% were 20-29, 17.4% were
30-39 and 21.7% were aged 40 years or older.
Discussion
The three most commonly notified STIs in 2001 were ano-
genital warts, C. trachomatis and non-specific urethritis. The
highest increases recorded during 2001, compared to 2000
were for syphilis (506.5%), infectious hepatitis B (160.0%),
genital herpes simplex (23.1%), C. trachomatis (22.8%) &
gonorrhoea (20.3%).1, 2 Recently concern has been raised over
a resurgence of STIs, particularly among MSM. The rising
incidence of gonorrhoea and syphilis reported since 1995
across Europe is consistent with an increase in unsafe sex,
Table 7: Notified sexually transmitted infections per 100,000* population by gender for 2001
Sexually Transmitted Infection Male Female Unknown Total
Ano-Genital Warts 100.04 103.70 0.05 101.93
Candidiasis 8.74 49.62 0.05 29.36
Chancroid 0.00 0.05 0.00 0.03
Chlamydia Trachomatis 39.31 44.24 0.31 42.10
Genital Herpes Simplex 6.17 10.55 0.08 8.45
Gonorrhoea 13.62 4.16 0.05 8.91
Granuloma Inguinale 0.00 0.00 0.00 0.00
Infectious Hepatitis B 1.54 0.46 0.00 1.00
Lymphogranuloma Venereum 0.00 0.00 0.00 0.00
Molluscum Contagiosum 3.49 2.18 0.00 2.83
Non-Specific Urethritis 65.00 18.67 0.03 41.71
Pediculosis Pubis 3.60 1.57 0.05 2.63
Syphilis 11.82 2.38 0.05 7.12
Trichomoniasis 0.72 2.49 0.03 1.63
Total 254.04 240.08 0.69 247.70
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perhaps reflecting an increase in risk behaviour associated
with the availability of highly active anti-retroviral therapy for
HIV infection and a loss of impact of the HIV prevention
campaigns of the 1980s and early 1990s.3, 4 STIs have been
shown to increase genital HIV viral load and could affect the
resistance patterns of genital HIV-1. Additionally, syphilis, like
other genital ulcer diseases increases the risk of transmitting
and acquiring HIV. 4 Since early 2000 there has been a
dramatic increase in syphilis amongst MSM in Dublin; this is
against a low incidence of syphilis throughout the 1990s. In
response to this increase the Director of Public Health in the
Eastern Regional Health Authority (ERHA) established an
outbreak control team in October 2000. An enhanced
surveillance system was introduced by NDSC to capture data
on all syphilis cases from January 2000.5 The enhanced
surveillance data for syphilis is presented on pages 38 to 42 of
this report.
While the majority of STIs notified during 2001 were from
the ERHA, it is important to reiterate that people may travel
from their area of residence to STI clinics outside their area.
The data presented in this report, therefore did not necessarily
reflect numbers of infections diagnosed among residents of a
particular health board area. The increases in STIs in Ireland
during 2001 are likely to be associated with an increase in
unsafe sexual behaviour. Although the rise in genital
chlamydia infections also reflects increased testing for this
infection. In addition, improved acceptability of STI clinic
services and greater public and professional awareness of
certain STIs may have also contributed to the increases.
A review conducted by NDSC in 2001, ‘Review of Notifiable
Diseases and the Process of Notification’ undertaken at the
request of the Department of Health and Children,
recommends the institution of a new national system for
surveillance of infectious diseases of public health importance
in Ireland. The report recommends that there should be four
categories of notifier: general practitioners, hospital clinicians,
laboratory directors, and public health doctors, and that each
of these categories of notifier would be required to notify a
specific subset of diseases contained in the list of notifiable
diseases. The report recommends the removal of candidiasis,
molluscum contagiosum and P. pubis from the list of
notifiable STIs in Ireland. In addition, the report recommends
that the system for STI surveillance should change from
collection of clinic-based aggregate data, on a quarterly basis,
to the collection of timely, non-aggregate geographic based
data. A subcommittee of the scientific advisory committee of
the NDSC is currently undertaking a review of the surveillance
of STIs in Ireland.2
Table 8: Notified sexually transmitted infections from 1989 to 2001
Sexually Transmitted Infection 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001
  Ano-Genital Warts 505 917 1089 1066 1432 1532 1972 2286 2514 2886 3049 3735 3993
 Candidiasis 688 1056 1257 1157 1400 1360 1271 1321 1521 1277 1105 1095 1150
 Chancroid 2 0 0 2 0 2 3 1 1 0 1 16 1
 Chlamydia Trachomatis 174 215 164 192 315 133 245 364 462 646 869 1343 1649
 Genital Herpes Simplex 78 123 109 125 124 173 198 181 211 243 275 269 331
 Gonorrhoea 27 90 73 51 24 98 91 83 98 125 175 290 349
 Granuloma Inguinale 0 0 0 0 6 0 0 1 1 0 1 0 0
 Infectious Hepatitis B 0 0 0 0 0 0 4 2 0 0 2 15 39
 Lymphogranuloma Venereum 0 0 0 0 0 0 0 0 5 1 2 0 0
 Molluscum Contagiosum 31 39 43 44 34 56 59 34 74 84 83 118 111
 Non-Specific Urethritis 600 738 549 585 756 610 781 823 1034 1 1265 1726 1634
 Pediculosis Pubis 60 70 72 70 77 69 86 79 81 105 113 138 103
 Syphilis 12 19 20 20 8 11 11 17 16 15 6 46 279
 Trichomoniasis 51 86 163 41 57 29 60 71 94 38 47 78 64
 Total 2228 3353 3539 3353 4233 4073 4781 5263 6112 6503 6993 8869 9703
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Table 9: Notified sexually transmitted infections per 100,000* population from 1989 to 2001
Sexually Transmitted Infection 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001
 Ano-Genital Warts 14.32 26.01 30.89 30.23 40.62 42.25 54.38 63.04 69.33 79.59 84.09 95.35 101.93
 Candidiasis 19.51 29.95 35.65 32.82 39.71 37.51 35.05 36.43 41.95 35.22 30.47 27.95 29.36
 Chancroid 0.06 0.00 0.00 0.06 0.00 0.06 0.08 0.03 0.03 0.00 0.03 0.41 0.03
 Chlamydia Trachomatis 4.94 6.10 4.65 5.45 8.93 3.67 6.76 10.04 12.74 17.82 23.97 34.28 42.10
 Genital Herpes Simplex 2.21 3.49 3.09 3.55 3.52 4.77 5.46 4.99 5.82 6.70 7.58 6.87 8.45
 Gonorrhoea 0.77 2.55 2.07 1.45 0.68 2.70 2.51 2.29 2.70 3.45 4.83 7.40 8.91
 Granuloma Inguinale 0.00 0.00 0.00 0.00 0.17 0.00 0.00 0.03 0.03 0.00 0.03 0.00 0.00
 Infectious Hepatitis B 0.00 0.00 0.00 0.00 0.00 0.00 0.11 0.06 0.00 0.00 0.06 0.38 1.00
 Lymphogranuloma Venereum 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.14 0.03 0.06 0.00 0.00
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 Pediculosis Pubis 1.70 1.99 2.04 1.99 2.18 1.90 2.37 2.18 2.23 2.90 3.12 3.52 2.63
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 Total 63.19 95.10 100.38 95.10 120.06 112.32 131.85 145.14 168.56 179.34 192.85 226.41 247.70
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Information and 
Communications Technology
NDSC continued to grow through 2002 both in terms of the
number of staff and the range of activities carried out. IT staff
have responsibility for the management, purchase and support
of the following systems and functions:
• network systems and infrastructure
• information security
• email system
• NDSC website
• telephone system & fax machines
• mobile phones
• mobile computing equipment
• building access control system
• security video system
Information Governance
Due to continuing growth of NDSC, increasing volumes of
data and information held by NDSC and forthcoming
requirements of the CIDR project, a decision was taken to
review existing information security structures and policies. An
Information Governance Committee consisting of NDSC staff
form all disciplines was formed- “To establish a framework to
ensure the privacy, confidentiality and security of information
within the NDSC and to ensure that the policies relating to
these are implemented and complied with.”
One of the first actions of the Information Governance
Committee was to review IT security. The primary
recommendations were:
• upgrading the internet firewall,
• enforcing stricter email security 
• improving security on the NDSC IT network 
• investigating the possibility of achieving accreditation to an
internationally recognised standard for Information Security.
It was agreed to resource and action all these
recommendations in 2002.
The initial assessments performed by the committee
recognized that all NDSC’s core roles involve information
handling. To ensure that NDSC maintains the highest
standards of confidentilaity for all the information we are
entrusted with it has been decided to persue accreditation to
the ISO Information Security Standard. This standard is
represented in Ireland by IS17799 and covers all aspects of
information security for all data formats. A proposal
summarising the benefits of achieving this accrediation and
identifying the related resource requirements has been
drafted  and was put before the NDSC Board early in 2003.
IT Support Staff
There are now three IT support staff comprising of an IT
Specialist and two IT Officers. This team provides
administration and support for all aspects of the centre’s IT
activities detailed above.
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Key Points
• Syphilis cases increased dramatically in early 2000
• An outbreak of syphilis among men who have sex with
men in Dublin, peaked in July 2001
• Late syphilis cases among non-nationals also increased
• There now remains a high level of endemic syphilis
Introduction
Outbreaks of syphilis among men who have sex with men
(MSM) have been reported across Europe and the US over the
last few years. Since early 2000 there has been a dramatic
increase in syphilis amongst MSM in Dublin.1, 2, 3, 4 This was
against a low incidence of syphilis throughout the 1990s,
which in 1999 reached its lowest level in 10 years.3 In
response to this increase in syphilis the Director of Public
Health in the Eastern Regional Health Authority (ERHA)
established an outbreak control team in October 2000.5
Interventions to control the outbreak were targeted primarily
at MSM in Dublin. An enhanced surveillance system was
introduced by NDSC to capture data on all syphilis cases from
January 2000.3
It should be noted that the number of syphilis cases reported
through the quarterly STI notification system differ slightly
from the number of syphilis cases reported through the
syphilis enhanced surveillance system. This report presents the
epidemiology of all syphilis cases reported to NDSC through
the enhanced surveillance system between January 2000 and
December 2002. Data reported is provisional and due to
delays in reporting to NDSC, the 2002 data is estimated to be
higher than the data presented in this report. All cases and
stages of syphilis are detailed, with particular emphasis on the
recent outbreak. Syphilis progresses in four stages: primary,
secondary, latent (early and late) and tertiary. Early syphilis
(primary, secondary and early latent) is infectious. Late
syphilis (late latent and tertiary) is non-infectious.6
Enhanced surveillance of syphilis,
2000-2002
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Materials and Methods
An enhanced surveillance system was implemented by NDSC
to capture data on all syphilis cases from January 2000.
Demographics recorded on all cases included age, sex, country
of birth and health board area of diagnosing clinic. Clinical
details and at risk behaviour data were also collected.
Results
All syphilis cases (n=595) 
Between January 2000 and December 2002, 595 cases of
syphilis were notified to NDSC through the enhanced syphilis
surveillance system. Five hundred and eleven (85.9%) of the
595 cases attended STI clinics or general practitioners in the
greater Dublin area (table 1). Of the 595 cases, 410 (68.9%)
were early (infectious) syphilis, 148 (24.9%) were late syphilis
and 37 (6.2%) were of unknown syphilis stage. Four hundred
and fifty-six (76.6%) cases were male, 137 (23.0%) were
female and data was incomplete for 2 cases. Three hundred
and forty-eight (58.5%) cases were amongst MSM (296 were
homosexual and 52 were bisexual); 232 (39.0%) were
amongst heterosexuals and sexual orientation was not
recorded for 15 cases.
Eighty-six syphilis cases were notified through the enhanced
surveillance system in 2000, 306 in 2001 and 203 in 2002. The
total number of syphilis cases peaked in Q3 2001(figure 1).
Early (infectious) syphilis cases (n=410)
Four hundred and ten early syphilis cases were notified to
NDSC between January 2000 and December 2002, peaking in
July 2001 (figure 2). One hundred and eighty-five (45.1%)
early syphilis cases were primary syphilis, 141 (34.4%) were
secondary, 76 (18.5%) were early latent and 8 (2.0%) were
early syphilis of unknown stage. Two hundred and fifty-eight
(62.9%) early cases were symptomatic, 127 (31.0%) were
asymptomatic; data was not recorded for 25 cases. Three
hundred and sixty-three (88.5%) cases were male, 46 (11.2%)
were female and gender data was missing for 1 case. The
mean age for male cases was 35 years (ranging from 18 to 67
years) and 29 years (ranging from 13 to 49 years) for female
cases (figure 3).
Three hundred and twelve (76.1%) early syphilis cases were
among MSM (64.4% were homosexual and 11.7% were
bisexual), 91 (22.2%) were heterosexual and 7 (1.7%) were of
unknown sexual orientation (figure 2). Three hundred and
twelve (76.1%) early syphilis cases were born in Ireland (Table
2); of which 262 (84.0%) were MSM, 48 (15.4%) were
heterosexual and 2 were of unknown sexual orientation.
Eighty-seven cases were not born in Ireland; 47 (54.0%) of
these were MSM, 36 (41.4%) were heterosexual and 4 were of
unknown sexual orientation. Eleven early syphilis cases were
of unknown nationality.
Table 1: Number of notified cases of syphilis by notifying health board in Ireland 
(January 2000 to December 2002)
Health board/ Total Early Late Unknown 
authority syphilis (infectious) (non-infectious) syphilis
cases syphilis syphilis stage
ERHA 511 356 124 31
MHB 1 0 0 1
MWHB 27 11 13 3
NEHB 2 2 0 0
NWHB 8 6 2 0
SEHB 18 12 6 0
SHB 7 5 1 1
WHB 21 18 2 1
Total 595 410 148 37
Table 2: Percentage of total, early and late syphilis cases in Ireland by geographic origin 
(January 2000 to December 2002) 
Geographic Origin % Total (n=595) % Early (n=410) % Late (n=148)
Ireland 62.2 76.1 30.4
Western Europe (excl. Ireland) 7.9 9.5 4.1
Central Europe 4.0 2.2 9.5
Eastern Europe 7.1 2.7 18.9
Sub-Saharan Africa 8.9 3.2 24.3
Other 3.4 2.9 5.4
Unknown 6.6 3.4 7.4
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HIV status & concurrent STIs 
Seventy-three (17.8%) early syphilis cases were HIV positive
(67 male, 5 female & 1 of unknown gender). Sixty-three
(86.3%) of these were MSM (52 homosexual and 11 bisexual)
and 10 (13.7%) were heterosexual. HIV was newly diagnosed
in 18 (24.7%) of the 73 HIV positive cases. Twelve cases
infected with HIV and infectious syphilis were co-infected
with another STI. Seven cases were co-infected with syphilis,
HIV and gonorrhoea.
Eighty-one (19.8%) early syphilis cases were concurrently
infected with at least one other STI (excluding HIV). Ten
(2.4%) early syphilis cases were concurrently infected with 2
or more STIs (excluding HIV). One hundred and thirty-three
(32.4%) early syphilis cases gave a history of having had an
STI in the past, 90.2% of these cases were MSM.
Risk behaviour
Five early syphilis cases reported links to the commercial sex
industry. Seven male cases reported sexual contact with male
commercial sex workers (CSWs) and 5 male cases reported
sexual contact with female CSWs in the past. In attempting
to identify the source of infection numerous networks were
associated with the increase in early syphilis cases: 179 cases
attended saunas, 157 cases implicated bars or clubs, 21 made
contact through internet chat rooms and 30 had sexual
contact outdoors or in parks. Eighty-two (20.0%) early
syphilis cases had sex abroad in the three months prior to
diagnosis (with London, Manchester and Amsterdam
commonly reported).
Information on sexual contacts was available for 86.7% of
early syphilis cases notified between January 2000 and
December 2002. The median number of sexual contacts self-
reported in the 3 months prior to diagnosis was one for male
heterosexuals (range 0-5), one for female heterosexuals (range
0-3), six (range 0-100) for male homosexuals and 3 (range 0-
40) male and one (range 0-4) female for male bisexuals.
Late syphilis cases (n=148)
One hundred and forty-seven late latent syphilis cases and 1
tertiary syphilis case were notified to NDSC between January
2000 and December 2002. Seventy-three (49.3%) of these
were male, 74 (50%) were female and the gender data was
missing for 1 case. The mean age for female cases was 32
years (ranging from 21 to 84 years) and 41 years (ranging
from 19 to 81 years) for male cases. One hundred and sixteen
(78.4%) of the late syphilis cases were heterosexual (42 male
& 74 female), 29 (19.6%) were MSM and 3 were of unknown
sexual orientation.
Ninety-two (62.2%) of the late syphilis cases were non-
nationals (31 male and 61 female) and 45 (30.4%) were born
in Ireland (Table 2). Of the 45 cases born in Ireland, 7 were
female and 38 were male. Twenty-six of the Irish-born late
syphilis cases were MSM, 18 were heterosexual and one was
of unknown sexual orientation. Ninety-eight percent of the
late syphilis cases in non-nationals were heterosexual and
2.2% were MSM.
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Figure 1: Number of early (infectious) and late (non-infectious) syphilis cases in Ireland by quarter and year of diagnosis (n=548). 
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Antenatal Screening (n=81)
Eighty-one syphilis cases were identified through antenatal
screening. Fifty-one (63.0%) of these cases were late syphilis
cases, 20 (24.7%) were early syphilis cases and 10 were of
unknown syphilis stage. The majority of late syphilis cases
(61.5%, n=83) attended STI clinics because of antenatal
referral. Self-referral was the commonest reason for early
(infectious) syphilis cases attending STI clinics. Sixty cases
identified through antenatal screening were non-nationals, 4
were Irish and 17 were of unknown nationality. Four cases
identified through antenatal screening were also HIV positive.
Six congenital syphilis cases have been reported to NDSC
between January 2000 and December 2002. Intrauterine
death was reported in 2 of the 6 congenital cases. In three of
the cases the mother was diagnosed with late latent syphilis,
two mothers were diagnosed with secondary syphilis and one
was diagnosed with primary syphilis.
Discussion
Two distinct groups have been associated with the increase in
syphilis in Ireland: (1) an outbreak of early (infectious) syphilis
mainly among MSM in Dublin and (2) late syphilis cases
particularly among non-nationals. Changes in sexual
behaviour patterns across Europe are reflected in Ireland with
large numbers of sexual contacts and the anonymous nature
of contacts & other at risk behaviour.1, 7, 8 Other worrying
trends associated with this outbreak include the numbers of
newly diagnosed HIV cases and concurrent STI infections
among early (infectious) syphilis cases and the reported
congenital cases. It is notable that 20% of infectious syphilis
cases in Ireland reported sexual contact abroad, in particular
in London, Manchester and Amsterdam, where recent syphilis
outbreaks have also been reported.1,2,3 The syphilis outbreak in
Ireland peaked in July 2001 and there now remains a high
level of syphilis endemicity.
Intervention measures have proven effective for case finding
in the context of this outbreak.5 On-site testing in particular
has accessed a population that may otherwise not have
attended for screening. It has also provided publicity,
increased awareness of the outbreak and knowledge about
syphilis, and fostered trust between the gay and bisexual
community and the health sector. The links developed in the
course of the outbreak will provide the basis for collaboration
on future sexual health projects.
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Figure 2.  Early (infectious) syphilis cases by sexual orientation and  months of diagnosis in Ireland (n=403).
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Figure 3: Early (infectious) syphilis cases in Ireland by age group (years) and gender, January 2000 to December 2002 (n=409)
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Ireland is one of 16 countries participating in the European
Sero-Epidemiology Network 2 (ESEN2). The aim of this
project is to co-ordinate and harmonise the serological
surveillance of immunity to communicable disease in Europe.
As part of Ireland’s participation in this project, immunity to
eight diseases will be monitored (measles, mumps, rubella,
pertussis, diphtheria, varicella zoster, hepatitis A and hepatitis
B).
In order to provide a context for this study, Ireland completed
an organisational analysis of national vaccination programmes
in November 2002. This analysis described the history and
development of national vaccination programmes and will be
a key element in the interpretation of results from all
participating countries. Furthermore, to facilitate comparisons
between countries, it is necessary for each country to test an
agreed set of standards supplied by reference laboratories
throughout Europe. The National Virus Reference Laboratory
began work on this aspect of the project in early 2002. In
collaboration with the NDSC and the National Virus Reference
Laboratory, hospitals from six health boards / authorities
began collecting samples for the ESEN2 study in August 2002.
Testing for the measles, mumps, rubella, varicella zoster,
hepatitis A and hepatitis B work-packages is being carried out
at the National Virus Reference Laboratory, Dublin while
testing for the diptheria and pertussis work-packages is being
carried out at the Communicable Disease Surveillance Centre,
Colindale, London. The ESEN2 project is due to be completed
in early 2004.
ESEN 2
Figure 1. Countries Participating in ESEN2: Belgium, Bulgaria, Czech Republic, Finland, 
Germany, Greece, Ireland, Israel (not shown on map), Italy, Luxembourg, Netherlands, 
Romania, Slovenia, Spain, Sweden, United Kingdom.
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Viral Hepatitis, 2002
Key Points
• Hepatitis A decreased for the third consecutive year,
reaching an all-time low of 0.7 cases/100,000 population.
• The number of hepatitis B notifications continued to
increase in 2002, with 458 cases being notified (11.7
cases/100,000 population).
• There were 89 notifications of “viral hepatitis, type
unspecified”, similar to 2001. Most of the unspecified viral
hepatitis cases notified in 2002 were due to hepatitis C. In
addition 68 cases were notified as aggregate data from
STI clinics in the ERHA.
• Comprehensive information on the epidemiology of viral
hepatitis and on the specific risk groups affected by viral
hepatitis is not available. Surveillance data would be
greatly improved by the introduction of laboratory
notification, case definitions for each infection and
enhanced surveillance, as well as by specifying hepatitis C
as a notifiable disease.
Viral Hepatitis
Viral hepatitis is notifiable under three categories: type A, type
B and type unspecified. These classifications were brought in
under the 1981 Infectious Disease Regulations. Prior to this,
infective hepatitis was notifiable. The numbers of notifications
under these categories since 1956 are illustrated in figure 1. The
trends in these historical data reflect both changes in the
process and practice of notification as well as the changing
epidemiology of viral hepatitis in Ireland. Given the large
numbers of unspecified viral hepatitis notifications (particularly
between 1982 and 1988), and a surprisingly small number of
hepatitis B cases notified in the early eighties (when a large
outbreak occurred in injecting drug users (IDUs)1) it appears
that viral hepatitis type A and B categories were under-utilised
when first introduced.
Hepatitis A
Introduction
Hepatitis A virus causes an acute, self-limiting disease. It is
transmitted via the faecal-oral route, and is most common in
areas of the world with poor sanitation. The clinical severity of
hepatitis A infection increases with age. Childhood infection is
usually quite mild, the majority of children under 5 years
showing no symptoms, but people infected as adults can suffer
severe and prolonged illness. Hospitalisation and mortality rates
also increase with age.2 Hepatitis A is preventable by vaccine.
Currently in Ireland vaccination is recommended for people in
certain high risk groups such as close contacts of known cases,
travellers to high endemicity countries, patients with chronic
liver disease and those at occupational risk.3
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Materials and methods
Hepatitis A is a notifiable disease under the Infectious Disease
Regulations (1981). Aggregate data on notifications are
available from 1982 and disaggregate data (including age and
sex) since mid-2000.
Data on hospital discharges with any diagnosis of hepatitis A
(up to 6 diagnoses are recorded) were obtained from the HIPE
(Hospital In-Patient Enquiry) Unit of the Economic and Social
Research Institute for the years 1999-2001. The HIPE system is
an event based system.
The number of liver transplants with an aetiology of viral
hepatitis between 1993 and 2002 was obtained from the
National Liver Transplant Unit, St Vincent’s University Hospital.
The number of deaths with an underlying cause of hepatitis A
between 1990 and 2002 was obtained from the Central
Statistics Office (CSO). Data for 2001 and 2002 are provisional.
Results
Clinical Notifications
In 2002 the number of hepatitis A cases notified continued to
decrease for the third consecutive year, from 112 in 2001 to 26
cases in 2002 (figure 1). This was the lowest number of cases
reported in a year since 1982, giving an incidence of just 0.7
cases/100,000 population. The age standardised incidence rates
varied between health boards, from no cases in the MHB and
WHB to 1.4 cases/100,000 in the SHB.
The majority (n=17) of cases in 2002 were female. Numbers
and rates of hepatitis A decreased from the levels in 2001 in all
age groups except those 65 years and over (table 1).
Morbidity and mortality
A diagnosis of hepatitis A was the principal diagnosis recorded
in 310 hospital discharges between 1999 and 2001 (there were
485 discharges in total with any diagnosis of hepatitis A). The
number of discharges a year decreased from 144 in 1999, to
104 in 2000 and 62 in 2001. There was a small excess of
female cases over the three years (54%), and the mean age was
24 years (range <1 year-83 years). The majority (95%) of cases
were in-patients, the median length of stay of in-patients was 4
days (range 1-66 days). The average length of stay increased
with age, from 4 days in people under 15 years of age to 17
days in people 65 years and older.
There were no liver transplants between 1993 and 2002 with
an underlying aetiology of hepatitis A.
There were 10 deaths due to hepatitis A between 1990 and
2002, the majority (n=7) being women.
Discussion
The incidence of hepatitis A continued to decrease in 2002,
with less than one case notified per 100,000 population. This
decrease occurred in most age groups. However, as can be seen
in figure 1, the incidence of hepatitis can vary greatly from year
to year. Hepatitis A has the potential to cause large scale
community outbreaks in susceptible populations (and the
majority of Irish people under the age of 30 are now likely to
be susceptible to hepatitis A)4. The burden of illness associated
Table 1. Notified cases of hepatitis A, number and rate /100,000 population by age 
group, 2001 and 2002
2001 2002
Age group (years) Number Rate Number Rate
0-4 9 3.2 0 0.0
5-9 26 9.8 4 1.5
10-14 19 6.7 2 0.7
15-19 5 1.6 1 0.3
20-24 10 3.0 2 0.6
25-34 20 3.2 6 1.0
35-44 10 1.8 2 0.4
45-54 6 1.2 1 0.2
55-64 3 0.9 2 0.6
65+ 4 0.9 6 1.4
Total 112 2.9 26 0.7
Table 2. Notified cases of hepatitis B, number and rate/100,000 population 
by age group, 2001 and 2002
2001 2002
Age group (years) Number Rate Number Rate
0-4 3 1.1 6 2.2
5-9 6 2.3 4 1.5
10-14 8 2.8 5 1.8
15-19 20 6.4 23 7.3
20-24 1 12.5 65 19.8
25-34 64 26.6 241 39.0
35-44 66 11.7 88 15.6
45-54 15 3.1 14 2.9
55-64 4 1.1 2 0.6
65+ 1 0.2 0 0
Total* 342 8.7 458 11.7
* Total includes cases of unknown age
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with hepatitis A can be high, especially those infected as adults.
As well as the more traditional sources of outbreaks such as
contaminated of food and water which continue to occur
around the world, outbreaks in injecting drug users have
occurred in the UK and other low-incidence countries.5,6 These
outbreaks have in some instances spilled over into the general
community.6 Risk factor information is not collected at a
national level in Ireland. More detailed information, including
risk factor details, is required to monitor and inform prevention
and control strategies and to plan services.
A proposal is currently being prepared for the European
Commission to develop a European surveillance network on
hepatitis A. One of the major areas to be included in this
network will be information on the molecular epidemiology of
hepatitis A. Molecular epidemiology can be used for a variety of
purposes, such as estimating the prevalence of subtypes of
hepatitis A at global or country level, helping identify the
country of origin of a case, monitoring shifts in viral strains over
time, and is particularly useful for linking apparently sporadic
cases occurring in different countries to a common source.
Currently no molecular typing of hepatitis A is carried out in
Ireland. The participation of Ireland in this network would
necessitate the development of this service in the future.
More information on the epidemiology of hepatitis A in Ireland
is available at http://www.ndsc.ie/Publications/EPI-
Insight/2003Issues/d608.PDF.
Hepatitis B
Introduction
Hepatitis B virus is spread via infected body fluids including
blood. Only a small proportion of acute hepatitis B cases (10%
children and 30-50% of adults) develop clinical symptoms.
Chronic infection can develop and is associated with increased
risks of chronic liver disease and liver cancer. The proportion of
cases who go on to develop chronic infection decreases with
age, from 90% of babies infected at birth to around 10% of
people infected as adults.2 In Ireland hepatitis B infection is
known to be prevalent in certain populations such as IDUs7,
prisoners,8 and immigrants from high endemicity countries.9,10 A
vaccine is available for the prevention of hepatitis B infection.
Currently immunisation is recommended for individuals who
are at increased risk of infection because of their occupation,
lifestyle or other factors.3
Materials and Methods
The Infectious Disease Regulations (1981) specify hepatitis B as
a notifiable disease. Currently no case definitions exist for any
of the notifiable diseases, and there is therefore no requirement
in the notification process to distinguish between cases of
acute and chronic hepatitis B.
The National Virus Reference Laboratory (NVRL) provided data
on the number of new hepatitis B surface antigen (HBsAg)
positive samples identified between 1990 and 2001.
Data on hospital discharges with any diagnosis of hepatitis B
(up to 6 diagnoses are recorded) were obtained from the HIPE
system for the years 1999-2001.
Table 3. Number and mean age of discharges with a principal diagnosis of hepatitis B 
(1999-2001), by sex.
Males Females
Number of Mean age Number of Mean age
Principle diagnosis discharges (years) discharges (years)
Acute or unspecified hepatitis B 98 31.7 27 26.6
Chronic hepatitis B 64 38.2 16 26.4
Table 4. Number and mean age of hospital discharges with a principal diagnosis of 
hepatitis C or unspecified viral hepatitis (1999-2001), by sex.
Males Females
Number of Mean age Number of Mean age
Principle diagnosis discharges (years) discharges (years)
Acute or unspecified hepatitis C 208 32 94 35
Chronic hepatitis C 440 35 358 43
Unspecified viral hepatitis 60 35 55 33
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The number of liver transplants with an aetiology of viral
hepatitis between 1993 and 2002 was obtained from the
National Liver Transplant Unit, St Vincent’s University Hospital.
The number of deaths with an underlying cause of hepatitis B
between 1990 and 2002 was obtained from the CSO. Data for
2001 and 2002 are provisional.
Results
Clinical notifications
The increase in hepatitis B notifications seen in recent years
continued in 2002, with a total of 458 cases being notified
(figure 2). The national incidence rate was 11.7/100,000
population, with the highest rates being reported by the SHB,
MHB and SEHB (figure 3).
The largest increases in 2002 were seen in those aged between
20 and 44 years of age (table 2). Just over half (52%) of all
notified cases were between the ages of 25 and 34 years. The
sex distribution was approximately equal (218 male, 213
female).
In addition, it is likely that some hepatitis B cases in 2002 will
be notified as sexually transmitted infections (STIs). These
infections are notified separately to the weekly notifications, in
aggregate form on a quarterly basis. Unfortunately the STI
reporting system is not as timely as the weekly notification
system and the hepatitis B data for 2002 are not currently
available. While the cases of hepatitis B notified through this
system may be duplicates of cases reported through the weekly
notification system, it is more likely that they are new cases as
they would have been identified through a different route (i.e.
identified in STI clinics). The number of cases of hepatitis B
notified through this system has increased in recent years, from
2 in 1999, to 15 in 2000, with 39 cases being reported in 2001.
Morbidity and mortality
In total, for the years 1999 to 2001 there were 205 hospital
discharges with a principal diagnosis of hepatitis B (there were
1190 discharges in total with any diagnosis of hepatitis B). One
hundred and twenty five of these had a diagnosis of acute or
unspecified hepatitis B, and 80 had chronic hepatitis B. The age
and sex distribution of the discharges with a principal diagnosis
of acute or unspecified and chronic hepatitis B can be seen in
table 3. The majority of discharges with a principal diagnosis of
either acute or unspecified (n=115) or chronic hepatitis B
(n=54) were in-patients, their median lengths of stay being 6
days and 2 days respectively.
Six liver transplants have been carried out with an underlying
aetiology of hepatitis B since the National Liver Transplant Unit
was established in 1993, accounting for approximately 2.3% of
all liver transplants.
Hepatitis B was recorded as the primary cause of death of 25
people between 1990 and 2002, 80% being male.
Discussion
Hepatitis B notifications have increased dramatically in recent
years. This increase may reflect the introduction of screening
programmes. Many of the notified cases are chronically infected
asylum seekers. In the SHB 95-96% of cases notified in 2000-
2002 were asylum seekers.11 Asylum seekers currently undergo
voluntary health screening, which includes testing for hepatitis
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Figure 1. Viral hepatitis notifications 1956-2002 (Sources of data: 1956-1981 Quarterly reports of births, deaths, marriages and certain infectious diseases (Department of Health), 
1982 –2000 Department of Health and Children, 2001 onwards NDSC)
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B infection. The high proportion of female cases notified might
also be a result of antenatal screening of pregnant women.
Laboratory data on hepatitis B are not routinely available as
laboratories are not obliged to notify notifiable diseases. In the
case of a disease such as hepatitis B, whose definitive diagnosis
requires laboratory confirmation, laboratory notification is
essential to accurately estimate the incidence and prevalence of
disease. A review of notifiable diseases and the process of
notification carried out by the NDSC at the request of the
Department of Health and Children has recommended that
laboratories should be specified as notifiers.12 Case definitions
to cover both acute and chronic disease have also been
proposed.
Although hepatitis B is a notifiable disease, under-reporting is
common as demonstrated by the discrepancy between the
number of HBsAg positive samples detected by the National
Virus Reference Laboratory and the substantially smaller
number of hepatitis B cases reported to the NDSC (see figure
2). Information currently reported on individual cases is
inadequate. More detailed information which would need to be
gathered through enhanced surveillance including risk factor
details, is required to monitor and inform prevention and
control strategies and to plan services.
More information on the epidemiology of hepatitis B in Ireland
is available at http://www.ndsc.ie/Publications/EPI-
Insight/2003Issues/d728.PDF.
Viral hepatitis Type Unspecified (including hepatitis C)
Introduction
Several other viral agents can cause hepatitis including hepatitis
C, hepatitis delta and hepatitis E. By far the most common of
these is the hepatitis C virus. Hepatitis C is spread via infected
body fluids. Initial infection is mainly asymptomatic (around
90% of cases). However, between 50% and 80% of cases go on
to develop chronic infection.2 Approximately half of chronically
infected people eventually develop cirrhosis or liver cancer.
There is no vaccine currently available for the prevention of
hepatitis C.
Materials and Methods
The current list of notifiable diseases includes “viral hepatitis,
type unspecified”. Hepatitis C may be notified under this
category, but it is not currently a notifiable disease in its own
right. Since the NDSC started collecting disaggregate data in
mid-2000, many of the notifications of unspecified viral
hepatitis have included information on the cause of the
hepatitis (e.g. hepatitis C virus).
Data on hospital discharges with a diagnosis of hepatitis C,
hepatitis delta, hepatitis E, other specified viral hepatitis and
unspecified viral hepatitis (up to 6 diagnoses are recorded) were
obtained from the HIPE Unit for the years 1999-2001.
The number of liver transplants with an underlying aetiology of
viral hepatitis between 1993 and 2002 was obtained from the
National Liver Transplant Unit, St Vincent’s University Hospital.
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Figure 2. Number of cases of hepatitis B notified and HBsAg positive samples identified by the NVRL, 1990-2002.
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The number of deaths with an underlying cause of other
specified (i.e. other than hepatitis A and hepatitis B) and
unspecified viral hepatitis between 1990 and 2002 was
obtained from the CSO. Data for 2001 and 2002 are
provisional.
Results
Clinical notifications
There were 89 cases of unspecified viral hepatitis notified in
2002. This was similar to the number notified in 2001 (n=90).
Ninety three percent of the cases in 2002 were identified as
hepatitis C.
The incidence of unspecified hepatitis was 2.3 cases/100,000
population in 2002. Rates varied across health boards, with
SEHB having the highest rate. The SEHB has experienced an
increase in the rate of notified unspecified viral hepatitis in the
last 3 years (figure 4). Hepatitis C was given as the cause of all
cases of unspecified viral hepatitis in the SEHB notified in 2001
and 2002. The age and sex distribution of notified cases can be
seen in figure 5.
In addition the ERHA notified a number of cases of viral
hepatitis type unspecified as aggregate STI data. While these
cases may be duplicates of cases reported through the weekly
notification system, it is likely that they are new cases of
hepatitis C infection identified during screening carried out at
STI clinics. These data have not been available for inclusion in
the annual report in previous years due to the lack of timeliness
of the STI data. In 2002 there were 68 cases notified this way.
This was a decrease compared to 2001 when 90 cases were
notified in aggregate form to the ERHA.
Morbidity and mortality
Over the three years 1999-2001 there were 1113 discharges
with a principal diagnosis of other specified hepatitis and a
further 115 with a principal diagnosis of unspecified viral
hepatitis. The vast majority (1100) had a principal diagnosis of
hepatitis C (there were 6085 discharges in total with any
diagnosis of hepatitis C). A small number (n=13) of discharges
were coded as hepatitis delta, hepatitis E or other specified viral
hepatitis. The mean age of hospitalised cases of acute or
unspecified hepatitis C, chronic hepatitis C, and unspecified
viral hepatitis by sex can be seen in table 4. The majority of
cases of acute or unspecified hepatitis C (n=272) or chronic
hepatitis C (n=558) were in-patients, their median length of
stay being 2 days and 1 day respectively.
The National Liver Transplant Unit carried out 21 liver
transplants with an underlying aetiology of hepatitis C
infection, accounting for 8% of all transplants since 1993.
There were 52 deaths due to other specified viral hepatitis
between 1990 and 2002. In addition there have been 32 deaths
from unspecified viral hepatitis over the same period (CSO). The
number of deaths due to other specified viral hepatitis has
increased over this time period, reaching an annual maximum
of 15 deaths in 2002 (provisional data, by year of registration),
while those coded as unspecified viral hepatitis have decreased.
Discussion
There is little routine information available on hepatitis C in
Ireland as it is not currently a notifiable disease (although it
may be notified as viral hepatitis, type unspecified). The need
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Figure 3. Rate of notified hepatitis B per 100,000 population by Health Board, 2000-2002
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for hepatitis C to be made notifiable, as well as the need for
laboratories to be specified as notifiers, has been recognised.12
The specification of hepatitis C as a notifiable disease and
laboratory reporting should greatly improve the quality of
routine data on hepatitis C. Enhanced surveillance would also
enable identification of risk factors and this information could
be used to monitor and inform prevention and control
strategies and to plan services.
National hepatitis C database
The Consultative Council on Hepatitis C commissioned a review
of health services available for people infected with hepatitis C
through the administration in this state of blood and blood
products. One of the recommendations of the review was that
a national database of people infected with hepatitis C through
the administration of blood or blood products within the state
be established for research purposes at an independent
coordinating agency and run in association with relevant
groupings.13 There was consensus that a unique opportunity
exists for internationally significant research which can inform
both treatment and understanding of the nature of the
hepatitis C process, and there was agreement that hepatitis C
research in Ireland would be greatly advanced by the availability
of a national database of those affected by the virus. The NDSC
was asked to set up this database, and the preparatory work
was started in 2002.
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Figure 4. Rate of notified viral hepatitis type unspecified  per 100,000 population by health board, 2000-2002
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Key points
• The incidence of salmonellosis in Ireland appears to be
decreasing, as evident from the weekly clinical
notification data.
• The crude incidence rate per 100,000 population of
salmonellosis in Ireland in 2002 was 10.2, compared to
11.8 in 2001
• There were 416 clinical isolates of Salmonella enterica
referred to the National Salmonella Reference
Laboratory in 2002 for serotyping, phage typing and
antimicrobial sensitivity tests
• 19.7% of cases were associated with travel outside of
Ireland in 2002
Introduction
Salmonella is a bacterial zoonotic pathogen that is a relatively
common cause of foodborne illness in Ireland and worldwide.
At present there are over 2,500 known serotypes of
Salmonella. In recent years, two serotypes, namely, S. enterica
serotype Enteritidis and S. enterica serotype Typhimurium
have accounted for the majority of cases of human
salmonellosis.
Salmonellosis presents as an acute enterocolitis, with sudden
onset of headache, abdominal pain, diarrhoea, nausea and
occasionally vomiting. Fever is almost always present.
Dehydration, especially amongst vulnerable populations such
as infants, the immunocompromised and the elderly, may be
severe. S. Typhi and S. Paratyphi can cause enteric fever, a
severe systemic life threatening condition, but this is very rare
in Ireland and mainly travel-associated.
A wide range of domestic and wild animals, as well as humans
can act as the reservoir for this pathogen, although chronic
carriage is rare in humans.
Prevention, surveillance and control of Salmonella infections is
of major public health importance. Measures have been
implemented from farm to fork in an attempt to control
spread of this zoonotic agent.
Salmonella in Ireland, 2002
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Materials and Methods
The National Salmonella Reference Laboratory (NSRL) was
established in 2000 in the Department of Medical
Microbiology, University College Hospital, Galway. This
laboratory accepts S. enterica isolates from all clinical and
food laboratories for serotyping, phage typing and
antimicrobial sensitivity testing.
This report reviews data available from the NSRL and weekly
clinical notifications for the year 2002. These data enable us
to provide an overview of the epidemiology and burden of
disease caused by Salmonella infections in Ireland today.
Results - NSRL data
Demographic information
There were 416 clinical isolates of S. enterica referred to NSRL
in 2002. The male: female ratio was 1.05:1. The age groups
and sex of those affected are shown in Table 1.
Seasonality
There was a marked seasonality in the overall number of
human cases of S. enterica reported in 2002, with a peak seen
in both July and October 2002 (see Figure 1). S. Enteritidis
cases were also shown to have this seasonal variation, but this
was not seen for S.Typhimurium cases.
Serotyping, phage typing and antibiotic susceptibility
results
The breakdown of Salmonella serotypes by health board is
shown in Table 2. The total figures and crude incidence rates
(CIR) are also presented. It should be noted however that
health board location refers to the location of the clinical
laboratory that the isolate was sent to, and may not
correspond with the geographic location of the cases.
The trend which began in 2001 of S. Enteritidis taking over
from S. Typhimurium as the predominant serotype associated
with human salmonellosis in Ireland, was again continued in
2002 (see Table 3). The next most commonly isolated
serotypes in 2002 were S. Bredeney and S. Kentucky. There
were 5 isolates of S. Typhi detected. Three of these were
travel-associated.
Travel-association
82 isolates (19.7%) reported to NSRL in 2002 were found to
be travel-associated. The majority of these cases were
associated with travel to Spain (n=26). The next most
common country reported was Tunisia (n=6), followed by
Thailand (n=5), Pakistan (n=4) and Portugal (n=4).
Further analysis of the 26 cases associated with travel to
Spain revealed that 19 of these were S. Enteritidis.
Interestingly a variety of different phage types of S. Enteritidis
were reported viz., 7 of PT1, 4 of PT6, 2 of PT4 and one each
of PT12, PT14b, PT3, PT5a, and PT8.
Antimicrobial resistance
The antimicrobial susceptibility of the most commonly
isolated serotypes in 2002 are presented in Table 4. High
levels of resistance were again found among S. Typhimurium
isolates, particularly S. Typhimurium DT104. Many of these
isolates were found to be resistant to at least five
antimicrobial agents, viz. ampicillin, chloramphenicol,
streptomycin, sulphonamide and tetracycline (ACSSuT).
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Figure 1. Isolates of Salmonella enterica, S. Enteritidis and S. Typhimurium referred to 
NSRL by month, 2002. (Note: month refers to the date the isolate was received in the 
reference laboratory).
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Table 1. Analysis of clinical isolates of S. enterica (n=416) referred to NSRL,
(2002) by age-group and gender.
Age group (years) No. of isolates (%) Male Female Unknown
0-4 89 (22) 43 38 8
5-14 39 (9) 22 16 1
15-24 59 (14) 32 26 1
25-34 66 (16) 30 33 3
35-44 40 (10) 21 19 0
45-54 42 (10) 20 22 0
55-64 30 (7) 15 14 1
65+ 30 (7) 16 13 1
Unknown 21 (5) 7 12 2
Total 416 (100) 206 193 17
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Table 2.  Serotypes of Salmonella enterica by health board, 2002.
Serotype ERHA MHB MWHB NEHB NWHB SEHB SHB WHB Total
Adelaide 0 0 0 0 1 0 0 0 1
Agama 0 0 0 0 0 0 1 0 1
Agona 1 0 0 3 0 1 0 0 5
Alachua 0 0 0 0 0 0 0 1 1
Apapa 1 0 0 0 0 0 0 0 1
Bareilly 1 0 0 0 0 0 0 0 1
Braenderup 0 1 0 1 0 0 0 0 2
Brandenburg 2 0 1 0 0 0 0 0 3
Bredeney 0 0 1 0 0 1 0 0 2
Colindale 1 0 0 0 0 0 0 0 1
Corvallis 1  0 0 0 0 0 0 0 1
Dublin 1 0 4 0 2 0 0 2 9
Durban 2 0 0 0 0 0 0 0 2
Enteritidis 57 8 16 10 10 15 29 20 165
Give 2 0 0 0 0 0 0 0 2
Hadar 2 0 1 0 0 2 1 0 6
Heidelberg 1 0 0 0 1 0 0 0 2
Infantis 1 0 0 0 0 0 2 0 3
Java 0 0 0 0 2 0 0 1 3
Johannesburg 1 0 0 0 0 0 0 0 1
Kentucky 0 0 0 0 0 0 0 1 1
Kottbus 1 1 0 4 0 0 0 0 6
Lexington 0 0 0 0 0 1 0 0 1
Mbandaka 0 0 1 0 0 1 0 1 3
Menston 0 0 0 0 0 0 0 1 1
Muenster 0 0 0 0 0 0 0 1 1
Newport 3 0 0 0 0 0 1 1 5
Ohio 1 1 0 0 1 0 0 0 3
Oranienburg 1 0 0 0 0 0 0 0 1
Panama 1 0 0 0 0 1 0 0 2
Poona 0 0 0 2 0 0 0 0 2
Putten 0 0 0 0 0 0 0 3 3
Redhill 1 0 0 0 0 0 0 0 1
Rissen 0 0 0 1 0 0 0 0 1
Rough 0 0 0 0 0 1 0 0 1
Schwarzengrund 0 0 0 0 1 0 0 0 1
Senftenberg 1 0 0 1 0 0 0 0 2
Singapore 0 0 1 0 0 0 0 0 1
Stanley 3 0 1 0 0 1 1 1 7
Thompson 1 0 0 0 0 0 0 0 1
Typhi 3 0 1 0 1 0 0 0 5
Typhimurium 45 12 10 15 11 28 4 15 140
Urbana 1 0 0 0 0 0 0 0 1
Virchow 5 0 0 0 2 2 0 1 10
Worthington 0 0 0 0 0 0 1 0 1
Unknown 0 1 0 2 0 0 0 0 3
Total 141 24 37 39 32 54 40 49 416
CIR* 10.9 11.7 11.7 12.7 15.2 13.8 7.3 13.9 11.5
*CIR = Crude incidence rate / 100,000 population
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Results - Clinical notification data
Salmonellosis is a notifiable disease. Medical practitioners are
legally obliged to report all suspected cases. Information on
trends in salmonellosis notifications shows that the crude
incidence rate rose in the 1990s to peak in 1998, and has
been steadily decreasing since then (Figure 2). The total
number of notifications in 2002 was 369 compared to 433 in
2001, and 640 in 2000.
Discussion 
The importance of Salmonella enterica as an enteric pathogen
and the significant burden of human illness that it is
responsible for, is evident from the data presented in this
report.
Similar trends regarding the epidemiology of this pathogen
were noted in 2002 as in previous years. All age-groups were
seen to be affected but the highest incidence was again noted
in the 0-4 age-group. Both males and females were equally
affected. There was a marked seasonality as reported in
previous years with a peak in cases noted in July and October
2002. Interestingly when the two commonest serotypes are
compared in terms of seasonality, S. Enteritidis is seen to
follow this pattern, but it is not evident for S. Typhimurium (as
shown in Figure 1).
Analyses of the serotyping results revealed that in 2002,
S. Enteritidis was the predominant serotype, followed by
S. Typhimurium. This followed the change in trend that was
first seen in 2001. For three years prior to that (1998-2000),
S. Typhimurium had been the commonest serotype in Ireland.
Improvements and advances in the detailed typing laboratory
data being generated by the NSRL is enabling us to monitor
salmonella trends more accurately and is providing us with
comprehensive information regarding the epidemiology of
this pathogen in Ireland. In particular, the advent of
molecular typing methods being employed by NSRL such as
plasmid profiling and Pulsed Field Gel Electrophoresis (PFGE)
has greatly enhanced our ability to identify clusters and
outbreaks and examine trends in human, food and veterinary
isolates to track this zoonotic agent through the food chain.
On a European and international level, the European-based
network Enter-net has proven in recent years to be invaluable
in terms of sharing knowledge and expertise, enabling
ourselves and our international colleagues to track clusters
and epidemics of salmonellosis and trace back through a
complex global food chain to identify the source of outbreaks.
When the antimicrobial susceptibilities of the various
serotypes isolated in 2002 were examined, high levels of
resistance were again found among S. Typhimurium isolates,
particularly S. Typhimurium DT104. Many of these isolates
were found to have the penta-resistance phenotype (ACSSuT)
that was reported in previous years. This continues to be a
worrying trend.
One of the more notable features of the data reported to
NSRL in 2002 has been the emergence of travel-associated
cases with almost 20% of the cases identified by NSRL having
acquired the illness outside of Ireland. The majority of cases
were associated with travel to Spain and the serotype most
commonly linked with Spain was S. Enteritidis. However a
Table 3. Serotypes of S. enterica referred to NSRL (1998-2002). 
Serotype 1998 1999 2000 2001 2002
Serotype 1998 1999 2000 2001 2002
S. Enteritidis 60 (8) 155 (33) 239 (36) 248 (46) 165 (40)
S. Typhimurium 578 (80) 200 (42) 286 (43) 165 (30) 140 (34)
S. Bredeney 15 (2) 55 (12) 24 (4) 11 (2) 2 (0.5)
S. Kentucky 14 (2) 12 (3) 15 (3) 4 (1) 1 (0.2)
All other serotypes 54 (7) 52 (11) 101 (15) 115 (21) 108 (26)
Total 721 474 665 543 416
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Figure 2.  Crude rate of Salmonellosis in Ireland per 100,000 population 1982-2002.
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wide variety of phage types of S. Enteritidis were reported in
these travel-associated cases. It is quite probable that the
overall proportion of travel-associated cases will increase in
coming years and a greater diversity of serotypes and sub-
types will be detected.
In conclusion, although the overall incidence of human
salmonellosis has decreased in Ireland over the past number
of years (in line with the control programmes in place for
S.Enteritidis and S. Typhimurium), there is still no room for
complacency regarding this pathogen as it is quite likely that
the relative importance of other serotypes will increase, and
the burden of illness due to this pathogen remains very
significant.
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Table 4. Antimicrobial susceptibilities of human Salmonella enterica serotypes 
isolated in Ireland in 2002.
     % Resistance
Serotype (Number)  Amp Chl Strep Sulph Tet Trim Nal
S. Enteritidis (165)  8 0 2 2 4 1 31
S. Typhimurium (140)  72 56 74 78 79 17 4
S. Virchow (10)  30 0 0 40 40 40 90
S. Dublin (9)  0 0 0 11 0 0 0
S. Stanley (7)  0 28 57 57 71 28 28
S. Heidelberg (2)  0 0 50 0 50 0 0
S. Bredeney (2)  50 0 50 0 50 0 0
Amp = Ampicillin, Chl = Chloramphenicol, Strep = Streptomycin, 
Sulph = Sulphonamide, Tet = Tetracycline, Trim = Trimethoprim, Nal = Naladixic acid
The medical team provides expert support and advice on
communicable diseases. NDSC doctors receive queries via e-
mail and telephone from the general public, health
professionals and others (Figure A). The queries concern a
range of health topics (Figure B).
SARS Information Line
The SARS Information Line was set up during the 2003 SARS
outbreak and was operated by NDSC staff. A total of 250
queries were dealt with during a 4-week period. The majority
came from the general public (Figure C).
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Operational Support 
and Medical Advice 
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Figure 1. Sources of contact with Operational Support 
(from September 1999 to13th August 2003). 
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Figure 2. Health topics dealt with by Operational Support 
(End September 1999 to 13th August 2003)
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Figure 3. SARS database of queries dealt with from 18th March 2003 to 11th of April 2003.
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Campylobacteriosis in Ireland,
2001
Key points
• Campylobacter continues to be the most common
bacterial cause of gastroenteritis in Ireland, despite a
decrease in the overall numbers reported in 2001
• In 2001, there were 1286 laboratory confirmed cases of
Campylobacteriosis in Ireland (compared to 1613 cases
in 2000, and 2085 cases in 1999).
• The highest burden of illness was again seen in the 0-4
age group in 2001.
• Campylobacteriosis was found predominantly in males
in several age groups.
Introduction
Infections due to Campylobacter spp are the most commonly
isolated bacterial cause of human gastrointestinal illness in
Ireland, the UK and many countries globally with temperate
climates. Campylobacter jejuni is the predominant species
associated with human illness, with the remainder mostly
being C. coli and C. lari.
Campylobacteriosis presents as a diarrhoeal illness. The
diarrhoea is often bloody and is frequently associated with
acute abdominal pain. Symptoms may subside after a number
of days or may persist for weeks. Rarely, some long-term
sequelae may develop such as arthritis and approximately one
in every 1000 cases leads to a severe neurological disorder
called Guillain-Barré Syndrome (GBS).
This review presents data from the third year of the NDSC
national survey of the incidence of human campylobacteriosis
in Ireland. Valuable information has again been derived
regarding the epidemiology of laboratory-confirmed
campylobacteriosis which supplements further investigations
in this field by the Food Safety Authority of Ireland and other
partners in infectious disease surveillance and control.
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Methods
NDSC requested public health doctors and laboratories to
provide disaggregated information on all laboratory-confirmed
cases of campylobacteriosis diagnosed in 2001.
The following minimum dataset was requested: identifier, date
of birth/age, sex, address and date of
onset/isolation/reporting. In regions where laboratory
surveillance systems were in place, this information was
requested from their databases. Duplicates were removed
where detected. Data were assigned a health board and a
county where address was supplied. Analyses were carried out
using MS Access and SPSS. Direct methods of standardisation
were applied using the Irish population as the standard
population. Population data were taken from the 1996 census.
Species differentiation of isolates was not requested.
Results
Information on Campylobacter was obtained from all Health
Boards. Information on age was not available in 3% of cases
and information on sex was incomplete in 1% of cases. Those
cases for whom age was not supplied are not presented in age
standardised charts.
Incidence
In total, 1286 cases of laboratory-confirmed campylo-
bacteriosis were reported in 2001 in Ireland. This gives a
crude incidence rate (CIR) of 35.5 per 100,000 population.
This compared with a CIR of 44.5 per 100,000 in 2000 and
57.5 in 1999 (Table 1). Figure 1 shows the crude incidence
rate by health board.
Sex
Males accounted for 55.7% of cases and females 43.2%,
(1.2% not available). This was a very consistent finding with
the same ratio also observed in 2000 and 1999.
Seasonality
Campylobacter is known to have a well characterised seasonal
distribution, with a peak in late spring/early summer seen
each year. In 2001, this seasonal pattern remains similar but
the characteristic peak seen in previous years was not as
pronounced. Figure 2 shows the occurrence of cases by month
for Ireland in 2001.
Age
Age standardised incidence rates (ASIR) were then calculated
to allow comparisons between areas to be made without the
confounding effects of age (Figure 3). In 2001, the highest
incidence was recorded in the western region of the country,
with the lowest incidence seen in the north eastern region.
These data are consistent with those observed in 1999 and
2000.
Table 4 shows the crude incidence rates and age standardised
incidence rates (per 100,000 population) by health board in
2001
The age-standardised data is mapped and presented in
Figure 4.
Figure 5 shows the breakdown of cases in each age group for
Ireland.
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Figure 1 illustrates crude rates (cases/100,000 population)of human 
campylobacteriosis for each health board in Ireland. (2001)
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This demonstrates that there is a large burden of illness in
children under 5 years of age, and mirrors the results found in
1999 and 2000. When we examine age specific incidence
rates for each age group, the burden of illness in this age
group is even more evident (Figure 6)
Gender distribution
The variance in gender distribution that was noted in 1999
and 2000 was again evident from analysis of the data in
2001. In every age-group except 55-64 years there was a
predominance of male cases. This is shown in Figure 7 when
the data are adjusted for age and sex.
Discussion
This review presents data from the third year of the NDSC
national survey of the incidence of human campylobacteriosis
in Ireland. Valuable information has again been derived
regarding the epidemiology of laboratory-confirmed
campylobacteriosis. These data reveal a crude incidence rate
of 35.5 cases per 100,000 persons in Ireland in 2001. Overall
a decrease was seen in Ireland when compared with 2000 CIR
(44.5/100,000). This decrease was most notable in three
health board regions, viz. Western, Southern and South-
Eastern. Despite the reduction in numbers however,
campylobacteriosis remains the single biggest cause of
bacterial gastroenteric infection in Ireland (almost three times
the number of salmonellosis cases reported in 2001). It
should also be noted that these are laboratory confirmed
cases and the real burden of illness is even higher.
Higher rates were seen for the same period in Northern 
Ireland (52.4/100,000), England and Wales (107.6/100,000)
and Scotland (106.1/100,000). These data also represented a
decrease from 2000 figures for Northern Ireland and Scotland,
however the rates in England and Wales increased for the year
2001.
The burden of human gastrointestinal illness due to
Campylobacter in Ireland is evident from the data available
from three years of this national study and work towards its
control has been identified as a priority. To this end, a report
was published in 2002 by the Food Safety Authority of Ireland
entitled “Control of Campylobacter species in the food
chain”.1 This was the work of a multi-disciplinary expert
group convened to examine existing knowledge regarding the
control and prevention of human infection with
Campylobacter spp, and also to recommend measures to
reduce the risk of infection with this zoonotic organism
throughout the food chain. A number of key
recommendations have been made in this report including the
need for more extensive epidemiological data on human cases
of campylobacteriosis in Ireland.
It has been recognised that investigations are needed in
Ireland to examine the epidemiology of this organism and
attempt to provide answers to the questions that the data
presented in this report pose, such as, the high incidence in
very young children, the bias towards male cases and the
geographical distribution of cases. To address this, it is hoped
to conduct a matched case-control study in Ireland later this
year to examine risk factors for human cases of
Campylobacter infection.
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Figure 3: Age standardised incidence rates compared to crude incidence 
rates in each health board, 2001.
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Figure 5. Cases of campylobacteriosis by age group for Ireland in 2001
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Figure 6. Age specific incidence rates for campylobacteriosis in Ireland, 2001
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Figure 7: Age-gender adjusted incidence according to age-group in 2001.
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Table 1: Number of cases and CIR by health board in Ireland for 2001 and 2000. 
2001 2000 Health 
Board No. of CIR (incl. 95% C.I.) No of CIR (incl. 95% C.I.)
cases cases
ERHA 481 37.1 [33.8-40.4] 472 36.4 [33.1-39.7]
Midland 65 31.6 [23.9-39.3] 63 30.7 [ 23.1-38.2]
Mid-Western 62 19.6 [14.7-24.4] 73 23.0 [ 17.7-28.3]
North Eastern 51 16.7 [12.1-21.2] 51 16.7 [12.1-21.2]
North Western 81 38.4 [30.0-46.8] 100 47.4 [38.1-56.7]
South Eastern 159 40.6 [34.3-46.9] 226 57.7 [50.2-65.3]
Southern 217 39.7 [34.4-45.0] 337 61.6 [55.1-68.2]
Western 170 48.2 [41.0-55.5] 291 82.6 [73.1-92.1]
Ireland 1286 35.5 1613 44.5
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Most cases of campylobacteriosis are sporadic and it is
thought that the primary mode of transmission is foodborne.
Suggested risk factors for infection have included ingestion of
undercooked poultry meats and handling raw poultry, but also
contact with pets, especially puppies, consumption of
unpasteurised milk or dairy products and drinking water from
contaminated/ untreated supplies. In addition, the fact that
Campylobacter has a low infectious dose (500 organisms or
less), implies that cross-contamination of ready-to-eat foods
by raw meats may be an important source of infection. The
role of person-to-person transmission of campylobacteriosis is
thought to be very low.
C. jejuni and C. coli can be isolated from the intestines of
healthy farm animals, poultry, pets and wild birds. These
organisms rarely cause disease in these animals and the
carriage rate is believed to be quite high, particularly in
poultry. The lack of sub-typing information in Ireland has
meant that currently it is not possible to trace human cases
of campylobacteriosis back through the food chain.
The strong seasonal distribution of human cases of
campylobacteriosis is another extremely interesting feature of
this disease, with a peak seen in late spring/early summer
seen each year. The WHO European Centre for Environment
and Health (ECEH) is currently undertaking a European study
to examine the effects of global climate change on a number
of gastroenteric pathogens including Campylobacter spp.
From examination of retrospective surveillance and
meteorological data from a large number of countries, it is
hoped to be able to extrapolate the mechanisms governing 
the impact of weather and climate on foodborne and
waterborne illness.
Table 2. Number of cases by health board and sex, in 2001.
Health Board Total Males Females Unknown
ERHA 481 269 210 2
Midland 65 40 2 2 3
Mid-Western 62 28 34 -
North Eastern 1 27 24 -
North Western 81 50 31 -
South Eastern 159 90 69 -
Southern 217 126 88 3
Western 170 86 77 7
Ireland 1286 716 555 15
Table 3.  Cases by month (2001) for each health board in Ireland
E M MW NE NW SE S W Total
Jan 14 5 6 1 5 15 9 11 66
Feb 27 5 7 2 8 21 20 15 105
Mar 29 3 4 6 1 12 24 16 95
Apr 28 10 5 5 7 11 32 8 106
May 40 12 10 7 10 11 23 17 130
Jun 28 7 6 6 10 8 29 18 112
Jul 53 5 5 3 7 22 18 19 132
Aug 45 2 5 4 8 12 14 17 107
Sept 37 3 2 4 9 11 17 17 100
Oct 34 2 9 3 5 11 12 12 88
Nov 26 5 1 3 6 15 10 14 80
Dec 27 6 2 7 5 10 9 6 72
N/K 93 0 0 0 0 0 0 0 93
Total 481 65 62 51 81 159 217 170 1286
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Table 4.  Crude incidence rates and Age standardised incidence rates (per 100,000 
population) by health board in 2001
Health Board CIR [95% CI] ASIR [95% CI]
ERHA 37.1 [33.8-40.4] 35.4 [32.2-38.6]
Midland 31.6 [23.9-39.3] 30.2 [22.7-37.8]
Mid-Western 19.6 [14.7-24.4] 19.8 [14.8-24.7]
North Eastern 16.7 [12.1-21.2] 15.9 [14.8-24.7]
North Western 38.4 [30.0-46.8] 38.9 [30.4-47.4]
South Eastern 40.6 [34.3-46.9] 40.4 [34.1-46.7]
Southern 39.7 [34.4-45.0] 38.2 [33.0-43.4]
Western 48.2 [41.0-55.5] 45.4 [38.3-52.6]
Ireland 35.5 [33.5-37.4] 
Table 5.  Age-distribution by health board
Age group E M MW NE NW SE S W Total
(years)
0-4 93 23 24 7 24 45 65 61 342
5-9 19 4 3 6 7 14 25 11 9
10-14 10 1 2 4 4 7 4 3 35
15-19 14 2 3 2 3 6 13 8 51
20-24 61 5 4 4 5 9 9 16 113
25-34 88 8 11 14 9 25 33 15 203
35-44 66 3 4 5 10 11 17 16 132
45-54 47 4 1 1 6 16 12 3 90
55-64 33 4 1 2 7 8 12 3 70
65+ 38 8 9 3 6 17 17 21 119
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The Epidemiology of
Verocytotoxigenic E. coli
O157 in Ireland, 2002
Key Points
• E. coli O157 is an emerging pathogen and a serious
global health concern.
• In 2002, there were 70 confirmed cases of VTEC O157
infection in Ireland, the highest number reported since
1998.
• The highest burden of illness was recorded in children
under 5 years of age.
• Five cases of haemolytic uraemic syndrome were
reported among confirmed cases.
• Fifty seven per cent of cases had a date of onset of
illness between July and September.
Introduction
Verotoxigenic E. coli (VTEC) are so-called because of their
ability to produce one or both of two verotoxins (VT1 and
VT2). They cause a wide range of illnesses, from mild
diarrhoea to haemorrhagic colitis with severe abdominal pain
and bloody diarrhoea. Illness is usually self-limiting and
resolves after about eight days. However, 2-7% of cases
develop haemolytic uraemic syndrome (HUS), a form of renal
failure; this is a more likely complication in young children. In
fact, VTEC are the most common cause of diarrhoea-
associated HUS in children.1 In adults, VTEC infection may be
followed by thrombotic thrombocytopaenic purpura (TTP).
The primary reservoir is cattle, although VTEC have been
isolated from a variety of healthy animal carriers including
sheep, horses, goats and wild birds. While this organism was
first recognized as a foodborne pathogen (the ‘burger bug’), it
is now known that it can also be transmitted through water,
the environment and by direct contact with infected animals.
Person-to-person spread has also been documented.
E. coli O157 is the most commonly reported VTEC in Ireland,
the UK and the US, although other serogroups are capable of
causing the same spectrum of illness, including O26, O111,
O103 and O145. Many cases of O26 have been reported in
Ireland, including several cases in children during an outbreak
in 1999.2
Facilities for VTEC diagnosis and confirmation in Ireland have
improved greatly over the last few years. Since October 2000,
the Public Health Laboratory at Cherry Orchard Hospital,
Dublin has provided an E. coli O157 and non-O157 diagnostic
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service for clinical and food samples, including E. coli
serotyping and verotoxin detection.
Methods
This is the fourth year that NDSC, in co-operation with
Directors of Public Health in each health board region, have
operated the epidemiological surveillance system for VTEC
O157. Since 1999, specialists in public health medicine, senior
area medical officers, area medical officers, microbiologists,
medical laboratory scientists, surveillance scientists, infection
control nurses, principal environmental health officers, and
environmental health officers participate in a system whereby
a standard dataset of information is collected at health board
level on each case identified, and reported to NDSC. This
information includes socio-demographic data, clinical data,
possible risk factors and information on links between cases.
Some participants in the system also report non-O157 VTEC.
The case definitions that have been used in this system are as
follows:
• Suspected: a case of post-diarrhoeal HUS or TTP.
• Probable: a case with isolation of E. coli O157 from a clinical
specimen (asymptomatic or symptomatic), pending
confirmation of H7 or Shiga toxin or a clinically compatible
case that is epidemiologically linked to a confirmed or
probable case.
• Confirmed: a case that has isolation of E. coli O157:H7 from
a specimen or isolation of Shiga toxin-producing E. coli
O157:NM (non-motile) from a clinical specimen.
Probable cases that are subsequently confirmed as not H7 or
Shiga toxin producing are removed from the database. A
travel-associated case is defined as one where there has been
international travel within two weeks prior to onset of illness.
Results
Seventy confirmed cases of VTEC O157 were notified to
NDSC that had a date of onset of symptoms during 2002.
Two of these cases occurred in non-residents and are not
therefore included in the estimation of population-based
rates. These two cases are however, included in the descriptive
epidemiology. The numbers of confirmed cases and the crude
incidence rates of VTEC O157 in Ireland from 1996-2002 are
shown in table 1.
Suspect/Probable cases
An additional 9 suspect/probable cases were reported to
NDSC in 2002 that were not subsequently confirmed. These
included 4 from the Mid-Western Health Board, three from
the Southern Health Board and 1 each from the Western and
North-Western Health Boards. Four of these cases had HUS.
The remaining 5 cases were symptomatic contacts of
confirmed cases; one of these was found positive by
serodiagnosis. However, as these cases do not fit the case
definition for confirmed cases, they are not included in any of
the following analyses.
Regional distribution
As in previous years, regional variation was noted in the
numbers of cases reported (Table 2), with the highest rates in
the Midland, Western and South-Eastern Health Boards. These
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Figure 1. Age-gender specific incidence rate (per 100,000 population) of confirmed 
cases of VTEC O157, Ireland 2002
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Figure 2. Confirmed cases of VTEC O157 by month of onset of symptoms, 
Ireland, 1999-2002
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3 health board regions appear to have consistently higher
rates of VTEC O157 infection.
Age-sex distribution
The highest incidence rate was recorded for young children, a
trend also noted over the last few years (Figure 1).
Clinical Features
In total, 61 out of the 70 confirmed cases (87%) were
symptomatic. Reported symptoms among symptomatic cases
included: bloody diarrhoea in 31 cases (51%), and HUS in 5
cases (8%). Of the 5 cases of HUS, 4 occurred in children
under 5 years of age. One person who was admitted to
hospital with VTEC O157 in 2002 developed additional
medical problems during their hospital stay and died a
number of weeks later. It is unclear to what extent the VTEC
infection contributed to the precipitation of their subsequent
medical problems.
Seasonality of VTEC O157 cases
The majority of cases in 2002 occurred in late summer/early
autumn, with a peak in August (figure 2).
Travel-association
Nine cases were travel-associated. The countries visited within
14 days of onset of illness were Canada (1), UK (1), France (1),
Spain (4), Canary Islands (1) and Tunisia (1).
Microbiological Investigation
In 2002, phage typing results were available for 54 cases out
of 70. In total seven different phage types were reported. As in
previous years, the predominant type detected was PT 32
(n=30). This was followed in frequency by PT 8 (n=9), PT
21/28 (n=6) and PT 14 (n=4), all of which were previously
reported in Ireland (Figure 3).
Epidemiological Investigation
As a result of following up apparently sporadic cases in 2002,
14 family outbreaks were detected by health board personnel
among 29 confirmed cases, demonstrating the importance of
investigating each case of VTEC infection. No general
outbreaks were reported and no links were found with any
food or water source.
Risk exposures
Descriptive epidemiological information was collected on all
reported cases in an attempt to identify potential risk factors
for exposure to VTEC. Seven (10%) cases reported
consumption of unpasteurised milk or cheese. Of 58 cases
where information was collected on water source, the water
supply was public in 34 (59%) cases, private well water in 12
(21%) cases, from a group scheme in 6 (10%) cases and
recorded as other (not public and not well) in 6 (10%) cases.
Contact with farm animals was reported in 25 (36%) cases.
Non-O157 VTEC
In 2002, one confirmed VTEC O26 was reported to the
enhanced surveillance system.
Discussion
Seventy confirmed cases of VTEC O157 infection (1.7 per
100,000 population) were reported in Ireland in 2002, the
highest rate recorded since 1998. The Irish incidence rate is
comparable to that published for Northern Ireland in 2002
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Figure 3. VTEC O157 phage types in Ireland 1999-2002
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Table 1. Number of cases of confirmed VTEC O157 and crude incidence rate (95% CI) 
in Ireland, 1996-2002
Year Numbers of  Crude incidence rate*  
confirmed cases (95% CI) per 100,000
(incl. non-residents) population
1996** 8 0.2 (0.1-0.4)
1997** 31 0.8 (0.5-1.2)
1998** 76 2.1 (1.6-2.6)
1999 51 1.4 (1.0-1.8)
2000 37(42) 0.9 (0.6-1.3)
2001 50 (52) 1.3 (0.9-1.6)
2002 68 (70) 1.7 (1.3-2.2)
* For the years 1996-1999, census figures for 1996 were used while figures from the 2002   
   census were used to calculate rates from 2000-2002. The latter rates consequently differ    
   from those published previously.
** Data for the years 1996-1998 were taken from the report of the FSAI VTEC 
   Working Group.3 
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(1.6/100,000).4 Higher rates have consistently been reported
for Scotland (4.5/100,000 in 2002).5
Fifty-seven per cent of cases had a date of onset between July
and September. While a higher incidence during this time is a
feature of VTEC infection, the particularly high rate in the
summer of 2002 was influenced by the reporting of 14 cases
of VTEC O157 in the Midland Health Board region with a date
of onset during these 3 months. Two family outbreaks made
up half of these cases, while the remaining 7 cases had 3
different phage types. Certain parts of the country appear to
have consistently higher rates of VTEC O157 infection. The
Midland Health Board, along with the Western and South-
Eastern Health Boards, reported the highest rates of infection
in 2000, 2001 and 2002.
Nine HUS cases were reported to the surveillance system in
2002, but only 5 were confirmed as being caused by E. coli
O157. The remaining 4 suspect cases were all under 7 years of
age; 2 were male and 2 were female. Three of the four also
suffered from bloody diarrhoea. In HUS surveillance studies  in
different countries, up to 91% of cases were found to have
evidence of VTEC infection.1 It is possible that some or all of
these 4 suspect cases were caused by VTEC.
An additional probable case in the database was
epidemiologically linked to a confirmed case but was
confirmed only by serodiagnosis. The current case definition
requires cases to be culture positive. While this case is a
laboratory-confirmed case, it is not included in our analyses
because it falls outside the case definition. Under the new
case definition in the proposed infectious disease legislation,
cases of HUS and TTP which are serodiagnosed as being
caused by VTEC, will be included.
The reporting of a VTEC O26 case again in 2002 highlights
the importance of extending the enhanced surveillance
system to non-O157 VTEC. This was probably not the only
confirmed case of O26 in Ireland in 2002. Additional O26
cases were notified under the weekly notification system,
although their toxin-producing abilities are not reported.
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Table 2. Crude incidence rate (CIR) and age standardised incidence rate (ASIR) with 
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residence, Ireland, 2002
Health board CIR [95% CI] per 100,000 ASIR [95% CI] per 100,000 
ERHA 0.9 (0.4-1.3) 0.9 (0.4-1.4)
MHB 6.7 (3.3-10.0) 6.5 (3.2-9.8)
MWHB 0.3 (0.3-0.9) 0.3 (0.3-0.9)
NEHB 0.3 (0.3-0.9) 0.3 (0.3-0.8)
NWHB 1.4 (0.2-2.8) 1.4 (0.2-3.0)
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Invasive Haemophilus influenzae 
in Ireland, 1996-2002
Key Points
• Incidence of Hib disease increased in 2002, particularly
in <5 year olds
• No increase due to non-b H. influenzae strains observed
• Number of true Hib vaccine failures ranged from 2-4 per
year
• Surveillance of invasive H. influenzae in Ireland requires
strengthening
Introduction
Diseases of early childhood associated with Haemophilus
influenzae type b (Hib) can now be prevented by vaccination.
Hib was a leading cause of serious invasive infections such as
meningitis, epiglottitis, pneumonia and septicaemia, prior to
the licensing of the Hib conjugate vaccines. It was the most
common cause of bacterial meningitis and occurred primarily
among children under five years of age. The Hib vaccine was
introduced in Ireland in October 1992 as part of the primary
childhood immunisation schedule. A catch-up programme
was also initiated at that time offering the vaccine to those
under five years of age. The vaccine is specific for the diseases
caused by Hib but does not protect against infections caused
by other Haemophilus strains. Despite the fact that the
incidence of Hib disease has dramatically declined since the
introduction of the vaccine, it is essential that the incidence
of all invasive H. influenzae infections continue to be closely
monitored in Ireland. This will ensure that any changes in the
epidemiology of the disease are detected promptly, that
reasons for these changes are identified and that the
necessary public health interventions are taken.
Materials and Methods
National data on invasive H. influenzae for 1996-1998 was
collated by Dr Jerry Fogarty, Department of Public Health,
WHB, while from 1999 onwards data have been collated by
NDSC. NDSC obtains these data from three main sources:
1. Enhanced bacterial meningitis surveillance system (on an
ongoing basis)
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2. Directly from the laboratories/microbiologists
(approximately once a year)
3. PHLS Haemophilus Reference Unit, Oxford, UK
(occasionally)
Details of all invasive cases are inputted in an MS Access
database. Vaccination details of cases are sought by
Departments of Public Health if (i) the case was born after
1986 and (ii) the isolate is type b or has not been typed. In
the event of a vaccine failure details on vaccination dates,
vaccine brand and batch numbers are obtained.
A case is defined as invasive H. influenzae disease in a person
with an isolate from a normally sterile site.
Hib vaccine failures are defined as:
True vaccine failure (TVF): Invasive Hib disease occurring  (i)
greater than two weeks after one dose of Hib vaccine given at
age greater than one year, or (ii) greater than one week after
three doses given at age less than one year.
Apparent vaccine failure (AVF): Invasive Hib disease occurring
where the case was incompletely immunised or insufficient
time had elapsed to be considered a TVF.
Possible vaccine failure (PVF): Invasive H. influenzae in a
vaccinated child but where the isolate was not serotyped.
Such a failure may be a possible true vaccine failure (PTVF) or
a possible apparent vaccine failure (PAVF).
Results
Epidemiology of invasive H. influenzae
Since the Hib vaccine was introduced in 1992, the number of
invasive Haemophilus influenzae type b (Hib) infections has
declined from approximately 100 cases per year in the late
1980s to approximately 10 cases per year from the mid-
1990s onwards (Figure 1).
Between 1996 and 2002, 156 cases of invasive H. influenzae
were reported in Ireland, which is an average of 22 cases per
year (0.61/100,000 total population; denominator data from
1996 census) (Figure 2). Over that period, 40% of the
invasive cases were confirmed as Hib. However, the
proportion of Hib cases may be higher since the serotype had
not been determined (not typed) for 29% of the cases
reported.
An increase in Hib infections was observed in 2002 (n=10;
0.26/100,000 total population, denominator data from 2002
census) when compared with the previous three years; this
gives a mean of seven cases per year (Figure 2). This increase
in 2002 was most pronounced in the latter half of the year
and was predominantly in the less than five year olds (Figure
3). A similar increase due to other H. influenzae serotypes has
not been observed in this age group (Figure 4).
The numbers of invasive H. influenzae and invasive H.
influenzae type b (Hib) cases reported between 1996-2002 by
age group are presented in Table 1a & 1b, respectively. Thirty
five percent of the invasive H. influenzae cases occurred in
under 5 year olds, while 31% occurred in over 65 year olds.
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Figure 2.  Number of invasive H. influenzae infections by serogroup (1996-2002)
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Figure 3.  Number of invasive Hib cases in Ireland by age group
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Figure 1.  Invasive H. influenzae type b infections in Ireland, 1987-2002. Updated from J. Fogarty forum 1996.
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Sixty two percent of Hib cases reported between 1996 and
2002 occurred in under 5 year olds (38/61). Seven cases of
Hib infection occurred in this age group in 2002, which is an
age specific incidence rate of 2.5 per 100,000 in 2002
(denominator data from 2002 census).
Between 1996 and 2002, 55 cases of invasive H. influenzae in
children under 5 years of age have been reported. The disease
presentations in these children were as follows: meningitis
(n=18); septicaemia (n=14); meningitis & septicaemia (n=4);
epiglottitis (n=7); osteomyelitis/septic arthritis (n=4);
pneumonia (n=4); cellulitis (n=1); other (n=1) and
unknown/not reported (n=2).
Hib vaccine failures
Since 1996, 28 Hib vaccine failures have been reported in
Ireland (19 TVF, 7 AVF, 1 PTVF, 1 PAVF). The vaccination
status is unknown for an additional five cases and therefore
these potentially could be vaccine failures also. The number
of TVF tends to vary between 2 and 4 per year (Figure 5).
Eighty nine percent (17/19) of the TVF occurred in the 1-4
years age group. The two exceptions were both between 5-9
years of age. Four AVF occurred in children less than one year
of age and three in 1-4 years old children. The PTVF was in a
1-4 year old and the PAVF was in a child less than one year of
age. One third (13/38, 34%) of the Hib cases that occurred in
under 5 year olds between 1996 and 2002 had not been
vaccinated (Figure 6).
Discussion
In England & Wales, an increase in Hib infections been
observed particularly in the under 5 year olds. A similar
increase has not been seen with other H. influenzae serotypes.
The incidence rate of Hib disease in this age group increased
from 1.0 in 1999, to 1.86 in 2000, to 2.7 in 2001 to 4.17 in
2002.1 The majority of these Hib cases (approx 90%)
occurred in vaccinated children, thereby leading to concerns in
the UK regarding the efficacy of the Hib vaccine.
Possible reasons for the increase in Hib disease in the UK
include2
1. Random variation in Hib disease occurrence
2. Decreasing herd immunity
3. Rapid infant vaccination schedule in the UK of 3 doses at 2,
3 and 4 months with no booster dose and also subsequent
waning of the initial impact of the catch-up campaign
4. A reduced immune response to Hib vaccines in part of the
vaccinated population may be occurring, which could be
related to the use of a combination acellular pertussis,
diphtheria, tetanus and Hib vaccine during 2000-2001,
which produces lower Hib antibody levels, compared with
whole-cell pertussis and Hib combinations. A similar
increase in invasive Hib has not been seen in other
countries using acellular pertussis vaccines; these countries
mostly use a routine booster at 12-15 months.
Although the number of cases of invasive H. influenzae
reported in Ireland did not change greatly between 1996 and
2002, an increase in Hib infections was observed in 2002.
This increase was most marked in the under 5 year olds, seven
Table 1b. Number of invasive H. influenzae type b cases by age group
Year <1 1-4 5-9 10-14 15-24 25-34 35-44 45-54 55-64 >65 Total  
1996 1 5 0 0 0 0 0 1 1 0 8
1997 3 3 0 0 0 1 0 0 1 2 10
1998 3 6 1 0 0 0 0 1 0 0 11
1999 1 2 1 0 0 0 0 1 1 1 7
2000 2 2 1 0 0 0 0 0 0 2 7
2001 1 2 2 0 0 0 1 0 0 2 8
2002 0 7 0 0 0 0 0 0 0 3 10
Total 11 27 5 0 0 1 1 3 3 10 61
Table 1a. Number of invasive H. influenzae cases by age group
Year <1 1-4 5-9 10-14 15-24 25-34 35-44 45-54 55-64 >65 Total  
1996 3 5 0 0 0 0 1 2 2 4 17
1997 7 4 0 2 2 2 0 1 1 4 23
1998 4 7 1 0 1 1 0 1 0 3 18
1999 2 2 2 0 2 1 1 6 2 11 29
2000 5 5 1 0 1 0 1 1 0 7 21
2001 2 2 2 2 4 1 2 1 2 9 27
2002 0 7 0 0 1 1 0 2 1 9 21
Total 23 32 6 4 11 6 5 14 8 47 156
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cases (2.5/100,000) were reported with five of these seen in
the latter half of 2002. The increase in this age group
continued into the first half of 2003 with six cases being
reported to the end of June. Although the incidence of Hib
infections in the under five year olds in Ireland in 2002 was
similar to that reported in England and Wales in 2001, a far
greater proportion of the cases in England & Wales were in
vaccinated individuals (90%) when compared with Ireland
(57%). Hib vaccine uptake at 24 months in UK is 94%
compared to 84% in Ireland. Based on these observations it
would indicate poor uptake of the Hib vaccine in Ireland may
be as much a contributory factor to the recent increase in Hib
infections as to any particular issue regarding the efficacy of
the vaccine.
It is vital that the surveillance of invasive H. influenzae is
improved in Ireland. Such improvements would ensure that
any changes in trends of the disease can be detected in a
timely manner and assist in identifying the reasons for these
changes. Such information in return would enable informed
public health decisions and actions to be taken regarding
improved prevention of the disease if so required.
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Figure 4.  Number of invasive H. influenzae infections by serogroup in under-5 year olds
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Figure 5. Number of Hib vaccine failures in Ireland, 1996-2002
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<5 year olds. 
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Key Points
• Influenza activity in Ireland was mild during the
2002/2003 season, peaking in February 2003
• Influenza B was the predominant circulating strain
• Respiratory syncytial virus positive detections reached
the highest level on record during the 2002/2003 season
• Human cases of influenza A (H7N7) and influenza A
(H5N1) were detected in the Netherlands and Hong
Kong, respectively during the 2002/2003 season 
Introduction
Influenza is one of the commonest and oldest diseases known
to man. The impact on public health varies depending on the
circulating strain of virus and the level of pre-existing
immunity in the community each season.1, 2
There are three types of influenza virus A, B and C. Influenza C
rarely causes human illness. The clinical course of influenza B
changes little from year to year and is usually milder than
influenza A. Influenza A varies considerably and is responsible
for epidemics and pandemics.3 Influenza A viruses are divided
into three subtypes, on the basis of two surface glycoproteins,
haemagglutinin (H) and neuraminidase (N). Minor changes in
the surface glycoproteins are known as antigenic drift.
Antigenic drift occurs between each influenza season,
necessitating the annual reformulation of the influenza
vaccine, which is based on the current circulating strains.
Major changes in the surface glycoproteins occur infrequently
and are known as antigenic shift. These result in the
emergence of a novel virus that may be capable of causing an
influenza pandemic. The Spanish Flu Pandemic of 1918 is
acknowledged as the most devastating, resulting in an
estimated 20-40 million deaths worldwide.3, 4
Influenza-like illness activity 
& surveillance during the
2002/2003 season
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The 2002/2003-influenza season was the third year of
influenza surveillance using computerised sentinel general
practices in Ireland. The National Disease Surveillance Centre
(NDSC) is working in collaboration with the National Virus
Reference Laboratory (NVRL) and the Irish College of General
Practitioners (ICGP) on this surveillance project. Influenza
activity in Ireland was mild during the 2002/2003-influenza
season, peaking in February 2003, with influenza B
predominating.
Materials and Methods
Clinical data
Thirty-four general practices were recruited to report
electronically, on a weekly basis, the number of patients with
influenza-like illness (ILI). ILI is defined as the sudden onset of
symptoms with a temperature of 380C or more, with two or
more of the following: headache, sore throat, dry cough and
myalgia. Patients were those attending for the first time with
these symptoms. In total, the 34 sentinel general practices
represent 2.4% of the national population. Practices were
located in all health boards with their location based on the
population of each health board.
Virological data
Sentinel GPs were requested to send a combined nasl and
throat swab on one patient per week where a clinical
diagnosis of ILI was made. Swabs were sent to the NVRL for
testing using Shell Vial and PCR techniques and results were
reported to NDSC. The NVRL also reported on a weekly basis
the results of respiratory specimens referred mainly from
hospitals. Antigenic characterisation was conducted by
Millhill, London.
Regional influenza activity
The Departments of Public Health sent an influenza activity
index (no report, no activity, sporadic-, localised-, regional- or
widespread activity) every week, to NDSC. The activity index
is analogous to that used by the WHO global influenza
surveillance system and the European Influenza Surveillance
Scheme (EISS). The index is based on sentinel GP ILI
consultation rates, laboratory-confirmed cases of influenza,
sentinel hospital admissions data and/or sentinel school
absenteeism levels. One sentinel hospital was located in each
health board. Sentinel primary and secondary schools in 
each health board were located in close vicinity to the
sentinel GPs.
Weekly influenza surveillance report
NDSC produced a weekly influenza report, which was posted
on the NDSC website each Thursday. Results of clinical and
virological data were reported, along with a map of influenza
activity and a summary of influenza activity worldwide.
Results for the 2002/2003-influenza season
Clinical data
GP consultations for influenza-like illness (ILI) were reported
on a weekly basis per 100,000 population from week 40 2002
to week 20 2003 (figure 1). Influenza activity was very mild
during the 2002/2003-influenza season, similar to the
2001/2002 season. The peak GP consultation rate occurred
during week 8, with a rate of 52.6 per 100,000 population.
This is compared to a peak rate of 29.0 per 100,000 in the
2001/2002 season and 121.0 per 100,000 in the 2000/2001-
influenza season. The peak age specific consultation rate
during the 2002/2003 season was in the 10-14 year age
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Figure 1: GP consultation rate for influenza-like illness per 100,000 population by report week, during the 2000/2001, 2001/2002 and 2002/2003 influenza seasons.
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Table 1: Sentinel GP influenza results by type and season for the 2000/2001, 
2001/2002 & 2002/2003 influenza seasons.
Season Total Positive % Positive Influenza A Influenza B
swabs swabs 
2000/2001 329 140 42.6 55 85
2001/2002 242 65 27.0 64 1
2002/2003 249 86 34.5 27 59
Total 820 291 35.5 146 145
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Table 2: Sentinel GP influenza results by type, subtype and report week for the 2002/2003 influenza season
Week number Total swabs  Positive swabs Percentage positive Influenza A (H1) Influenza A (H3N2) Influenza B
40 4 0 0.0 0 0 0
41 1 0 0.0 0 0 0
42 4 0 0.0 0 0 0
43 3 0 0.0 0 0 0
44 3 0 0.0 0 0 0
45 7 0 0.0 0 0 0
46 1 0 0.0 0 0 0
47 4 0 0.0 0 0 0
48 6 0 0.0 0 0 0
49 3 0 0.0 0 0 0
50 5 0 0.0 0 0 0
51 8 0 0.0 0 0 0
52 5 0 0.0 0 0 0
1 7 0 0.0 0 0 0
2  11 1 9.1 0 0 1
3 9 1 11.1 0 1 0
4 15 3 20.0 0 2 1
5 16 5 31.3 0 1 4
6 16 12 75.0 1 0 11
7 17 11 64.7 1 0 10
8 21 11 52.4 0 1 10
9 12 9 75.0 0 2 7
10 9 7 77.8 0 0 7
11 8 3 37.5 0 0 3
12 7 4 57.1 0 3 1
13 10 5 50.0 2 2 1
14 10 4 40.0 0 3 1
15 8 7 87.5 2 3 2
16 7 0 0.0 0 0 0
17 6 3 50.0 0 3 0
18 4 0 0.0 0 0 0
19 2 0 0.0 0 0 0
20 0 0 0.0 0 0 0
Total 249 86 34.5 6 21 59
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Figure 2: Cumulative age and sex specific ILI rate per 100,000 population from week 40 2002 to week 20 2003. The denominator used in the age and sex specific consultation rate is from 
the 2002 census data; this assumes that the age and sex distribution of the sentinel general practices is similar to the national age and sex distribution. 
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group (figure 2). A total of 347 ILI cases were reported by
sentinel GPs during the 2002/2003 season.
Virological data
Since the start of the 2002/2003-influenza season, the NVRL
have tested 249 sentinel specimens for influenza virus, 86
(34.5%) were positive: 27 influenza A and 59 influenza B
(tables 1 & 2). Influenza B was the predominant circulating
influenza virus type this season, circulating between weeks 2
and 15 2003. This was followed by detection of influenza A
between weeks 3 and 17 2003. The highest number of
positive swabs detected this season was during weeks 6, 7, &
8 with between 52.4%-75.0% of swabs positive (figure 3),
coinciding with the period of peak clinical activity. Influenza A
accounted for 31.4% of positive swabs this season: 6 influenza
A (H1) and 21 influenza A (H3N2). Influenza B accounted for
68.6% of positive swabs. Positive influenza virus detections
peaked in the 10-14 year age group, mainly infected with
influenza B (figure 4).
The NVRL tested a total of 1032 non-sentinel respiratory
specimens mostly from hospitals during the 2002/2003
influenza season. Four (0.39%) were positive for Adenovirus,
303 (29.4%) for respiratory syncytial virus (RSV), 4 (0.39%)
for parainfluenza virus type 1, 1 (0.10%) for parainfluenza
virus type 2, 4 (0.39%) for parainfluenza virus type 3 and 1
(0.10%) for influenza A virus.
Vaccination status & antigenic characterisation
Of the 86 positive influenza virus cases, 64 (74.4%) were not
vaccinated, 2 (2.3%) were vaccinated and 20 (23.3%) were of
unknown vaccination status. The NVRL referred one influenza
B and 2 influenza A (H3N2) virus isolates to the WHO
Laboratory in London for antigenic characterisation. The
influenza B virus was antigenically closely related to B/Hong
Kong/330/2001-like virus. The 2 influenza A (H3N2) isolates
were closely related to A/Panama/2007/99. All isolates were
covered by the 2002/2003 influenza vaccine.
Influenza activity by health board/authority
Regional influenza activity peaked between weeks 5 and 13
2003, with 4 to 7 health boards reporting sporadic activity
weekly. During week 8, the period of peak clinical activity,
localised influenza activity was reported from the NEHB, with
6 other health boards reporting sporadic activity (figure 5). In
some health boards increases in the number of ILI cases were
reflected by increases in hospital respiratory admissions and
also occasionally by increases in school absenteeism. Between
weeks 6 and 8, increased absenteeism was reported in several
sentinel primary and secondary schools in the ERHA, NEHB
and the SEHB, often associated with ILI.
Respiratory Syncytial Virus
Respiratory syncytial virus (RSV) is the single most important
cause of hospitalisation for viral respiratory tract disease in
infants and young children and is a major cause of
nosocomial infection.5 The NVRL have been collecting data on
RSV positive specimens since September 1988. RSV data from
the NVRL provides comprehensive surveillance of RSV
infection in infants treated in hospitals and is a good indicator
of seasonal patterns. Between October 2002 and May 2003,
the number of RSV positive detections from hospital
respiratory specimens referred to the NVRL reached the
highest level on record.6, 7 Three hundred and three RSV
N
um
be
r 
of
 p
os
it
iv
e 
sw
ab
s
Pe
rc
en
ta
ge
 o
f p
os
it
iv
e 
sw
ab
s
Week 40, 2002 to week 20, 2003
Figure 3: Number and percentage of sentinel influenza virus positive detections during the 2002/2003-influenza season.
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positive specimens were detected (figure 6), peaking in weeks
48 and 49 2002, earlier than normal. RSV usually peaks in late
December /early January each year. Prior to the 2002/2003
season, the highest number of RSV positive specimens
detected by the NVRL was 250 in the 1998/1999 season. Of
the 303 positive RSV cases identified between October 2002
and May 2003, 11.2% (34) were less than 1 month old,
67.7% (205) were between 1 and 6 months, 16.8% (51) were
between 7 and 12 months and 2.3% (7) were over 12 months
old.
During the 2002/2003 season, the NVRL carried out a pilot
study to assess the incidence of RSV in sentinel specimens. All
sentinel specimens received at the NVRL, from week 40 2002
to week 5 2003 (n=77), which tested negative for influenza
were included in the study. This timeframe coincided with the
RSV season for 2002/2003. The pilot was carried out using
molecular technology. Of the 77 sentinel swabs tested, 7
(9.1%) were positive for RSV. Subsequent subtype analysis
identified 4 of the samples as RSV A and 3 as RSV B viruses.
These results confirm international experience and suggest
that consideration should be given to expanding the
respiratory screen in sentinel specimens to include RSV in
future surveillance.
Influenza activity worldwide
In Northern Ireland, morbidity levels for influenza and ILI were
low during the 2002/2003 season, with influenza B
predominating. Laboratory confirmed RSV infection peaked in
weeks 50 and 51, 2 to 3 weeks earlier then expected, as in the
Republic of Ireland.8 In England, Scotland and Wales, ILI
consultation rates peaked in January 2003, with the highest
consultation rates among children. During late January and
early February 2003, influenza B outbreaks were reported in
schools in England.9
Across Europe, influenza activity was heterogeneous during
the 2002/2003 season. Influenza B was the dominant type
until week 6 2003, mainly circulating in the south west and
west of Europe. From week 7 2003, influenza A was the
dominant type, mainly circulating in Central Europe. More
than 99% of the viruses reported by EISS have been closely
related to the 2002/2003 influenza vaccine strains. A very
small number of influenza A (H3N2) viruses (detected in
England, Norway, and Switzerland) have, however, shown
reduced reactivity to A/Panama/2007/99 antiserum (similar
to A/Fujian/411/2002).10
In February 2003, outbreaks of highly pathogenic avian
influenza, influenza A (H7N7), were reported in several Dutch
poultry farms. Following this, avian cases were reported in
Belgium and Germany. Human cases of conjunctivitis and ILI,
including one death, were associated with the outbreaks.
There was also evidence of human-to-human transmission in
the Netherlands and Belgium.11 
In the US, the 2002/2003 influenza season was also mild,
peaking in February 2003. Influenza A (H1) and B viruses
circulated widely, with the predominant virus varying by
region and time of season.12 In Canada, influenza A (H1N2)
was the predominant circulating subtype during the
2002/2003 season; all viruses identified in Canada this season
were closely related to the current vaccine strains.13 
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Figure 4: Number of sentinel swabs positive for influenza virus by type, subtype and age group (years),  between week 40 2002  and week 20 2003.
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In Hong Kong, influenza activity was mild to moderate during
the 2002/2003 season, with influenza A (H3N2) peaking in
March 2003.14 In February 2003, an outbreak of influenza A
(H5N1) in Hong Kong was limited to two cases, one of who
died; both cases were members of the same family. The
influenza virus that infected these two cases contained no
human genes (the virus genes were purely avian in origin);
therefore the risk of human-to-human transmission was very
low and unlikely to lead to an epidemic. The virus belongs to a
different genetic lineage then that of a similar H5N1 virus
that caused an outbreak in Hong Kong in 1997, resulting in 18
human cases and six deaths.15 
The WHO announced the composition of the vaccine for the
2003/2004 Northern Hemisphere influenza season on the
28th of February 2003: A/New Caledonia/20/99 (H1N1)-like
virus, A/Moscow/10/99-(H3N2)-like virus (the widely used
vaccine strain is A/Panama/2007/99) and B/Hong
Kong/330/2001. They recommend that all people in high-risk
groups and healthcare workers caring for them be vaccinated
as a matter of urgency.16 This strategy would reduce the
burden of influenza and reduce cases of respiratory disease
that could be mistaken for SARS or raise suspicion requiring
costly investigations.
Discussion
Influenza activity was mild in Ireland during the 2002/2003-
influenza season; similar to the 2001/2002 season.17 This low
level of influenza activity was also reflected throughout much
of Europe.10 Influenza B was the predominant virus type
circulating this season in Ireland. Influenza activity can be
measured not only by GP consultation rates, and laboratory
confirmed cases of influenza but also through school and
work absenteeism, hospital admission rates, sales of “over the
counter” medications and deaths. It is of interest to note that
the majority of influenza B cases identified in Ireland were
aged between 10 and 19 years of age, corresponding with the
highest GP consultation rates for ILI. The peak in influenza B
detections also coincided with increases in school
absenteeism associated with ILI. Increases in the number of ILI
cases were also reflected by increases in hospital respiratory
admissions in some health boards.
Further expansions and improvements in the present influenza
surveillance system are now being planned for forthcoming
seasons, including an increase in the number of sentinel GPs,
testing sentinel specimens for respiratory syncytial virus and
increasing the number of sentinel swabs. The detection of
influenza A (H7N7) in the Netherlands and influenza A
(H5N1) in Hong Kong during the 2002/2003-influenza season
has emphasised the importance of a timely national
surveillance system for influenza.
Figure 5: Map of influenza activity by health board during week 8 2003, 
the period of peak influenza activity
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Corporate Services
The corporate services division provides NDSC with the
necessary resources, skills, competencies, internal support
structures and systems, and policies and procedures to
achieve its objectives.
The divisional objectives are:
• To ensure NDSC has a qualified and competent workforce
necessary to meet its objectives and that NDSC is an
employer of choice
• To develop and implement systems, policies and procedures
that ensure the most effective and efficient use of NDSC’s
financial resources to enable it to achieve its objectives
• To facilitate the enhanced performance of NDSC by the
provision of office accommodation and other support
services
• To provide skilled administration support to the functional
teams at NDSC
• To ensure NDSC meets all its obligations and requirements
in relation to planning and compliance issues
Office Accommodation
At the beginning of 2002 NDSC was accommodated in three
offices: at Sir Patrick Dun’s Hospital, Lower Grand Canal
Street, Dublin 2, at 11-12 Warrington Place, Dublin 2, and at
60 Lower Baggot Street, Dublin 2.
As part of the NDSC office accommodation plan and
following the approval of the Department of Health and
Children, work commenced on the fit-out of the new NDSC
offices at 25-27 Middle Gardiner Street, Dublin 1, in January
2002. A staff consultation process was carried out for all
aspects of the building design and development, which proved
to be an invaluable source of ideas and advice. The move to
Gardiner Street was completed in late April 2002 and NDSC
began operating from its new offices on 29th April 2002. The
provision of new modern offices with high standard meeting
and technology facilities has greatly facilitated the
development of NDSC during 2002.
Human Resources
During 2002 NDSC continued to expand its staff through the
recruitment of highly qualified and experienced medical,
scientific, IT and administration professionals. NDSC
encourages staff to avail of training courses considered to be
of value to them in their work and in their personal
development. In addition to attendance at relevant courses,
seminars and conferences during 2002, many staff of NDSC
availed of the opportunity to attend computer skills courses
during the year. In line with NDSC’s policy of supporting a
work-life balance, flexible working was introduced at the
Centre in 2002.
Finance
Following the appointment of an Accountant at NDSC in
October 2002, a new computer-based accounting system was
implemented to facilitate the extraction of cost data and
management information and new financial procedures were
approved and introduced accordingly.
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Surveillance of Outbreaks 
of Infectious Intestinal Disease 
in Ireland, 2001
Key points
• 64 outbreaks of IID were reported to the national
outbreak surveillance system in 2001, compared to 33 in
2000
• These outbreaks were responsible for at least 2500
persons becoming ill
• Norovirus (or suspect viral) outbreaks have emerged as
the primary cause of IID outbreaks
Introduction
Investigation of outbreaks of infectious diseases is one of the
most important and challenging components of public health.
Outbreak investigations aim to identify the source of the
outbreak, institute control measures and prevent additional
cases. The information gathered during outbreak
investigations can be used to determine possible ways of
preventing future outbreaks. The Food Safety Authority of
Ireland (FSAI) was responsible for initiating the first enteric
outbreak system in Ireland in 1998 and commenced
collection on outbreaks of illness caused by infectious
intestinal disease (IID) in that year.
In July 2001, the National Disease Surveillance Centre (NDSC)
took over this function and set up a national surveillance
system for all outbreaks of infectious disease in Ireland. The
data for 2001 was therefore gathered by FSAI and NDSC.
Objectives of surveillance
The principal objectives of the national outbreak surveillance
system are to gain information on the epidemiology of all
outbreaks of infectious disease in Ireland.
More specific objectives include estimating the burden of
illness caused by outbreaks, identifying high-risk groups in the
population and estimating the workload involved in the
management of outbreaks. The information gathered can be
used to inform public health professionals about the causes
and factors contributing to outbreaks, to target prevention
strategies and to monitor the effectiveness of prevention
programmes.
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Outbreak definitions
Outbreak
Two or more linked cases thought to have a common
exposure who experience a similar illness, or proven infection.
Outbreaks may be general or confined to one household
(family) and may involve cases locally, nationally and
internationally.
General Outbreak
An outbreak affecting members of more than one private
residence or residents of an institution.
Methods of surveillance of outbreaks
Since July 2001, outbreaks are reported to NDSC by the
Departments of Public Health using a preliminary notification
form (by fax or email). A full report is then forwarded by the
lead investigator once more complete data are available. The
data collected include information on the source of reporting
of the outbreak, the extent of the outbreak, mode of
transmission, location, pathogen involved, laboratory
investigation, morbidity and mortality data, suspect vehicle
and factors contributing to the outbreak. These data are then
stored and analysed in a Microsoft Access database.
Results
During 2001, 64 outbreaks of infectious gastrointestinal
disease were reported in Ireland, resulting in 2506 people
becoming ill. Eighty one people were reported to have been
hospitalised (3%). Table 1 shows the regional distribution of
outbreaks during 2001.
Causative Pathogen
One of the prominent features of the outbreaks reported in
2001 was the proportion due, or suspected as being due to
gastroenteric viruses (Figure 1). Norovirus (NV) - the virus
responsible for Winter Vomiting Disease, previously known as
“Norwalk-like virus” or Small Round Structured Virus - was
confirmed as being responsible for nine (14%) outbreaks of
IID. Another 28 outbreaks were not laboratory-confirmed but
were suspected as having a viral cause, meaning that 58% of
outbreaks were either confirmed NV, or suspected viral in
aetiology. E. coli O157 accounted for eleven outbreaks (17%
of the reported total). Ten of these outbreaks occurred in
private homes and one was associated with a crèche. There
were three outbreaks due to Salmonella enterica. Two of
these, (the outbreaks caused by S. Heidelberg and S.
Enteritidis) were both due to person-to person transmission
and the outbreak due to S. Typhimurium was confined to one
household and thought to be associated with animal contact.
There were two Cryptosporidium spp outbreaks; both of these
had a waterborne route of transmission. The first report of an
outbreak due to Campylobacter spp was received in 2001.
When the number of people becoming ill as a result of
reported outbreaks of IID is examined, viral or suspected viral
causes were responsible for 2203 cases of illness, representing
88% of those becoming ill. Bacterial and protozoal causes
account for approximately three percent of reported illness
(Table 2).
Mode of Transmission
In 2001, the majority of outbreaks of IID were associated with
person-to-person transmission or person-to-person
Table 1. Number of outbreaks of IID and total numbers ill in each health board area 2001.
Health Board Number of Outbreaks Number ill
ERHA 21 673
MHB 6 294
MWHB 1 140
NEHB 12 258
NWHB 0 0
SEHB 9 150
SHB 12 525
WHB 3 466
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Figure 1. Outbreaks of IID reported in 2001 by pathogen
Cryptosporidium spp Suspect Viral
E coli O157 Not Known
Norovirus Other
Salmonella spp.
Table 2.  Number of cases of Illness arising as a result of outbreaks of IID, 
by Pathogens: 2001.
Pathogen Number of Outbreaks Number ill
Campylobacter spp 1 14
Cryptosporidium spp 2 6
E. coli O157 11 42
Norovirus 9 802
Rotavirus 1 7
Salmonella Enteritidis 1 7
Salmonella Heidelberg 1 2
Salmonella Typhimurium 1 2
Shigella sonnei 1 4
Staph aureus 1 5
Suspect Viral 28 1401
Not Known 7 214
Total  64 2506
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transmission in conjunction with foodborne/ waterborne
transmission (as seen in Table 3). Interestingly however, when
the number of people ill is examined, a suspect waterborne or
combined waterborne/ person-to-person mode of
transmission was seen to account for the majority of cases ill
(36% of cases). The route of transmission was not known in a
quarter of the reported outbreaks.
When the mode of transmission is analysed by pathogen (as
seen in Figure 2), the role of person-to-person spread is seen
to explain the high attack rates in the confirmed or suspect
noroviral outbreaks.
Location
Excluding private households, hotels were the commonest
cited location of outbreaks of IID during 2001(Table 4). Hotel
outbreaks were also responsible for causing the greatest
number of people to become ill. Residential homes and
hospitals were the next most common outbreak settings.
Seasonal distribution
When the outbreaks are analysed in terms of seasonality, it is
noted that in 2001 the largest number of outbreaks occurred
in the summer months, with a peak seen in July (as shown in
Figure 3). Many of the noroviral outbreaks associated with
tourist settings occurred during this period.
Conclusions
In Ireland in 2001 the number of outbreaks reported was 64
which is an increase over the previous three years where there
was an average of 34 outbreaks reported each year. This
database includes information on all reported outbreaks of IID
but there is still likely to be a considerable degree of under-
reporting of outbreaks as many family outbreaks are not
formally investigated and hence not reported at national level.
One of the most striking features of the analysis of the
outbreak data in 2001 has been the emergence of viruses as a
prime cause of outbreaks of gastroenteritis. Over half of all
reported outbreaks were shown to either be confirmed
norovirus or suspect viral aetiology. The significant morbidity
associated with these viral outbreaks is evident as the data
reveals that confirmed or suspected viral causes were
responsible for 2203 cases of illness in 2001, representing
88% of those becoming ill in outbreaks of IID. Undoubtedly
the true burden of illness due to this pathogen is even higher
than this.
Another important feature of these viral outbreaks is the
range of locations in which they occurred. Outbreaks were
seen to occur in healthcare settings (hospitals and nursing
homes) and were also associated with commercial catering/
tourist settings such as hotels and restaurants. Because of
this, viral outbreaks were noted to take place throughout the
year, with the majority occurring in the summer months.
The importance of water as a mode of transmission is also
evident from the data presented here. Just seven outbreaks
were associated with a suspect waterborne or waterborne
combined with another route of transmission, however these
outbreaks were seen to account for over 40% of all cases
reported ill during outbreaks of IID.
In recent years, with the advent of food safety agencies in
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Figure 2.  Number of Outbreaks of IID by pathogen and by Mode of Transmission (2001).
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0
4
8
14
12
2
6
10
16
J F M A M J J A S O N D
NDSC Annual Report 2002 83
Ireland such as the Food Safety Authority of Ireland and the
Food Safety Promotion Board (Safefood), many efforts are
being made to reduce the burden of illness due to foodborne
disease in this country and in many areas significant advances
have been made, e.g. Salmonella control programmes.
However, as we become better at controlling the threat of
some aetiological agents of IID, other threats will emerge to
pose new challenges. We must consider and safeguard to the
greatest possible degree, the quality of our drinking water.
We must become better at identifying outbreaks by newer
agents as well as those well known to us. Effectively
formulated policy depends on high quality data. As the
quality of data improves, particularly in relation to the factors
contributing to outbreaks of IID, so will our ability to control
and prevent such disease outbreaks.
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Table 3.  Number of cases of illness arising as a result of outbreaks of IID, 
by mode of transmission (2001).
Mode of Transmission Number of Outbreaks Number ill
Person-to-person 18 357
Foodborne 10 143
Waterborne 3 417
P-P/Animal 2 4
P-P/Airborne 1 45
P-P/Foodborne 10 205
P-P/Waterborne 2 493
Waterborne/Animal 1 2
Foodborne/Waterborne 1 150
Unknown 16 690
Total 64 2506
Table 4. Number of cases of illness arising as a result of outbreaks of IID, 
by location in 2001.
Location Number of Outbreaks Number ill
Crèche  3 29
Hospital 7 117
Hotel 15 1228
Private House 16 47
Residential Institution 9 556
Restaurant / Café 6 163
School 2 73
Staff Canteen 2 58
Other 4 235
Total 64 2506
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Antimicrobial Resistance 
in Ireland, 2002
Key Points
In 2002,
• 1042 invasive isolates of Staphylococcus aureus were
reported. The proportion of isolates that were
methicillin-resistant S. aureus (MRSA) was 42.7%, one of
the highest in countries reporting to EARSS.
• 278 invasive isolates of Streptococcus pneumoniae were
reported. The proportion that was penicillin-non-
susceptible S. pneumoniae (PNSP) was 11.5%, which is
moderately high compared to other European countries.
Of the 32 PNSP isolates identified, four were found to be
high-level resistant [minimum inhibitory concentration
(MIC) ≥2 mg/L] and 27 were determined to have
intermediate levels of resistance (MIC 0.1-1.0 mg/L). No
MICs were available for one isolate.
• 741 invasive isolates of E. coli were reported. The
proportions of isolates that were resistant to third-
generation cephalosporins, fluoroquinolones and
aminoglycosides were 3.0%, 5.4% and 2.7%, respectively.
These figures are low compared with other European
countries.
• 168 invasive isolates of E. faecalis were reported. The
proportion of isolates that were vancomycin-resistant
was 2.4%. Although this figure is low, it is higher than
observed in most other European countries (<1%).
• 85 invasive isolates of E. faecium were reported. The
proportion of isolates that were vancomycin-resistant
was 11.1%, which is moderately high compared with
most other European countries.
• Implementation of the Strategy for the control of
Antimicrobial Resistance in Ireland (SARI) continued in
2002 with the Department of Health and Children
providing s6.9 million of SARI funding to the Health
Boards and convening the SARI National Committee.
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European Antimicrobial Resistance Surveillance System
The European Antimicrobial Resistance Surveillance System
(EARSS) was established in 1998 and is funded by DG SANCO
of the European Commission. It is an international network of
national surveillance systems, encompassing over 600
laboratories in 28 countries, which aims to collect comparable
and reliable antimicrobial resistance data on invasive
infections of Staphylococcus aureus, Streptococcus
pneumoniae, Escherichia coli, and Enterococcus
faecium/faecalis for public health action.
EARSS in Ireland started in 1999 with the surveillance of
S. aureus and S. pneumoniae and expanded in 2002 to include
three further pathogens, E. coli and the enterococci, E. faecalis
and E. faecium. Three additional laboratories joined the
program in 2002 bringing the total number of participating
laboratories to 23 giving an estimated population coverage 
of 90%.
Protocol
Data are collected on the first invasive isolate per patient per
quarter of S. aureus and enterococci (from blood only) and
S.pneumoniae and E. coli [from blood and cerebrospinal fluid
(CSF)]. Laboratories report routinely generated qualitative
disc diffusion data on:
• oxacillin/methicillin for S. aureus
• oxacillin/penicillin for S. pneumoniae
• ampicillin, cetotaxime/ceftriaxone and/or ceftazidime [third-
generation cephalosporins (3GCs)], ciprofloxacin/ofloxacin
and gentamicin for E. coli. Laboratories are also asked to
specifically test for the presence of extended-spectrum beta-
lactamases (ESBLs)
• ampicillin, high-level gentamicin and vancomycin for
enterococci.
All methicillin-resistant S. aureus (MRSA) isolates are
submitted to the National MRSA Reference Laboratory
(NMRSARL) at St James’s Hospital, where minimum inhibitory
concentrations (MICs) are determined for oxacillin and
vancomycin. Up to the end of June 2002, all isolates of
S.pneumoniae were submitted to the Pneumococcal Referral
Laboratory at RCSI/Beaumont but this service was suspended
due to funding problems. Laboratories are now requested to
submit data on MICs or Etests performed in-house for
penicillin and cefotaxime or ceftriaxone on all penicillin-non-
susceptible S. pneumoniae (PNSP) isolates.
Results
S. aureus
In 2002, 1042 reports of S. aureus isolates from bacteraemia
were received from 23 laboratories, of which 445 (42.7%)
were resistant to methicillin. There was a peak in Q2 when
the proportion of MRSA was 47.5% compared with the other
three quarters of the year when the proportion ranged from
41.2-41.7% (see Figure 1).
Data from the NMRSARL showed that gentamicin resistance
among MRSA isolates decreased from 33.9% in 2001 (and an
initial high of 58.4% in 1999) to 24.0% in 2002. This
continues to reflect the growing trend in which epidemic
strains of MRSA that are less multi-resistant to antibiotics are
becoming more prevalent. Resistance data to other common
anti-staphylococcal antibiotics among the MRSA isolates
referred to the NMRSARL are shown in Figure 2.
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Figure 1.  Trends for S. aureus by time period: by year for 1999-2002 and by quarter for 
2002 (Q1-Q4) – total numbers of S. aureus/MRSA and percentage MRSA with 95% 
confidence intervals.  Changes in the numbers of laboratories participating in the 
surveillance system are indicated above the chart.
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Figure 2.  Antibiogram results of MRSA isolates (n=400) referred to NMRSARL during 2002.
Antibiotic codes:  CHL – chloramphenicol, CIP – ciprofloxacin, ERY – erythromycin, 
FUS – fusidic acid, GEN – gentamicin, LIN – lincomycin, MUP – mupirocin, RIF – rifampicin, 
TCY – tetracycline, TMP – trimethoprim, VAN – vancomycin.
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The overall annual proportion of MRSA observed in Ireland
remains high and is comparable with proportions observed in
the UK, France and most southern European countries (see
Figure 3). The Scandinavian countries and The Netherlands
report the lowest proportions of MRSA in Europe.
S. pneumoniae
In 2002, 278 reports of S. pneumoniae isolates from
bacteraemia/meningitis were received from 23 laboratories.
The majority (n = 275) of isolates were from blood but three
were from CSF. Thirty-two isolates (11.5%) were PNSP.
As in previous years, a seasonal variation was seen in the
numbers of S. pneumoniae isolates reported with a peak in
Q1 and a trough in Q3, reflecting the busy winter and quieter
summer periods, respectively (see Figure 4). Of the 32 PNSP
isolates reported, MIC data for penicillin and cefotaxime were
available for 31 and 23 isolates, respectively. Four isolates
were found to be high-level penicillin resistant (MIC ≥ 2 mg/L)
and the remaining 27 isolates were determined to have
intermediate levels of resistance (MIC 0.1-1.0 mg/L). Three
isolates were resistant to cefotaxime (MIC ≥1.0 mg/L), of
which one exhibited high-level resistance to penicillin and two
were intermediate to penicillin. The remaining 20 isolates
were cefotaxime susceptible (MIC ≤0.5 mg/L).
Data on susceptibility to erythromycin or clarithromycin were
available for 236 isolates. Thirty (12.7%) were reported to be
resistant.
Of the three CSF isolates reported in 2002, all were
susceptible to penicillin.
Based on the total population of 3,917,203 in the Republic of
Ireland as determined in the 2002 census and approximately
90% coverage of the population by the EARSS surveillance
system, the crude incidence of invasive pneumococcal disease
in Ireland is estimated to be 7.8 per 100,000 population. In
1999, the incidence was estimated to be 6.6 per 100,000.1
The overall annual proportion of PNSP observed in Ireland
remains moderately high (see Figure 5) compared to the UK,
Scandinavia and some central European countries, such as
Germany, which are generally associated with lower PNSP
proportions. Higher proportions of PNSP are observed in
Belgium, southern Europe and some countries of the former
Eastern Bloc.
E. coli
In 2002, 741 reports of E. coli isolates from
bacteraemia/meningitis were received from 21 laboratories.
The majority (n=739) of isolates were from blood but two
were from CSF.
The proportions of isolates reported that were resistant to
ampicillin, 3GCs, fluoroquinolones (ciprofloxacin/ofloxacin)
and gentamicin were 62.2%, 3.0%, 5.4% and 2.7%,
respectively.
The total numbers of E. coli isolates and proportion of
resistance reported by quarter for 3GCs, fluoroquinolones
and gentamicin are shown in Figure 6. For all three antibiotic
classes, the proportions that were resistant were highest for
Q1 and Q4 and lowest for Q2 and Q3.
Figure 3.  Map illustrating the distribution of MRSA in EARSS countries in 2002.
No data
<1%
1-5%
5-10%
10-25%
25-50%
>50%
Time period
N
um
be
r 
of
 is
ol
at
es
Figure 4.  Trends for S. pneumoniae by time period: by year for 1999-2002 and by quarter 
for 2002 (Q1-Q4) – total numbers of S. pneumoniae/PNSP and percentage PNSP with 
95% confidence intervals.  Changes in the numbers of laboratories participating in the 
surveillance system are indicated above the chart.
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Seventeen isolates were identified as multi-drug resistant
[defined as resistance to three or more of the mandatory
antibiotics (ampicillin, 3GCs, fluoroquinolones and
gentamicin)]:
• five isolates were resistant to ampicillin, 3GCs,
fluoroquinolones and gentamicin - ESBL data were reported
on two of these, and both were positive
• eight were resistant to ampicillin, fluoroquinolones and
gentamicin
• three were resistant to ampicillin, 3GCs and
fluoroquinolones
• one was resistant to ampicillin, 3GCs and gentamicin
In total, 224 (30%) of the 741 isolates were examined for the
presence of ESBLs. ESBLs were detected in five (2.2%) of
these.
The two CSF isolates, one from a newborn child aged 6 days
and one from an adult aged 48 years, were resistant to
ampicillin and susceptible to 3GCs and gentamicin. One of
these isolates was also tested for susceptibility to
ciprofloxacin and was susceptible.
The proportion of ampicillin resistance reported in
participating countries in Europe in 2002 was generally 
categorised as moderately-high (25-50%) to high (>50%).
The proportion in Ireland was high (62.2%) and was
comparable with proportions seen in France, Spain and
Portugal. Only Sweden reported <25% resistance to
ampicillin. The proportion of resistance to 3GCs,
fluoroquinolones and gentamicin observed in Ireland in 2002
was low compared with most other European countries (see
Figures 7-9). The lowest proportions of resistance were
observed in the Scandinavian countries while the highest
proportions were seen in Southern and Eastern Europe.
E. faecalis
In 2002, 168 reports of E. faecalis isolates from bacteraemia
were received from 21 laboratories.
The total numbers of E. faecalis isolates and proportion of
resistance reported by quarter for ampicillin, high-level
gentamicin and vancomycin are shown in Figure 10.
Thirteen (8.1%) isolates were reported to be ampicillin-
resistant. Ampicillin resistance in E. faecalis is unusual and
further investigation of these isolates is warranted to confirm
their identity as speciation of enterococci can be problematic.
Twenty isolates (39.2%) of the 51 tested were reported to be
high-level gentamicin resistant but only three of these were
confirmed by MIC determination. Most Irish laboratories do
not routinely test enterococci for susceptibility to high-level
gentamicin and so there may be some problems associated
with methodology and interpretation of the results obtained.
In light of this, caution should be exercised in drawing
conclusions from these data.
Four (2.4%) isolates were reported to be vancomycin
resistant.
One isolate was resistant to ampicillin, high-level gentamicin
and vancomycin. This isolate is one of the 13 ampicillin-
resistant E. faecalis isolates mentioned above for which
Figure 5.  Map illustrating the distribution of PNSP in EARSS countries in 2002.
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Figure 6.  Trends for E. coli by quarter for 2002 – total numbers of E. coli and percentage 
resistance to 3GCs, ciprofloxacin/ofloxacin (CIP/OFX) and gentamicin (GEN).  
Number of participating laboratories is indicated for each quarter.
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confirmation of the species identity might be helpful.
In 2002, the proportion of resistance to high-level gentamicin
observed in Ireland, as well as in most other European
countries (see Figure 11), was generally high (25% and
higher). The majority of countries reported proportions of
<1% for vancomycin resistance (see Figure 12). The
proportion in Ireland was slightly higher than this and was
comparable with Finland, Germany and the Netherlands.
E. faecium
In 2002, 85 reports of E. faecium isolates from bacteraemia
were received from 21 laboratories.
The total numbers of E. faecium isolates and proportion of
resistance reported by quarter for ampicillin, high-level
gentamicin and vancomycin are shown in Figure 13.
Seventy-two (88.9%) of the 81 isolates for which ampicillin
susceptibility data were available were reported to be
ampicillin-resistant, which is not unexpected as most
E. faecium are resistant to this antibiotic.
Five (16.7%) of 30 isolates tested were reported to be high-
level gentamicin resistant. Three of these were confirmed by
MIC determination.
Nine (11.1%) isolates were reported to be vancomycin
resistant.
One isolate was resistant to ampicillin, high-level gentamicin
and vancomycin.
In 2002, the proportion of resistance to high-level gentamicin
observed in Ireland was moderately high (10-25%), which is
at the lower end of the spectrum observed across Europe (see
Figure 14). The majority of countries reported proportions of
<5% for vancomycin resistance (see Figure 15). The
proportion in Ireland was moderately high (10-25%) and
together with Italy, Greece and Croatia, was one of the
highest observed in Europe.
Additional information
For the most up-to-date maps showing the distributions of
resistance for all the EARSS pathogens in Europe, see:
http://www.earss.rivm.nl/PAGINA/interwebsite/home_earss.html
The quarterly EARSS Newsletter produced by NDSC can be
accessed on the NDSC website: http://www.ndsc.ie/
Publications/AntimicrobialResistance-EARSSReports/
The Future
In Ireland, we have one of the highest rates of participation by
laboratories in EARSS in Europe, which is an excellent result
considering that participation by laboratories is entirely
voluntary. Ideally, all laboratories in Ireland should participate
in the surveillance system to give a complete picture of
antimicrobial resistance and thereby allow more detailed
analysis.
The Strategy for the control of Antimicrobial Resistance
in Ireland (SARI) was launched in June 2001. Compared to
most European countries Ireland has a shortage of relevant
health professionals needed for the diagnosis, surveillance,
management and prevention of infectious diseases. The initial
Figure 7.  Map illustrating the distribution of resistance to 3GCs among E. coli in 
EARSS countries in 2002.
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Figure 8.  Map illustrating the distribution of resistance to aminoglycosides among E. coli 
in EARSS countries in 2002.
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focus in implementing SARI has been to correct this shortfall.
Up to the end of 2002 the Department of Health and
Children have provided a total of s6.9 million in recurring
SARI funding, divided among each Health Board/Authority on
a population basis.
Each Health Board/Authority has a multi-disciplinary Regional
SARI Committee to oversee regional surveillance programmes,
educational interventions and other aspects of regional SARI
implementation.
The SARI National Committee, based at DoHC, was set up
and met for the first time in 2002. The committee includes
representatives from various professional bodies and
healthcare organisations and other key groups.
The organisations/bodies represented on the SARI National
Committee are:
• Academy of Medical Laboratory Science
• Consumers’ Association of Ireland
• Department of Agriculture, Food and Rural Development
• Department of Health and Children (3 representatives)
• Department of Health, Social Services and Public Safety,
Northern Ireland (Observer) analysis.
• Faculty of Paediatrics
• Faculty of Pathology
• Faculty of Public Health Medicine
• Faculty of Veterinary Medicine
• Food Safety Authority of Ireland
• Health Board/Authority CEO Group (3 representatives)
• Infection Control Nurses’ Association
• Irish College of General Practitioners
• Irish Pharmaceutical Healthcare Association
• National Disease Surveillance Centre
• Pharmaceutical Society of Ireland
• Royal College of Physicians of Ireland
• Royal College of Surgeons in Ireland
• University Dental School and Hospital
The National Committee is responsible for developing
national policies, guidelines and strategies, as well as
overseeing the funding of national level SARI implementation
projects.
Five multidisciplinary SARI working groups advice the
National Committee on specific areas of SARI
implementation, namely:
• Surveillance of antimicrobial resistance
• Surveillance of antibiotic consumption
• Community antibiotic stewardship
• Hospital antibiotic stewardship
• Infection control
The working groups prepared draft recommendations for
consideration by the SARI National Committee.
As SARI implementation progresses, and the current shortfall
in relevant staffing is corrected, national guidelines can be
adapted for local and regional implementation. Copies of the
SARI report can be downloaded from the NDSC website
(www.ndsc.ie).
Figure 9.  Map illustrating the distribution of resistance to fluoroquinolones among E. coli 
in EARSS countries in 2002.
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Figure 10.  Trends for E. faecalis by quarter for 2002 – total numbers of E. faecalis and 
percentage resistance to ampicillin (AMP), high-level gentamicin (GEH) and vancomycin 
(VAN).  Number of participating laboratories is indicated for each quarter.
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Figure 11.  Map illustrating the distribution of high-level resistance to aminoglycosides 
among E. faecalis in EARSS countries in 2002.
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Figure 12.  Map illustrating the distribution of resistance to glycopeptides among 
E. faecalis in EARSS countries in 2002.
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Figure 13.  Trends for E. faecium by quarter for 2002 – total numbers of E. faecium and 
percentage resistance to ampicillin (AMP), high-level gentamicin (GEH) and vancomycin 
(VAN).  Number of participating laboratories is indicated for each quarter.
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Figure 14.  Map illustrating the distribution of high-level resistance to aminoglycosides 
among E. faecalis in EARSS countries in 2002..
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Figure 15.  Map illustrating the distribution of resistance to glycopeptides among 
E. faecium in EARSS countries in 2002.
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Infectious Disease Notifications,
2002
Key Points
• Acute viral meningitis notifications declined in 2002
compared to 2000 and 2001.
• Bacterial meningitis, gastroenteritis, rubella,
salmonellosis, viral hepatitis type A and whooping cough
notifications continued to decline in 2002.
• Food poisoning notifications increased in 2002
compared to 2001.
• An increase in measles notifications was observed in late
2002.
• Viral hepatitis type B notifications continued to rise in
2002.
Introduction
The Health Act, 1947, enables the Minister for Health and
Children to specify by regulation diseases that are infectious.
The infectious diseases currently notifiable in Ireland are
regulated in the 1981 Infectious Disease Regulations, which
were revised in 1985, 1988 and 1996. These regulations
require medical practitioners, who become aware of or who
suspect a person is suffering from or is a carrier of an
infectious disease specified in the regulations, to notify the
relevant medical officer in the appropriate health board.
Under the Infectious Disease (Amendment) Regulations, 2000,
the medical officers in the health boards furnish weekly
notification data to NDSC. At NDSC the data is collated and
analysed, and a weekly infectious disease report on national
data is produced. This weekly analysis of notification data
provides timely information about potential or actual
outbreaks of infectious disease.
A summary of the 2002 infectious disease data is presented
in this report. The purpose of this review is to identify and
describe infectious disease patterns and trends in Ireland
during 2002.
Materials and Methods
Since July 1st 2000, the health boards provide case based
information (ID number, date of birth, age, sex, date of onset,
date of notification/week of notification, Community Care
Area, county, disease and organism-if available) by the
Wednesday of each week, to NDSC, on infectious diseases
(excluding sexually transmissible infections) notified to them
during the previous week. At NDSC this information is
inputted onto a MS Access database and analysed using MS
Access and Excel.
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Incidence rates were calculated using population data taken
from the 2002 census.
Notifiable infectious diseases in 2002, excluding sexually
transmissible infections (STIs), are presented in this report. A
report on the 2001 notifiable STIs is presented in a separate
chapter within this document.
Results
Notifiable infectious diseases
Table 1 compares annual notifiable infectious disease figures
for 2002 with annual figures obtained from 1982-2001. There
were several notable disease trends, in 2002, compared to
previous years:
• a 4.5-fold reduction in the number of acute viral meningitis
cases notified in 2002 compared to 2001
• bacterial meningitis (including meningococcal septicaemia)
notifications in 2002 are the lowest since the enhanced
surveillance system commenced in 1997
• food poisoning (bacterial other than salmonella)
notifications increased in 2002 compared to 2001
• gastroenteritis (when contracted by children under 2 years
of age), rubella, viral hepatitis type A and whooping cough
notifications continued to decline in 2002 compared to
previous year 
• salmonellosis (other than typhoid or paratyphoid)
notifications are the lowest when compared to the previous
seven years
• notifications of viral hepatitis type B continued to rise in
2002 compared to previous years 
In 2002, as for 2001, no cases of acute anterior poliomyelitis,
anthrax, variant Creutzfeldt Jakob disease (vCJD), diphtheria,
plague, rabies, smallpox, typhus, viral haemorrhagic disease or
yellow fever were notified. In addition, in 2002, no cases of
ornithosis or tetanus were reported.
The numbers of infectious diseases notified in 2002 by health
board, by age group and sex are outlined in tables 2, 3 and 4,
respectively.
Acute encephalitis
Four cases of acute encephalitis were notified in 2002, similar
to five cases in 2001. The causative organism was reported as
herpes simplex virus type 1 for one case while the causative
organism was not reported for the remaining three cases.
Three of the cases were less than fifteen years of age (table
3). Three of the cases were female and one case was male
(table 4).
Acute viral meningitis
In 2002, 36 cases of acute viral meningitis were notified, in
contrast to 161 cases notified in 2001. This represents a 4.5-
fold decrease in notified cases. In 2000, 98 cases of acute viral
meningitis were notified. Seventy-eight percent of cases, in
2002, occurred in those aged less than 15 years while 47% of
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Figure 1.  Food poisoning (bacterial other than salmonella) notifications in 
2002 by organism.
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Figure 2. Gastroenteritis (when contracted by children under 2 years of age)
notifications in 2002 by organism.
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Table 2. Number of notifiable infectious diseases by health board in 2002
Infectious disease ERHA MHB MWHB NEHB NWHB SEHB SHB WHB Total
Acute Encephalitis ** ** ** ** ** ** ** ** 4
Acute Viral Meningitis 23 0 1 4 2 1 2 3 36
Bacillary Dysentery (Shigellosis) 14 2 0 2 0 2 5 1 26
Bacterial Meningitis (including meningococcal septicaemia)*** 108 24 32 27 16 26 47 17 297
Brucellosis ** ** **  ** **  ** ** ** 4
Cholera      ** ** **  ** **  ** ** ** 1
Creutzfeldt Jakob Disease      4 0 1 0 0 0 0 0 5
Food Poisoning (bacterial other than salmonella) 501 107 33 44 89 243 164 213 1394
Gastroenteritis (children < 2 years of age) 645 97 28 101 72 250 317 237 1747
Infectious Mononucleosis 53 2 45 12 1 29 23 8 173
Infectious Parotitis (Mumps)  17 2 1 1 0 2 9 0 32
Influenzal Pneumonia      ** ** **  ** **  ** ** ** 2
Legionnaires' Disease 3 0 0 0 0 1 0 2 6
Leptospirosis 0 1 1 1 0 4 1 0 8
Malaria 13 1 2 0 0 1 2 1 20
Measles    105 18 10 41 1 14 18 36 243
Rubella 19 2 3 5 1 2 1 0 33
Salmonellosis (other than typhoid or paratyphoid) 117 16 22 46 30 57 37 44 369
Tuberculosis*! 156 18 26 24 12 52 79 33 400*!
Typhoid & Paratyphoid 4 0 0 0 1 0 0 0 5
Viral Hepatitis Type A 7 0 4 1 1 5 8 0 26
Viral Hepatitis Type B 139 46 24 15 5 63 164 2 458
Viral Hepatitis Unspecified 18 3 7 4 1 42 13 1 89
Whooping Cough 32 13 10 8 2 33 12 21 131
** Data not reported to health board level when total figures for ROI less than 5 cases.  
*** Taken from the Enhanced Surveillance System for Bacterial Meningitis
*!  Taken from the Enhanced TB Surveillance System, figure for 2002 provisional 
Table 3. Number of notifiable infectious diseases by age group (years) in 2002
Infectious disease   0-4 5-9 10-14 15-19 20-24 25-34 35-44 45-54 55-64 65+ Unknown Total
Acute Encephalitis 2 0 1 0 0 0 0 0 0 1 0 4
Acute Viral Meningitis 17 4 7 2 0 3 2 1 0 0 0 36
Bacillary Dysentery (Shigellosis) 4 1 1 1 6 9 2 1 1 0 0 26
Bacterial Meningitis (including meningococcal septicaemia)** 171 28 25 26 14 10 7 2 6 8 0 297
Brucellosis 0 0 0 0 1 1 0 0 2 0 0 4
Cholera 1 0 0 0 0 0 0 0 0 0 0 1
Creutzfeldt Jakob Disease  0 0 0 0 0 0 0 0 2 3 0 5
Food Poisoning (bacterial other than salmonella) 433 74 38 52 112 221 148 92 58 127 39 1394
Gastroenteritis (children < 2 years of age) 1730 0 0 0 0 0 0 0 0 0 17 1747
Infectious Mononucleosis 9 5 23 87 24 16 5 1 1 0 2 173
Infectious Parotitis (Mumps) 10 7 3 3 2 4 0 1 2 0 0 32
Influenzal Pneumonia 0 0 0 0 0 0 0 2 0 0 0 2
Legionnaires' Disease 0 0 0 0 0 2 1 2 1 0 0 6
Leptospirosis 0 0 0 1 0 1 3 2 0 1 0 8
Malaria 3 2 0 0 0 8 5 1 1 0 0 20
Measles 179 30 21 5 4 0 1 2 0 0 1 243
Rubella 29 2 1 0 0 0 0 0 0 0 1 33
Salmonellosis (other than typhoid or paratyphoid) 92 17 16 15 36 57 29 38 31 26 12 369
Tuberculosis*! 5 7 5 7 26 85 68 49 40 82 26 400*!
Typhoid & Paratyphoid 0 0 0 0 0 5 0 0 0 0 0 5
Viral Hepatitis Type A 0 4 2 1 2 6 2 1 2 6 0 26
Viral Hepatitis Type B 6 4 5 23 65 241 88 14 2 0 10 458
Viral Hepatitis Unspecified 4 1 0 2 15 36 17 8 3 3 0 89
Whooping Cough 72 25 15 2 0 0 3 7 0 0 7 131
** Taken from the Enhanced Surveillance System for Bacterial Meningitis
*! Taken from the Enhanced TB Surveillance System, figure for 2002 provisional   
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cases were in the age group 0-4 years. In 2002, the age
specific incidence rate of those aged 0-4 years was
6.1/100,000, compared to 15.8/100,000 in 2001. In 2002
twenty cases occurred in males, 15 in females, while sex was
not reported for one case. The causative organism for one
case was reported as coxsackievirus B5 while the causative
organism was not reported for the remaining 35 cases.
Coinciding with the decrease in acute viral meningitis
notifications, the National Virus Reference Laboratory (NVRL)
reported a decrease in the number of laboratory confirmed
non-polio enterovirus (NPEV) isolates in 2002 were 72 cases
reported in 2002 in contrast to 170 cases in 2001.1,2
Bacillary dysentery
Twenty-six cases (0.66/100,000) of bacillary dysentery
(shigellosis) were notified in 2002 similar to 28 cases in 2001.
Seventy-three percent of cases in 2002 occurred in those
aged 20 years or older while 58% of all cases were aged
between 20 and 34 years. Eighteen cases (69%) were female,
seven cases  (27%) were male while sex was not reported for
one case. Eleven cases were due to Shigella sonnei, four due
to Shigella flexneri, two due to Shigella boydii and species was
not reported for nine cases.
Bacterial meningitis (including meningococcal septicaemia)
Bacterial meningitis (including meningococcal septicaemia)
notifications declined in 2002 (n=297) compared to the
previous seven years. Enhanced surveillance of bacterial
meningitis (including meningococcal septicaemia)
commenced in Ireland in 1997. A detailed report on bacterial
meningitis notifications in 2002, obtained through the 
enhanced surveillance system, is presented as a separate
chapter within this document.
Brucellosis
Four cases of brucellosis were notified in 2002 compared to
14 in 2001. All four cases in 2002 were male and all were
aged 20 years or older.
Cholera
In 2002, one case of cholera was notified. Laboratory tests
identified Vibrio cholerae serogroup O1 biotype El Tor
serotype Ogawa as the causative organism. The infection was
acquired in Bangladesh.
Creutzfeldt Jakob disease (CJD)
In 2002, five cases of classical CJD were notified compared
with six in 2001. Four cases occurred in males and one in a
female. All five cases were aged greater than 54 years.
Food poisoning (bacterial other than salmonella)
Food poisoning (bacterial other than salmonella) notifications
increased in 2002, with 1394 cases (35.6/100,000) notified,
compared to 1219 cases (31.1/100,000) notified in 2001. The
highest incidence rates and the highest number of cases in
2002 were in those aged 0-4 years (156/100,000, n=433,
31%) followed by those aged 25-34 years (35.8/100,000,
n=221, 16%). In 2002, in the majority of cases, the causative
organism was Campylobacter spp (n=1193, 86%), followed by
Escherichia coli (n=108, 8%) including verocytotoxigenic E.
coli (VTEC), Yersinia enterocolitica (n=8), Listeria
monocytogenes (n=2) and Clostridium perfringens (n=1),
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Figure 3. Weekly number of measles cases notified in Ireland, 2002/2003*.  
*Please Note: Data for 2003 are up to Week 37, 2003 (week ending 13/09/2003).  2003 data are provisional.
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while the causative organism was not reported for 82 (6%)
cases (figure 1).
Comprehensive reports on campylobacter (2001) and VTEC
(2002) in Ireland are presented as separate chapters elsewhere
within this document.
Gastroenteritis (when contracted by children under 2 years 
of age)
Notifications of gastroenteritis in those aged less than 2 years
continued to decline in 2002 compared to previous years with
1747 cases (44.6/100,000) notified in 2002. The causative
organisms were reported as rotavirus (n=1148, 66%),
adenovirus (n=170, 10%), Cryptosporidium (n=149, 9%),
norovirus (n=20, 1%), echovirus (n=7, 0.4%), Giardia lamblia
(n=2, 0.1%) and Clostridium difficile (n=1, 0.1%) while the
causative organism was not reported for 250 (14%) cases
(figure 2).
Infectious mononucleosis
During 2002, 173 cases of infectious mononucleosis were
notified compared to 150 in 2001 and 151 in 2000. In 2002,
the highest age specific incidence rates occurred in the 15-19
year olds (27.8/100,000, n=87) followed by the 10-14 year
olds (8.1/100,000, n=23). Of the 173 cases notified, 102
cases (59%) occurred in females, 69 cases (40%) occurred in
males while sex was not reported for two cases.
Infectious parotitis (mumps)
Thirty-two cases of infectious parotitis (mumps) were notified
in 2002 compared to 40 cases in 2001. In 2002, the cases
were aged between <1 year and 62 years (mean age=15.3
years and median age=8.5 years) with 63% of cases aged less
than 15 years. The highest number of cases and the highest
age specific rates were in the 0-4 year olds (3.6/100,000,
n=10) followed by the 5-9 year olds (2.7/100,000, n=7).
Approximately two-thirds of the cases were male (n=21) and
one third were female (n=11).
Influenzal pneumonia
Two cases of influenzal pneumonia were notified in 2002.
Both cases in 2002 were male and in the age group 45-54
years.
Legionnaires’ disease
Six cases of Legionnaires’ disease were notified in 2002 while
three cases were notified in 2001. The six cases in 2002 were
aged between 32 and 61 years (mean age=43.9 years and
median age=43.5 years). Three of the cases were male and
three were female. One of the six cases of Legionella was
confirmed by serology, one by both urinary antigen detection
and culture of sputum, three by urinary antigen detection and
for one case the laboratory method of confirmation was not
reported. The culture confirmed case was reported as
Legionella pneumophila serogroup 1. All six cases were known
to have survived. Three of the cases were travel-associated
(Lanzarote, Portugal and Sicily) and were notified to the
European Working Group for Legionella Infections (EWGLI)
surveillance scheme. The aim of this surveillance scheme
(EWGLI) is to detect cases of travel-associated Legionnaires’
disease and thereby rapidly identify outbreaks and implement
control measures. 3
Leptospirosis
Eight cases of leptospirosis were notified in 2002 similar to
nine cases in 2001. All eight cases were aged greater than 15
years (mean age=41.3 years and median age=42.5 years) and
seven of the cases were male, reflecting the fact that the
infection is usually found in males of working age. The
possible source of infection was; contact with animals (n=3),
river water (n=2), gardening/firewood (n=1) and source
unknown (n=2). Five of the cases were reported to have
survived while the outcome was not reported for three of the
cases.
Malaria
During 2002, twenty cases of malaria were notified. Fourteen
(70%) cases were male, five (25%) were female and sex was
not reported for one case. The cases ranged in age from
under one year to 57 years (median age=33 years and mean
age=27.7 years). Eight of these cases were Irish, eight were
Nigerian, one was recorded as African and nationality was not
reported for three cases. Countries where the malaria
infection was acquired included Nigeria (n=9), Ghana (n=3),
Africa, Gambia, Kenya/Tanzania, Liberia, Zambia (one case
each) and for three cases the country was unspecified. The
reasons for travel to a malarious region were: visiting family in
country of origin (n=6), holiday (n=5), new entrant to Ireland
(n=2), foreign visitor ill while in Ireland, business/professional
travel, volunteer worker (n=1 each) and unknown (n=4). In
thirteen cases Plasmodium falciparum was the causative
organism, Plasmodium vivax in one case and the malarial
parasite was not reported for the remaining six cases.
Information on malaria prophylaxis was available for 14 of the
20 cases. Eight cases did not take any malaria prophylaxis.
Of the remaining six cases who took malaria prophylaxis
while abroad, all discontinued prophylaxis within one month
following return to Ireland (three of these patients
discontinued prophylaxis on return to Ireland due to
illness/treatment for malaria). Twelve cases recovered and the
outcome was not reported for the remaining eight cases.
Measles
During 2002, 243 cases (6.2/100,000) of measles were
notified. The majority of cases and the highest age specific
incidence rates (n=179, 74%, 64.5/100,000) were in the age
group 0-4 years followed by those in the age group 5-9 years
(n=30, 12%, 11.4/100,000). Of the 243 cases notified, 132
cases were male, 106 cases were female and sex was not
reported for five cases.
There were two peaks in measles activity in 2002. The first
increase in measles notifications was observed in April/May
2002. During week 17 and week 18, 18 and 20 cases of
measles were notified, respectively (figure 3). Of these 38
cases, 14 were notified by the NEHB, 11 were notified by the
WHB and the remainder were notified by the ERHA (n=6),
SHB (n=3), MHWB (n=2) and SEHB (n=2).
A second increase in measles notifications commenced in late
November 2002, this continued into early 2003 (figure 3;
2003 data are provisional). The majority of these cases were
notified in the ERHA and MHB followed by the WHB. 4 
The WHO have targeted 2010 for measles elimination in the
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European Region. Despite the introduction of a measles
vaccine in 1985 in Ireland followed by the MMR in 1988
measles continues to be a problem with outbreaks occurring.5
A national measles elimination plan needs to be developed
and implemented in order to eliminate measles in Ireland. A
vital component to eliminating measles in Ireland will include
increasing the uptake of MMR. Since the national collation of
cohort based immunisation uptake data commenced in
Ireland in Quarter 1 1999, MMR1 uptake at 24 months has
been as low as 69% (Quarter 4, 2001) and has not exceeded
83% (Quarter 4 2000). An enhanced measles surveillance
system also needs to be implemented in order to facilitate
the control and elimination of measles in Ireland.
Rubella
The number of rubella notifications continued to decline in
2002, compared to previous years, with 33 cases notified
giving a national incidence rate of less than one case per
100,000. Thirty-two of the cases notified in 2002 were less
than 15 years of age (age unreported for remaining case),
with 88% of the cases aged less than five years. Nineteen
cases were male, 13 cases were female and sex was not
reported for one case.
Salmonellosis (other than typhoid or paratyphoid)
Salmonellosis (other than typhoid or paratyphoid)
notifications decreased further in 2002 with 369 cases
(9.4/100,000) notified, the lowest number of cases notified
since 1994. In 2002, the highest age specific incidence rate
(33/100,000, n=92) was in those less than five years of age
followed by those aged 20-24 years (11/100,000, n=36). In
2002, the breakdown by serotype was as follows: Salmonella
Enteritidis (n=80), S. Typhimurium (n=55), S. Virchow (n=4), S.
Newport (n=3), S. Stanley (n=3), S. Dublin (n=2), S.
Heidelberg (n=2), S. Infantis (n=2), S. Othmarschen (n=2), S.
Panama (n=2), S. Agona, S. Anatum, S. Bareilly, S. Brandenburg,
S. Bredeney, S. Colindale, S. Corvallis, S. Durban, S. Give, S.
Hadar, S. Johannesburg, S. Kentucky, S. Kottbus, S. Montevideo,
S. Ohio, S. Redhill, S. Thompson, S. Urbana, S. Worthington
(n=1, each) while serotype details were not reported for 53%
of cases (n=195). A separate and comprehensive report on
salmonella is presented elsewhere within this document.
Tuberculosis
The final figure for 2002 tuberculosis data will not be
available until late 2003, however, a provisional figure of 400
cases were notified through the enhanced national
tuberculosis surveillance system. In 2001, 381 cases were
notified. A separate and comprehensive report on the 2001
data is included elsewhere within this document.
Typhoid and Paratyphoid
Five cases of typhoid and paratyphoid were notified in 2002
similar to four cases notified in 2001. Salmonella typhi was
the aetiological agent in all five cases. The countries of
infection were India, Nigeria, Pakistan, Philippines and not
reported (n=1 each). All five cases were in the age group 25-
34 years. Four of the cases were female and one case was
male.
Viral hepatitis type A
The number of viral hepatitis type A cases notified decreased
4-fold in 2002 compared to 2001, with 26 cases
(0.7/100,000) notified in 2002 and 112 cases (2.9/100,000)
notified in 2001. A comprehensive report on viral hepatitis is
presented as a separate chapter within this document.
Viral hepatitis type B
Cases of viral hepatitis type B continued to increase in 2002
with 458 cases notified (11.7/100,000). In contrast in 2000
and 2001, 187 and 342 cases were notified, respectively. A
more detailed report on viral hepatitis is presented as a
separate chapter within this document.
Viral hepatitis unspecified
In 2002, 89 cases (2.3/100,000) of viral hepatitis type
unspecified were notified. A separate and more detailed
report on viral hepatitis is presented elsewhere in this
document.
Whooping cough
During 2002, 131 cases (3.3/100,000) of whooping cough
were notified, contributing to a continued decline in incidence
(table 1). The majority (85%) of cases were aged less than 15
years and 55% of cases were in the age group 0-4 years. In
2002, 12 cases (9%, 12/131) occurred in those aged 15 years
or older while in 2001 only three cases (2%, 3/142) were
reported in those aged 15 years or older. In 2002, the
causative organism was reported as Bordetella pertussis for 28
cases while the causative organism was not reported for the
remaining cases.
Discussion
The collection of notifiable infectious disease data allows the
incidence and trends of infectious diseases to be monitored,
thereby aiding decisions relating to infectious disease control
and prevention. An increase in the incidence of a particular
disease may indicate a new health problem requiring public
health intervention. For example, following the increase in
measles activity observed in Ireland starting in late 2002, the
affected health boards implemented control measures to curb
the spread of the disease.4 The study of infectious disease
trends can be used to assess the impact of various public
health initiatives. For example, the continued decline in
Ireland of meningococcal disease particularly Group C
highlights the success the meningococcal group C conjugate
(MenC) vaccine has had since its introduction in October
2000 (table 1).
The list of notifiable diseases specified in the current
infectious disease regulations has not been subject to regular
review and a number of diseases of public health concern
requiring infectious disease control are not currently included
e.g. enterohaemorrhaghic Escherichia coli (including E. coli
O157, O26 and O111) and influenza. There are also a
number of other limitations to the current notification
system. There are no case definitions for the current list of
notifiable infectious diseases, therefore, for the majority of
diseases both suspected and confirmed cases are notifiable
making differences in disease rates difficult to interpret. In
addition, the regulations do not specify laboratories, an
important source of infectious disease data, as notifiers of
infectious diseases. Due to these and other short-comings of
the current notification process a review of the notification
NDSC Annual Report 2002 99
system was carried out with the aim of developing an
effective surveillance system to address current public health
concerns. A number of recommendations made by the
review, including amending the infectious disease regulations
to include laboratories as notifiers of infectious diseases and
specifying a new list of notifiable diseases, are hoped to be
implemented by the end of 2003.
This new list of notifiable diseases will include diseases
highlighted for surveillance by the European Union and will no
longer include a couple of currently notifiable diseases that do
not require public health action (e.g. infectious mononucleosis
and ornithosis). Case definitions will be included with this
new list. In the coming years, with the implementation of
recommendations from this review and also with the
implementation of computerised infectious disease reporting
(CIDR) Ireland will have a vastly improved surveillance system
reflecting current public health concerns.
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Immunisation Uptake 
in Ireland, 2002
KEY POINTS
• Annual immunisation uptake rates at 24 months
continued to decline in 2002.
• MMR1 uptake at 24 months was 72.5%.
• D3, P3, Polio3, T3 and Hib3 uptake at 24 months was
between 82-83%.
• MenC3 uptake at 12 months was 74%.
Introduction
In 2002, the National Immunisation Advisory Committee of
the Royal College of Physicians of Ireland issued an updated
report on Immunisation Guidelines for Ireland.1 The
recommended primary childhood immunisation schedule is
that children are vaccinated against diphtheria (D), tetanus
(T), pertussis (P, acellular pertussis vaccine), polio,
Haemophilus influenzae type b (Hib) and group C
meningococcal disease (MenC) at 2, 4 and 6 months and
against measles, mumps and rubella (MMR) at 15 months. It
also recommends that children receive the BCG vaccine at
birth or by one month of age. A booster dose of DTaP/Polio
should be given at 4-5 years of age and the second dose of
MMR should also be given at this time. To effectively control
vaccine-preventable diseases, it is essential that 95% of
children complete the primary childhood immunisation
schedule by two years of age. The meningococcal group C
conjugate (MenC) vaccine was introduced to the primary
childhood immunisation schedule in October 2000. A catch-
up programme was also launched at this time, offering the
vaccine to all those under 23 years of age. The MenC catch-
up programme was completed nationally by March 2002.
Materials and Methods
Each health board is responsible for maintaining an
immunisation register. In 2002, the health boards provided
NDSC with quarterly immunisation uptake data on children
who reached their first or second birthday (uptake at 12 and
24 months, respectively) during the quarter in question and
who had completed the primary immunisation schedule (i.e.
D3, P3, T3, Polio3, Hib3, MenC3 and MMR1; subscript signifies
number of doses). MenC3 uptake data at 12 months was
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collated nationally for the first time in 2002, however, MenC3
uptake rates at 24 months were only available from quarter 3
2002 onwards. Data on the number eligible for immunisation
in each cohort, the number who completed the primary
immunisation schedule and the percentage immunised were
provided. NDSC collated and analysed these data in MS Excel.
The annual uptake rates presented in this report were
calculated from the quarterly reports submitted by the health
boards.
In July/August 2002, the eight health boards in Ireland ran
reports on MenC uptake in those targeted by the catch-up
programme (1-22 year olds). Uptake data was extracted
according to annual birth cohort (1978-1999). For the less
than five year olds, denominator data was obtained from the
health board birth registers, whereas for those aged five years
or greater, denominator data was extrapolated from the 1996
census.
Results
Immunisation uptake rates at 12 months in 2002
Overall, immunisation uptake at 12 months in 2002 (i.e. for
the cohort born between 01/01/2001 & 31/12/2001) was
75% for D3, T3, Hib3 and Polio3, and 74% for P3 and MenC3.
Uptake rates at 12 months in 2002 by health board are
presented in Table 1. Uptake rates ranged from 68% in ERHA
to 84-85% in NWHB for D3, P3, T3, Hib3 and Polio3 and from
68% in ERHA to 82% in the MWHB for MenC3.
Uptake of all vaccines at 12 months increased steadily
throughout 2002. By quarter 3 2002 the rates had recovered
to levels last seen in quarter 3 2000. The uptake rates at 12
months in quarter 4 2002 were the highest recorded to date
(Figure 1). MenC3 uptake at 12 months was collated
nationally for the first time in 2002. The uptake for MenC3
increased by 10% between quarter 1 (68%) and quarter 4
2002 (78%).
Immunisation uptake at 24 months in 2002
Immunisation uptake rates at 24 months in 2002 (i.e. for the
cohort born between 01/01/2000 & 31/12/2000) were 83%
for D3, T3, Hib3 and Polio3, 82% for P3 and 73% for MMR1. The
national uptake rate for MenC3 (quarter 3 and quarter 4 only)
was 75%. Uptake rates at 24 months in 2002 by health board
are presented in Table 2. Rates for D3, T3, P3, Hib3 and Polio3
ranged from 77-78% in ERHA to 90-92% in NWHB, while
MMR1 uptake rates ranged from 64% in ERHA to 82% in
SEHB. Uptake rates for MenC3 for the second half of 2002
varied from 65% in the ERHA to 85% in the MWHB.
In 2002, immunisation uptake rates at 24 months declined for
all antigens apart from P3 when compared with previous years
(Figure 2). D3, T3, Polio3 and Hib3 uptake all declined by 1% to
83%. MMR1 uptake decreased slightly (0.7%) while uptake of
P3 showed a very small increase (0.1%) (Figure 2).
The uptake of MMR1 increased throughout 2002 (Figure 3),
and by quarter 4 2002 the levels were approaching the levels
seen between quarter 3 1999 and quarter 2 2000. An increase
in uptake of the other vaccines was also observed in quarter 4
2002, but the fluctuations have not been as dramatic as those
seen for MMR1 (Figure 3).
Q3
2000
95.0
85.0
75.0
65.0
90.0
80.0
70.0
60.0
Q4
2000
Q1
2001
Q2
2001
Q3
2001
Q4
2001
Q1
2002
Q2
2002
Q3
2002
Q4
2002
Quarter/year
%
 u
pt
ak
e
Figure 1. Quarterly immunisation uptake rates at 12 months in Ireland
(Note scales range from 60-95% on this figure)
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Figure 2.  Annual immunisation uptake rates at 24 months 
(Note scales range from 70-95% on this figure)
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MenC uptake in those targeted by the catch-up
programme
National uptake of the MenC vaccine from the catch-up
programme was 70% overall in the 1-22 year olds (Figure 4).
It was highest in the 5-12 year olds (89%) and 13-17 year
olds (81%). It declined to 77% in the 1-4 year olds, while
only 30% of the 18-22 year olds availed of the vaccine.
Discussion
Immunisation uptake figures at 12 months in 2002 (74-75%)
displayed an improvement on those recorded in 2001 (68-
70%).2 Although overall uptake at 24 months declined
slightly in 2002, uptake of all antigens did improve in the
latter half of the year. In particular a recovery in MMR1
uptake was observed which reached 75% in quarter 4,
compared to the same period in 2001 when it had declined to
69%, which is the lowest uptake rate for MMR1 recorded to
date. Despite the improvement in MMR1 uptake throughout
2002, the maximum MMR1 uptake of 83% recorded in
quarter 4 2000 has not been reached in Ireland since. These
uptake rates still fall well short of the target uptake of 95%,
the level required at 24 months to effectively control vaccine-
preventable diseases. While MMR1 uptake rates continue to
remain at these low levels, Ireland is going to continue
experiencing outbreaks of measles, mumps and rubella.
The highest uptake levels of MenC vaccine through the catch-
up programme were achieved in the 5-17 year age group. This
age group corresponded to those in primary and secondary
school who would have largely been targeted by
immunisation teams visiting the schools, or alternatively, if
missed at school, this group also had the option of being
vaccinated by their local GP. These uptake figures
demonstrate that high uptake levels can be achieved when
specific groups are targeted and when the combined efforts of
dedicated vaccination teams in schools and GPs are well co-
ordinated. A marked decline in uptake for MenC was noted in
those aged 18 years and over, decreasing from 56% in 18 year
olds to 8.5% in 22 year olds. The poor MenC uptake in this
age group reflects the difficulty in targeting and in
communicating preventive health messages to young adults.
Although immunisation teams visited colleges and extensive
advertising was undertaken, getting vaccinated was not a high
priority for many college students. Furthermore, this group of
the population is generally very healthy and rarely have cause
to attend their GP so opportunistic vaccination was difficult.
However, the impact of the MenC campaign was reflected in
the 90% decline in notifications in Group C disease observed
between 2000 and 2002. Furthermore, there were no deaths
in 2002 due to group C disease whereas on average six people
died each year from the disease prior to the introduction of
the vaccine. Therefore, the MenC vaccine has been a great
public health success story in Ireland, with major reductions in
group C morbidity and mortality being observed since its
introduction.
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Figure 3. Quarterly immunisation uptake rates at 24 months in Ireland
(Note scales range from 65-95% on this figure)
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Figure 4. MenC uptake in Ireland in those targeted by MenC catch-up programme i.e. those aged between 1-22 years in 2000 (1978-1999 birth cohorts)
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Table 1. Immunisation uptake rates in children 12 months of age in 2002
      % Uptake at 12 months
               Cohort born 01/01/2001 - 31/12/2001
Health Board No. in cohort D3 P3 T3 Hib3 Polio3 MenC3
ERHA 21,812 68 68 68 68 68 68
MHB 3,654* 74 73 74 74 74 73
MWHB 4,854 83 81 83 82 82 82
NEHB 6,074 80 80 80 80 81 78
NWHB 3,102 85 84 85 84 85 81
SEHB 6,596 82 81 82 82 82 81
SHB 7,999* 78 76 78 77 77 76
WHB 5,158* 73 72 73 74** 73 70
Ireland 59,249 75 74 75 75 75 74
* As the number in cohort varied depending on the vaccine, 
   the most commonly used number was taken
** Based on data from Quarter 2-4 only
Table 2. Immunisation uptake rates in children 24 months of age in 2002
       % Uptake at 24 months
                Cohort born 01/01/2000 - 31/12/2000
Health Board No. in cohort D3 P3 T3 Hib3 Polio3 MenC3* MMR1
ERHA 21,733 78 77 78 78 77 65 64
MHB 3,535 81 79 81 80 81 79 72
MWHB 4,851 86 84 86 86 86 85 80
NEHB 5,362 91 90 91 90 90 81 79
NWHB 2,924 92 90 92 91 91 82 80
SEHB 6,303 88 85 88 87 87 84 82
SHB 7,926 84 82 84 83 83 79 76
WHB 4,979 83 81 83 82 82 73 74
Ireland 57,613 83 82 83 83 83 75 73
* Based on uptake rates for Quarter 3 and Quarter 4 2002 only
NDSC Annual Report 2002104
Computerised Infectious 
Disease Reporting System (CIDR)
Key Points:
• CIDR is a national multi-agency partnership project to
introduce an internet based integrated electronic
system for surveillance of both clinical and laboratory
information on communicable diseases in Ireland
• CIDR will provide high quality timely information for
surveillance and control of communicable diseases, and
for surveillance of anti-microbial resistance
• CIDR will be a robust, enterprise-strength solution that
will be adaptable with changing surveillance needs
Introduction
CIDR is an internet based Computerised Infectious Disease
Reporting (CIDR) system being developed by the National
Disease Surveillance Centre in collaboration with its partners,
the Department of Health and Children, the Health Boards,
the Food Safety Authority of Ireland and the Food Safety
Promotion Board, and with the help of external IT consultants
who advise on each step of the process. CIDR aims to provide
an integrated and standardised electronic surveillance system
to collect, collate, analyse and disseminate good quality
laboratory-based and clinical notification data on
communicable disease in a timely manner in Ireland. CIDR
will provide:
• An easily accessible one-stop shop for surveillance and
control of communicable diseases and antimicrobial
resistance
• One common system for all surveillance work 
• Standard reports on line and the ability to customise reports
to your needs
• Controlled and secure access to information 
• An adaptable and flexible system that can meet future
needs  
CIDR System Design
In October 2001 a EU Tender for detailed design of the CIDR
core system, including specification of the hardware
configuration and software infrastructure required to operate
CIDR was initiated. By July 2002 Fujitsu Consulting
completed the design, including the uploading of data from
Laboratory Information Management Systems (LIMS) to CIDR.
CIDR System Development
A second, restricted, EU procurement was initiated in May
2002 to identify a partner to develop, implement and support
the CIDR system from the design documentation. Following
confirmation of funding for CIDR development in January
2003, the contract was awarded to Fujitsu Consulting. By the
end of 2003, both development and user acceptance testing
of the system will be completed. The CIDR system has been
built using the latest .NET development environment with
SQL Server 2000 as the backend database and it makes
extensive use of XML technology, in line with the inter-
operability requirements of e-government initiatives.
Access to the CIDR system will be provided via the
Government Virtual Private Network (G-VPN). This provides a
cost-effective network with increased security and enhanced
bandwidth for public sector organisations, including the health
service. Other health agencies utilising this network include
the General Medical Services Payments Board (GMS-PB) and
the General Registry Office (GRO). Public health departments,
community care offices and clinical microbiology laboratories
will enter and retrieve infectious disease information from
CIDR via standard browser software on their personal
computers. No additional software will be required.
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To ensure that information within CIDR is stored and accessed
appropriately, the core system is firewall-protected and access
to the system is limited to authorised users. In addition to
usernames and passwords these users will require
authentication provided by unique key fob tokens.
Information transmitted from local PCs to the core system
will be protected by 128-bit encryption.
The information in CIDR will come from two principal sources.
Public health doctors working in community care offices and
public health departments will register clinical notifications on
the system. Clinical microbiology laboratories in hospitals will
upload files exported from their laboratory information
systems into CIDR, again using standard browser software.
These files will be transformed and translated by the core
system in the CIDR format. To ensure that this is done
accurately and that the files exported by the laboratory
information system contain the appropriate information, CIDR
users will be able to view uploaded data in its unmodified
state and after transformation / translation. Laboratories will
authorise all information prior to its release for view by public
health and other CIDR partners.
Information from these sources will be combined into events
of infectious diseases. This means that for example for an
event of TB, all clinical epidemiological and laboratory
information on this disease in an individual will be available in
the one place, and can be reported on.
The information collected and stored by CIDR will be available
for analysis utilising a report writing / business intelligence
application called ‘Business Objects’. This software enables
information to be retrieved from complex relational databases
in a user-friendly fashion yet leaves the underlying data safe.
As with the CIDR application itself, viewing and analysing 
CIDR information with ‘Business Objects’ will require only
standard browser software locally.
CIDR Pilot implementation
Following user acceptance testing, pilot implementation will
commence in the North Eastern Health Board, in NDSC and
in the 4 reference laboratories, namely the National Virus
Reference Laboratory, the Irish Meningococcal and Meningitis
Reference Laboratory, the Salmonella Reference Laboratory
and the Methicillin Resistant Staphylococcus Aureus
Laboratory. National implementation will happen
subsequently.
CIDR Project Team
During 2002 and 2003 the CIDR project team has grown. The
team now includes the following new members: Colm Grogan,
Senior Surveillance Scientist, Gillian Cullen, Surveillance
Scientist, John Foy and Liam O’Connor, IT officers, Orla
Bannon, administrative lead on training, Karen Savage CIDR
Communications Officer and Deirdre Hyland administrative
officer.
CIDR committees work
The CIDR committees continue to work hard to support the
work of the CIDR project in developing and delivering this
major public health initiative. This is much appreciated by the
CIDR project team. Dr Ann Shannon stepped down as Chair of
the National Business Rules Committee in 2002, and has been
replaced by Dr Peter Finnegan. We wish to thank Dr Ann
Shannon for all her hard work as Chair of this committee. One
of the important pieces of work completed by this committee
was a national template Business Rules for participation in
CIDR, which was agreed in 2002. The suitability of this
template will be tested in the pilot implementation locations.
NDSC Annual Report 2002106
Website
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Figure 1. Number of Connections to the NDSC Website per Quarter. 
The NDSC website (www.ndsc.ie) continues to be one of the
most important communications tools available to NDSC. A
wide range of information is published on the web site,
including versions of all reports produced by the NDSC,
weekly and annual infectious disease statistics, disease specific
factsheets, press releases and other general information.
Following the move to a new website design at the end of
2001 the level of use of the site increased significantly during
the year. At the beginning of 2002 the average number of 
log-ons to the site per day was 374. During the last quarter it
averaged 575 users per day.
Usage information for the NDSC website during 2002 
was as follows:
Figure 1 represents the total number of connections to the
site for each quarter of 2002 and for Q4 2001. The 2001
figure is included for reference purposes.
Table 1 indicates that the transfer of data from the site
increased at a slightly greater rate than the number of
connections to the site. The ratio of connections in Q4 2001
compared to Q4 2002 is approximately 1:3, whereas the ratio
of data downloaded for the same period is 1:3.6.
The number of different national domains from which users
connected to the NDSC website increased from 58 different
countries in Q4 2001 to 74 in Q4 2002 (see Table 1).
  
Quarter Total Average Daily No. of Distinct
Connections Transfer Rate National Domains
(MB/day) Connecting Site
Q4 2001 17607 14 58
Q1 2002 33748 22 62
Q2 2002 26725 22 70
Q3 2002 44099 39 72
Q4 2002 52968 51 74
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ERHA – Eastern Regional Health Authority
(Dublin, Kildare, Wicklow)
MHB – Midland Health Board
(Laois, Offaly, Longford, Westmeath)
MWHB – Mid-Western Health Board
(Clare, Limerick, Tipperary NR)
NEHB – North Eastern Health Board
(Cavan, Monaghan, Louth, Meath)
NWHB – North Western Health Board
(Donegal, Sligo, Leitrim)
SEHB – South Eastern Health Board
(Carlow, Kilkenny, Tipperary SR, Waterford, Wexford)
SHB – Southern Health Board
(Cork, Kerry)
WHB – Western Health Board
(Galway, Mayo, Roscommon)
ACE – Assistant Chief Executive
CSSD – Central Sterile Suppliers Department
EHSS – Eastern Health Shared Services
FPHM – Faculty of Public Health Medicine
FSAI – Food Safety Authority of Ireland
FSPB – Food Safety Promotions Board
IBTS – Irish Blood Transfusion Service
IMU – Information Management Unit
NDSC – National Disease Surveillance Centre 
OLHSC – Our Lady’s Hospital for Sick Children
TCD – Trinity College Dublin
UCD – University College Dublin
Glossary of Terms 

